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ÁGRIP
Notkun sýklalyfja og beratíðni penicillín ónæmra 
pneumókokka hjá börnum 
– Endurteknar þversniðsrannsóknir á 10 ára tímabili
Vilhjálmur Ari Arason
Heimilislæknisfræði, Háskóla Íslands, Heilsugæsla höfuðborgar-
svæð­isins, Sólvangur og Fjörð­ur, Hafnarfirð­i,  Íslandi.
Tilgangur: Að athuga notkun sýklalyfja meðal forskólabarna á Ís-
landi og meta hugsanlegt samband slíkrar notkunar við beratíðni 
penicillín ónæmra pneumókokka í nefkoki þeirra.
Efniviður og aðferðir: Upplýsingar voru fengnar hjá foreldrum og 
úr sjúkraskrám heilsugæslustöðva um sýklalyfjaávísanir 2.612 barna 
á aldrinum 1-6 ára sem bjuggu á  mismunandi stöðum á landinu. Úr 
þessum hóp voru teknar nefkoksræktanir frá 2.486 börnum. Gerðar 
voru þrjár þversniðsrannsóknir á sömu svæðum á 10 ára tímabili (I. 
hluti 1993, II. hluti 1998 og III. hluti 2003). Þátttökuhlutfall var frá 
75 til 88%. Einnig var unnið úr upplýsingum apóteka sömu svæða 
varðandi 22.132 ávísanir á sýklalyf til inntöku (utan spítala) fyrir 
alla aldurshópa árið 1993 og 15.153 ávísanir árið 1998. 
Aðal mælibreytur: Tíðni penicillín ónæmra pnemókokka í nefkoki 
og áhættuþættir berasmits, heildarnotkun sýklalyfja, notkun þeirra 
vegna bráðrar miðeyrnabólgu (acute otitis media), væntingar foreldra 
og notkun hljóðhimnuröra.
Niðurstöður: 
• Sýklalyfjaávísunum heimilislækna til barna fækkaði um 1/3 
á rannsóknartímabilinu. Munur var á ávísanavenjum lækna 
milli svæða, sérstaklega varðandi meðferð við bráðri miðeyrna-
bólgu. 
• Fylgni var á milli væntinga foreldra til sýklalyfjanotkunar og 
ávísana lækna á sýklalyf til barna eftir búsetu. 
• Yfir 30% barna á Íslandi fá hljóð­himnurör á fyrstu 6 aldursár­
unum. Á svæðum þar sem sýklalyfjanotkunin var mikil var 
meiri notkun á breiðvirkum sýklalyfjum borið saman við hin 
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svæðin og notkun röra í hljóðhimnur fór vaxandi (upp í 44% 
allra barna). Á öðrum stöðum, þar sem sýklalyfjanotkunin 
hafði minnkað, var röranotkunin komin mest niður í 17%. 
• Sterkt samband var á milli sýklalyfjanokunar einstaklinga og 
tíðni penicillín ónæmra  pneumókokka í nefkoki þeirra. 
• Fjölónæmir (ónæmir fyrir mörgum tegundum sýklalyfja) og 
jafnframt penicillín ónæmir pneumókokkar af sermisgerð 6B 
(með sömu svipgerð og Spain6B-2 stofninn) fundust á svæðun-
um. Tíðni þeirra náði vissu hámarki en minnkaði síðan aftur 
eða að þeir hurfu með öllu á þessu 10 ára tímabili, bæði á 
svæðum þar sem sýklalyfjanotkunin var mikil og eins þar sem 
hún var lítil. 
Ályktanir: Sterkt samband ríkir á milli sýklalyfjanotkunar og 
tíðni penicillín ónæmra pneumókokka í nefkoki barna. Eftir sýkla-
lyfjanotkun er barnið  næmara fyrir utanaðkomandi smiti svo sem 
í leikskólum. Líklegt er að­ faraldsfræð­ileg dreifing nýrra ónæmra 
pneumókokkastofna skýri megin sveiflur í beratíð­ninni. Hugsanlega 
er samband á milli (of)notkunar sýklalyfja við bráðri miðeyrnabólgu 
og endurtekinna eyrnabólgusýkinga síðar meir og ísetningu hljóð-
himnuröra.
Lykilorð: Sýklalyfjanotkun, lyfjaávísanir, bráð miðeyrnabólga, börn, 
sýklalyfjaónæmi, penicillín ónæmir pneumókokkar, sermisgerð 6B, 
útbreiðsla bakteríustofna, Spain6B-2, hjarðarónæmi, hljóðhimnurör, 
heilsugæsla, heimilislækningar.
vABSTRACT
Use of antimicrobials and carriage of penicillin-resistant pneu-
mococci in children
– Repeated cross-sectional studies covering 10 years
Vilhjalmur Ari Arason
Department of Family Medicine, University of Iceland, Primary 
Healthcare Centre of Solvangur and Fjordur, IS-220 Hafnarfjordur, 
Iceland.
Objectives: The overall aim of this thesis was to analyse the use of 
antimicrobials in pre-school children in Iceland and the connection 
between such use and the carriage of penicillin-nonsusceptible pneu-
mococci (PNSP).   
Study populations and methods: Prescription data and medical 
histories from 2,612 children, aged 1 to 6 years, living in different 
geographically well­defined study areas in Iceland, and nasopharyn-
geal specimens from 2,486 children were analysed in three cross-
sectional studies covering 10 years (Phase I 1993, II 1998, and III 
2003). Participation varied from 75% to 88%. Annual analysis of 
oral antimicrobial sales/prescriptions for whole communities (hos-
pital use excluded) were based on 22,132 prescriptions in 1993, and 
15,153 in 1998.
Main outcome measures: The prevalence and risk factors for naso-
pharyngeal carriage of PNSP, total antimicrobial use, antimicrobial 
use for acute otitis media (AOM), parental expectations and tympa-
nostomy tube placements.
Results: 
• Antimicrobial prescription rates among GPs diminished by 
about 1/3 over the study period. Prescription habits varied 
greatly between communites especially because of AOM. 
• Parents’ expectations of antimicrobial prescriptions were as-
sociated with the antimicrobial prescription rate in each area.
• The cumulative prevalence of tympanostomy tube placement 
among pre-school children is high in Iceland (over 30%). In 
vi
areas where the prescription rate was high, broad-spectrum 
antimicrobials were prescribed relatively more often than in 
other areas, and the tympanostomy tube placement rate was 
increasing (up to 44% of all children). In other areas, tympa-
nostomy tube rate among children deceased (down to 17%) at 
the same time as antimicrobial use for AOM diminished.
• There was a strong association between antimicrobial use on 
the individual level and the nasopharyngeal carriage of PNSP.
• PNSP, multiresistant, serotype 6B (phenotypically identical to 
the Spain6B-2 clone) appeared and disappeared over a 10-year 
period, in communities with both high and low antimicrobial 
use. 
Conclusions: There is a strong association between antimicrobial 
use for individual children and the nasopharyngeal carriage of PNSP. 
Pneumococcus is acquired from other children, usually in day-care 
settings and PNSP selectively colonised when receiving antimicro-
bials. Spread of novel resistant clones appears  to be the main reason 
for marked changes in pneumococcal resistance rates in individual 
communities over time. Antimicrobial drug (over)use for AOM my 
be associated with future episodes of AOM and tympanostomy tube 
placements. 
Key words: antimicrobial use, drug prescription, acute otitis media, 
children, antimicrobial resistance, penicillin-nonsusceptible pneu-
mococci, clonal spread, Spain6B-2, herd immunity, tympanostomy 
tube placement, primary healthcare, general practice.
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ABBREVIATIONS AND DEFINITIONS
Abbreviations
AOM Acute otitis media 
B Bolungarvik
CI Confidence interval
DDD  Defined daily dose 
E Egilsstadir
G Gardabaer
GP General practitioner
H Hafnarfjordur
HG Hafnarfjordur and Gardabaer
HH Hella and Hvolsvöllur
MIC  Minimal inhibitory concentration
NS Not significant
OR Odds ratio
PNSP  Penicillin-nonsusceptible pneumococci
PSP Penicillin-susceptible pneumococci
SD Standard deviation
V Vestmannaeyjar
Definitions
Antimicrobials = antibiotics
Strain = serotype
Clone = subtype (serotype) of a bacteria with the same DNA origin 
(fingerprint)
DDD/1000/day = defined daily dose per 1000 individuals daily
Herd immunity = immunity status in the population against specific 
organisms    
Intermediate­resistant pneumococci = penicillin MIC ≥ 0.1­1.0 mg/l
Multiresistant (multidrug-resistant) = resistant to three or more 
different antimicrobial groups
Penicillin-nonsusceptible pneumococci (PNSP) = penicillin MIC 
 ≥ 0.1 mg/l
Penicillin­resistant pneumococci, MIC ≥ 2.0 mg/l 
PNSP carrying rate = percentage of PNSP of all carrying pneumococci
INTRODUCTION
Infections have been one of the major causes of human disease and 
suffering throughout history. The introduction of antimicrobials for 
bacterial infections, beginning in the 1930s, is clearly one of the 
milestones in the history of modern medicine (Le Fanu 1999). It has 
been claimed that the use of antimicrobials has added approximately 
10 years to human life expectancy in many industrialised countries 
(McDermott and Rogers 1982). However, bacteria resistant to an-
timicrobial treatments soon became a worldwide problem, proba-
bly partly because of overuse of antimicrobial drugs (Tenover and 
Hughes 1996; Wise et al. 1998). 
In contemporary Western societies, infections from the upper respi-
ratory tract are one of the most common reasons for visiting a doctor 
in primary healthcare (Monto and Ullman 1974). This is especially 
true regarding upper respiratory tract infections in children (McCaig 
and Hughes 1995; Söderström 1995; Njalsson et al. 1996; Petursson 
1996). Of particular concern in this connection has been the rapid in-
crease of antimicrobial resistance in the bacteria Streptococcus pneu-
moniae, causing problems in the management of common childhood 
infections, such as acute otitis media (Klugman 1990; Appelbaum 
1992; Neu 1992; Levy 1993; Tomasz 1994; Levy 1998; Dagan 2000). 
The prevalence of penicillin-resistant pneumococci is highest in coun-
tries with relatively unrestricted antimicrobial use. It has been low in 
northern Europe except Iceland, which is disconcerting as antimicro-
bial use in Iceland has been relatively restricted (Kristinsson 1995).
This thesis is about the use of antimicrobials in children in the com-
munity and the possible association of such with the risk of carriage of 
penicillin­resistant pneumococci, better defined as penicillin­nonsus-
ceptible pneumococci (PNSP). The emphasis is on acute otitis media, 
which is the main reason for prescribing antimicrobials in children. 
Furthermore, the spread of one specific PNSP clone over a 10­year pe-
riod in four well­defined communities in Iceland is examined. Finally, 
the thesis examines the tympanostomy tube placements as a treatment 
option for otitis media in association with antimicrobial use.
Bacterial resistance to antimicrobials
Sulphonamides were introduced for clinical use in the 1930s. Peni-
cillin had already been discovered in 1928, but it was not until 1941 
that it was first used for the treatment of a patient with a bacterial 
infection (Fletcher 1984). Penicillin and the other antimicrobials that 
followed rapidly thereafter were a therapeutic revolution for treat-
ment of lethal infections as well as many chronic and disabling in-
fections. Later, a large number of different antimicrobials were in-
troduced in the market for treatment of bacterial infections. In recent 
decades, however, the prevalence of human pathogens resistant to 
antimicrobials has increased rapidly, especially those involved in 
respiratory tract infections (Levy 1998; Wise et al. 1998; Klugman 
2002).
The community-acquired bacterial pathogens currently creating 
one of the biggest antimicrobial resistance problems in respiratory 
tract infections in the world are PNSP, representing up to 40% of all 
pneumococcal isolates from infected patients in some parts oft the 
world (Felmingham 2005). Many of these strains are also multidrug-
resistant (resistant to three or more different antimicrobial groups). 
Of special concern in the last decade is also the increasing prevalence 
of macrolide-resistant pneumococcus in community-acquired infec-
tions. 
Comparative and analytical studies have demonstrated a relation-
ship between the use of antimicrobials and increase in bacterial resis-
tance to these drugs in the community (Molstad et al 1988; Reichler et 
al 1992; Arason et al. 1996; Seppala et al. 1997; Melander et al. 2000; 
Granizo et al. 2000; Arason et al. 2002 a; Bergman et al. 2004; Dias 
and Caniça 2004;  García-Rey et al. 2004; Goossens et al. 2005; Ara-
son et al. 2006). Because of the overwhelming threat of antimicrobial 
resistance in community-acquired infections, partly because of wide-
spread antimicrobial use, the World Health Organisation (WHO) has 
advised not treating other than established bacterial infections with 
antimicrobials and using as narrow spectrum of antimicrobials as pos-
sible in most instances (WHO 2001).
There is much discussion worldwide of how to gather appropriate 
data regarding antimicrobial resistance. The major problem is getting 
useful data regarding different study populations, that is, to obtain an 
accurate picture of resistance on a community level where resistance 
rates of common pathogens can vary greatly between close areas (Ara-
son et al. 1996; Wise and Andrews 1998; Melander et al. 2000; Felm-
ingham et al. 2005). Such investigations must therefore be undertaken 
both nationally and locally, so that meaningful broad-based  policies 
can be devised and relevant clinical guidelines can be developed. It 
has also been pointed out that there is an increasing need to analyse 
available data on antimicrobial usage and the prevalence of antimicro-
bial-resistant organisms in order to help construct mathematical mod-
els to use as a tool to predict the likely outcomes of various antibiotic 
policy options (Wise and Andrews 1998; Austin et al. 1999; Huovinen 
2005). These are the main reasons for the study design described in 
this thesis. 
Biochemical processes behind antimicrobial resistance
The biochemical process of bacterial resistance to a specific anti-
microbial agent results from chromosomal changes, mutation or 
the exchange of genetic material via plasmid and transposons. Af-
ter a resistant clone appears in the community, the resistant clone 
can spread with selection of resistance, i.e., when most of the fully 
susceptible bacteria in the population are eliminated, and a resistant 
sub-population is given the opportunity to proliferate. This is hard 
to explain except in epidemiological studies, taking into account all 
possible factors, such as (selective) antimicrobial pressure (antimi-
crobial use) in the community, changes in use over time and possible 
herd immunity against this resistant clone, which will be a further 
topic of the research data in this thesis.
The mechanisms by which bacteria protect themselves from anti-
microbials can be classified into four basic types (Hawkey 1998):  1) 
Alterations in the primary site of action like penicillin-binding pro-
teins in pneumococcus. The pneumococcus has at least five different 
penicillin-binding proteins. Molecular alterations in the primary site 
of action or in the penicillin-binding proteins in pneumococci may 
reduce the binding affinity of penicillin to the target as well as for 
other ß-lactams.  2) Resistant bacteria retain the same sensitive target 
as antimicrobial-sensitive strains, but the antimicrobial is prevented 
from reaching it. This happens, for example, with ß-lactamases; the 
ß-lactamase enzymatically cleaves the four-membered ß-lactam ring, 
rendering the antibiotic inactive (ß-lactamase-producing bacteria Hae-
mophilus influenzae and Moraxella catharralis).  3) Production of an 
alternative target (usually an enzyme) that is resistant to inhibition by 
the antimicrobial.  4) Bacteria protect themselves from antimicrobials 
by preventing the antimicrobial from entering the cell or by pumping 
it out faster than it can flow in. Bacterial resistance to macrolides can 
be explained by the two last described pathways.
Streptococcus pneumoniae
Streptococcus pneumoniae, usually named pneumococcus is one of 
the most clinically significant pathogens with emerging antibiotic re-
sistance. It was first isolated by Pasteur in 1881 and has been observed 
to have been the most common reason for lobar pneumonia, with very 
high mortality (33%) before antimicrobial treatment was available. 
After the introduction of sulphonamides, the mortality decreased to 
8%, and after the introduction of penicillin, mortality has been very 
low (Swartz 2002). Pneumococcus, is at present, considered to be the 
commonest and most important pathogen in acute otitis media, acute 
sinusitis, pneumonia, septicaemia and meningitis (Musher 1992). The 
risk, especially of the invasive disease, is higher for children and the 
elderly (Burman et al. 1985). The main habitat of pneumococcus is the 
nasopharynx. Pneumococcal carriage is age-related. It increases dur-
ing the first year of life and is highest in children aged 1­2. Thereafter, 
carriage rates slowly decline, and adults have much lower rates than 
children (Gray et al. 1980). Colonised children may transmit pneumo-
cocci easily to each other.
An essential immunogenic determinant of pneumococci is its 
capsule made of polysaccharide, which provides protection from 
phagocytosis. Thus, non-encapsulated strains have less protection 
and, thereby, have also greatly reduced virulence (Tuomanen et al. 
1995; Hall et al. 1996). The antigenicity of the capsule forms the 
basis for the classification of the 90 known pneumococcal serotypes 
(Henrichsen 1995; Hall et al. 1996). If sub-typing of the pneumococ-
cus is possible, the number assignment is referred to as a serogroup, 
e.g., serogroup 6, with subtypes referred to as serotype or subtype 
6A, 6B, etc. The host’s protective antibodies are directed against the 
polysaccharide capsule, and the protection is therefore type-/group-
specific, with only slight or no cross­reactivity between antibodies of 
differing type/serogroup specificity.
Pneumococcae vaccination 
Vaccination against pneumococci with polysaccharide vaccine has been 
available on the market since 1977, but the immunogenicity of polysac-
charide vaccines, especially among children, is low (King et al. 1996). 
New protein-polysaccharide conjugate vaccine, including serotypes 4, 
6B, 9V, 14, 18C, 19F and 23F, has much higher immunogenicity among 
children and has been available on the market since 2000 and is part of the 
routine childhood immunization schedule in the United States (MMWR 
2000). Clinical trials have shown efficacy of the vaccine against sero-
type­specific invasive disease of > 70% (Whitney 2005). Among chil-
dren under two years of age, the rate of all PNSP invasive diseases has 
diminished by about 80% in the United States from 1999 to 2004 (Kyaw 
et al. 2006). Studies evaluating pneumococcal conjugate vaccines ef-
fects on nasopharyngeal carriage demonstrate though that vaccination 
does not impact the overall risk of pneumococcal nasopharyngeal colo-
nization but reduces the acquisition of vaccine-type strains and increases 
the risk of non-vaccine serotype strain acquisition (O’Brien and Dagan 
2003; Veenhoven et al. 2003). The natural balance of microbial species 
in the nasopharynx might also be altered by pneumococcal vaccination. 
In studies from the Netherlands, there was a negative correlation for co-
colonisation of Staphylococcus aureus and vaccine-type pneumococci, 
findings suggesting a natural competition between these bacteria, which 
might also explain an increase in Staphylococcus aureus-related otitis 
media after vaccination (Bogaert et al. 2004).
In Northern California, it has been shown that in those receiving 
this vaccination there was an 8% reduction in otitis media episodes, 
a 10% reduction in frequent otitis media and a 24% reduction in 
tympanostomy tube placements compared with children receiving 
control vaccine (Fireman et al. 2003). Other studies from the North-
America, Israel and Europe (Finland) have also evaluated the effect 
of pneumococcal conjugate vaccines on clinical or culture-proved 
pneumococcal otitis media with similar results (Black et al. 2000; 
Dagan et al. 2001 a; Eskola et al. 2001). 
Penicillin resistance among pneumococci
Most strains of pneumococcus  are highly susceptible to both peni-
cillins and cephalosporins but can acquire DNA from other bacteria, 
that changes  the penicillin-binding proteins so that they develop a 
low affinity for penicillins and hence become resistant to inhibition by 
penicillins (Tomasz and Munoz 1995). Pneumococcal strains resistant 
to penicillin and other antimicrobial drugs came on the scene during 
the late 1960s. The first patient with pneumococcus of decreased sen-
sitivity to penicillin was reported from Australia in 1967 (Hansman 
1967). However, a high degree of resistance (minimum inhibitory 
concentration, MIC ≥ 2.0 mg/L) was observed during the late 1970s 
and, furthermore, multidrug-resistant strains began to appear, with an 
increasing rate of treatment failures (Appelbaum 1992; Dagan 2000; 
Felmingham and Gruneberg 2000; Klugman 2002; Swartz 2002).
In the literature, penicillin-resistant pneumococci are often de-
fined to include both resistant strains with MIC for penicillin of 
≥ 2.0 mg/L, and intermediate­resistant strains with MIC of 0.1­1.0 
mg/L. Thus, the choice of antimicrobial group as an empirical treat-
ment of respiratory tract infections from pneumococcus is harder to 
define now than before throughout the world, but higher doses of 
traditional agents are sometimes enough to avoid treatment failure if 
the pathogen is only intermediate-resistant to a given antimicrobial 
class (Pallares et al. 1995). Today the term penicillin-nonsusceptible 
pneumococccus (PNSP) is therefore often used for all intermediate-
resistant and high-resistant strains together. 
The first report of PNSP in Iceland came in 1988 (Kristinsson et 
al 1992). In the following years, 20% of the pneumococcal strains 
in Iceland isolated from infected patients were PNSP, the majority 
multiresistant serotype 6B, which was shown to be phenotypically 
identical by antibiotic susceptibility testing as the Spain6B-2 clone 
(Soares et al. 1993; Kristinsson 1995).
 
Otitis media
Otitis media continues to be one of the commonest childhood diseases 
and is a major cause of morbidity in children (Rovers et al. 2004). 
The pathogenesis is multifactoral, involving the adaptive and native 
immune system, eustachian-tube dysfunction, viral and bacterial load, 
and genetic and environmental factors (Bluestone 1996; Rovers et al. 
2004). Otitis media with effusion, or ‘glue ear’, may occur as a pri-
mary disorder or as a sequel to acute otitis media (Teele et al. 1980). 
It is very common in children, especially between the ages of one and 
three years with a time-point prevalence of 10% to 30%, slightly high-
er during the winter than during the summer (Lous 1995). Bacteria are 
isolated fairly often in middle-ear exudates, but in spite of this, most 
patients recover spontaneously (Glasziou et al. 2004). 
Acute otitis media and otitis media with effusion are different 
stages of the otitis media continuum. Acute otitis media is defined as 
the presence of middle-ear effusion in conjunction with rapid onset 
of one or more signs or symptoms of inflammation/infection in the 
middle-ear, such as otalgia, otorrhoea, fever, or irritability (Gates 
et al. 2002). Diagnosis of precise acute otitis media, though, can be 
hard to define and also differ according to national perspectives and 
specialty (Rosenfeld 2002). By the age of two, up to 70% of children 
have had at least one, and every fifth, three or more episodes of acute 
otitis media in Finland (Alho et al. 1991). Similar incidence has been 
found in the United States (Teele et al. 1989; Paradise et al. 1997). 
The high incidence and high rate of spontaneous recovery from otitis 
media suggest that it is a natural phenomenon, inevitable like the 
common cold, and play part of the gradual maturation of the child’s 
immune system. 
Even though the prevalence of acute otitis media may vary be-
tween countries, international rates of antibiotic prescription and 
surgery for acute otitis media vary greatly, which can largely be ex-
plained by the lack of uniform evidence-based guidelines (Schilder 
et al. 2004). The percentage of patients given antibiotics for acute 
otitis media varies from 31% in the Netherlands to more than 90% 
in most other Western countries (Froom et al. 1990; Schilder et al. 
2004). Untreated acute otitis media may possibly, though very un-
commonly, lead to suppurative complications, such as acute mas-
toiditis. Even though there are national differences in the incidence 
of acute mastoiditis, which may possibly be related to prescribing 
pattern of antibiotics for acute otitis media, the differences are negli-
gible (3.8/100,000 person years for children 14 years and younger in 
the Netherlands but 1.9/100,000 in United States (Van Zuijlen et al. 
2001; Rovers et al. 2004). Initial observation as a treatment strategy 
seems therefore to be suitable for many children with acute otitis 
media, but only if appropriate follow-up can be assured. In children 
younger than two years with a clear clinical picture of acute otitis me-
dia, antibiotics are most often advised (Diagnosis and Management 
of Acute Otitis Media 2004 (The American Academy of Pediatrics 
and American Academy of Family Physicians guideline); and http://
www.sign.ac.uk/guidelines/fulltext/66/index.html, a national clinical 
guideline in Scotland (SIGN), last viewed in February 2006).
The prediction of recurrent acute otitis media or persistent mid-
dle-ear effusion in individual young children remains poor. Young 
age, childcare outside the home and parental smoking are three of 
the main risk factors found to significantly increase the occurrence 
of acute otitis media among children. Other important risk factors in 
the development of single and recurrent episodes of acute otitis me-
dia may include ethnicity, genetic factors, underlying disease, sea-
sons and social and economic condition (Uhari et al. 1996; Strachan 
and Cook 1998; Rovers et al. 2004).
Chemoprophylaxis as a specific intervention in the prevention of 
recurrent acute otitis media, may be more effective than tympanos-
tomy tubes (Casselbrant et al. 1992).  In one meta-analysis, antibiot-
ics, appear to have beneficial but limited effect on recurrent otitis 
media and short-term resolution of otitis media with effusion but no 
longer­term benefit (Williams et al. 1993). 
Surgical candidacy depends more on associated symptoms, the 
child’s developmental risk, and the anticipated chance of timely 
spontaneous resolution of the effusion. Hearing loss caused by bi-
lateral chronic otitis media might lead to behavioural changes and 
delays in communicative development, although this is still under 
discussion (Teele et al. 1990; Lous 1995; Rovers et al. 2004; Para-
dise et al. 2005). The recommended approach for surgery is to start 
with tympanostomy tube placement, eventually followed by ad-
enoidectomy. The ideal intervention for chronic or recurrent acute 
otitis media does though not yet exist, and an urgent need remains to 
explore new and creative options, based on modern insights into the 
pathophysiology of otitis media (Rovers et al. 2004). 
Chronic or recurrent acute otitis media has a considerable nega-
tive impact on the quality of life of children and worries their care-
givers (Brouwer et al. 2005). The parents of young children hold 
views on acute otitis media and antibiotics that differ markedly from 
the medical model in Iceland (Jonsson and Haraldsson 2002).  These 
outcomes should therefore be included in the evaluation of the child 
with otitis media in both the clinical and research setting. 
Acute otitis media and antimicrobial use 
Acute otitis media is the most common diagnosis (30-65%) leading to 
antimicrobial prescription for children in the Western world (McCaig 
and Hughes 1995; Arason et al. 1996; McCaig et al. 2002; Arason 
et al. 2002 b; Rovers et al. 2004; Arason et al. 2005). Nevertheless, 
antimicrobial treatment of acute otitis media is debatable. Several ran-
domised clinical trials (Damoiseaux et al. 2000; Little et al. 2001; Le 
Saux et al. 2005; McCormick et al. 2005) and meta-analyses (Rosen-
feld et al. 1994; Del Mar et al. 1997; Takata et al. 2001; Glasziou et al. 
2004) indicate that antimicrobial treatment of acute otitis media may 
often be unnecessary, even for young children. A restrictive antibiotic 
policy for acute otitis media appears therefore justifiable, and the re-
cent emphasis in Iceland as well as elsewhere has been on watchful 
waiting for management of children with acute otitis media, especially 
for those two years and older with mild symptoms or with uncertain 
diagnoses (see the Icelandic drug guidelines, at  http://landlaeknir.is/
template1.asp?PageID=672, last viewed in February 2006). In gen-
eral, the literature lacks studies comparing antibiotic treatment with 
placebo administration for acute otitis media and there are no clini-
cal trials using standardised methods for assessing acute otitis media 
severity. Restrictive policy in antimicrobial use is supported by the 
documented link between high consumption of antimicrobials and the 
development of antimicrobial resistance among common pathogens 
in the community (see chapter “Bacterial resistance to antimicrobials” 
above). A strong association between antimicrobial use for acute otitis 
media specifically and carriage of penicillin non­susceptible pneumo-
cocci in children has also been demonstrated (Dagan et al. 1998 a; 
Arason et al. 2002 a; Brook and Gober 2005; McCormick et al. 2005). 
The increasing rate of resistance to antibiotic drugs is, as a conse-
quence, associated with a decrease in the rate of successful eradica-
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tion of pathogens from middle­ear fluid in acute otitis media, which 
is associated with clinical failure (Dagan 2000). Further knowledge of 
the short- and long-term impact of different antimicrobial treatment 
strategies for acute otitis media is therefore important. 
Healthcare systems, health-seeking behaviour, and medical man-
agement including management, and treatment decision for acute 
otitis media, differ worldwide. Therefore, when comparing the prev-
alence of antimicrobial treatments for acute otitis media, it is neces-
sary to adjust for baseline characteristics between countries (Froom 
et al. 2001). Furthermore, consistency in the treatment pattern within 
the same practice or healthcare centre in one community is also more 
likely than that between communities (Diwan et al. 1992; Petursson 
1996; Gabbay and le May 2004). 
Acute otitis media was known to be one of the most common 
causes of antimicrobial use in children in Iceland when the study was 
conducted (Bjarnason 1991; Petursson 1996), and pneumococcus is 
known to be the most common cause, accounting for approximately 
50 percent of all cases of acute otitis media (Bluestone 1996; Dowell 
et al. 1999). One of the most common serotype comprising pneumo-
coccal isolates from middle­ear fluid samples include serotype 6B 
(Hausdorff et al. 2002). This is the main reason why prescriptions for 
acute otitis media in different communities and the resistance pattern 
of pneumococcus are the focus of our studies. 
Tympanostomy tube placements
Tympanostomy tube placement is a well-established treatment option 
for chronic effusion in the middle-ear and recurrent episodes of acute 
otitis media, yet the consequences of this intervention are not always 
clear (Gates et al. 1987; Franklin and Marck 1998; Rosenfeld 2000; 
Lous et al. 2005; Paradise et al. 2005; Rovers et al. 2005). Tube otor-
rhea, often in combination with acute otitis media, is a common and 
often recurrent and/or stubborn problem in young children who have 
undergone tube placement for persistent middle-ear effusion (Ah-Tye 
et al. 2001). No previous data were available about the prevalence of 
tympanostomy tube among Icelandic children before the present study. 
This information should also indicate, at least partly, the prevalence of 
otitis-prone children in Iceland. Even though there are some clinical 
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trials indicating lower antimicrobial treatment frequencies after tube 
placements (Franklin and Marck 1998), there is a lack of epidemio-
logical studies showing positive effects in diminishing antimicrobial 
use among children in the community by using tubes on a bigger scale 
among (all) otitis-prone children. This was one reason to include tym-
panostomy tube placements in our research.
Background for a study of antimicrobial use in relation to resis-
tant bacteria in Iceland
Sales statistics of antimicrobials
Antimicrobials are commonly used, as can be seen from sales sta-
tistics. Figure 1 shows the sales of antimicrobials in the five Nordic 
countries. Based on these figures, the use of antimicrobials is high and 
had been much higher in Iceland than in the other Nordic countries 
before the study period. Of special interest was the rapidly increasing 
use of trimethoprim-sulfamethoxazole (trim-sulfa.) in the early 90s 
(Fig. 2), which was commonly used for acute otitis media. 
Fig. 1. Antimicrobial consumption in the Nordic countries based on 
total sales statistics from the Ministry of Health and Social Security, 
Iceland, and The Nordic Council on Medicine (data from Denmark 
do not include hospital usage).
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Penicillin-resistant pneumococci in Iceland
Another reason for studying the association between the use of anti-
microbials and the appearance of antimicrobial-resistant bacteria in 
Iceland was that a new PNSP appeared in Iceland in the late 1980s, 
causing clinical problems and a risk of treatment failure, especially 
when treating children for acute otitis media caused by these pneumo-
cocci. The first case of antimicrobial­resistant pneumococcus in Ice-
land was observed in 1988 and in the next years proved to be mainly 
a multiresistant serotype 6B strain (Kristinsson et al. 1992), probably 
coming from Spain, where this tribe, now registered as Spain6B-2, had 
previously been observed (Soares et al. 1993). Later on it was shown 
that the prevalence of this particular strain (clone) increased rapidly 
in Iceland (Vilhelmsson et al. 2000; Sa-Leao et al. 2002). When this 
study started, cultivation of bacterial sampling from hospital series 
indicated a PNSP prevalence rate of about 20%, almost all of them 
being multiresistant serotype 6B (Kristinsson 1995). The prevalence 
in the community was at that time not known.
Fig. 2. Total sales of antimicrobial mixtures in Iceland 1989-1997 
based on sales statistics from the Ministry of Health and Social Se-
curity.
DDD/year
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
1989 1990 1991 1992 1993 1994 1995 1996 1997
amoxicillin
±clavulanic acid
penicillin V
cloxacillin
cephalosporin
trim-sulfa
macrolides

It has been previously pointed out, that there has been lack of 
population studies, based on studies of both accurate antimicrobial 
sales statistics and antimicrobial resistance in the community (Wise 
and Andrews 1998; Felmingham et al. 2005). A study of antimicro-
bial consumption and antimicrobial resistance in Iceland was there-
fore considered propitious for several reasons:
• The study could be carried out in well­defined geographical 
areas.
• Computerised medical records were available and had been 
used for several years.
• Computerised sales records for drug sales were available from 
the pharmacies.
• Areas could be studied where there was only a single primary 
healthcare centre in each community, to which the vast major-
ity of subjects with upper respiratory tract infections turned.
• The personnel working at the primary healthcare centres are 
stable.
• The GPs have an international view, as the vast majority of 
Icelandic GPs have been educated abroad in different parts of 
the world.
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RESEARCH QUESTION AND AIM OF 
THE STUDY
Main research question
The main question of this study was the potential association be-
tween the use of antimicrobials outside hospitals and the develop-
ment and spread of antimicrobial-resistant bacteria, mainly Strepto-
coccus pneumoniae, in the community (Fig. 3).
As mentioned above, one of the most common reasons for pre-
scribing an antimicrobial is middle-ear infection (acute otitis media) 
in children. This was a reason to confine our 1998 and 2003 studies 
(phase II and III) to pre-school children, 1-6 years of age, and to 
include the occurrence of acute otitis media as a main reason for 
antimicrobial usage and use of tympanostomy tubes as a well-estab-
lished treatment option for recurrent episodes of acute otitis media, 
in the study plan. Most pre-school children one year of age or older 
(about 80%), are enrolled at day-care centres and were therefore eas-
ily available for possible participation. 
Figure 4 includes the main potential associations being focused 
on in our studies.
Aim of the study
In summary, the overall aim was to analyse the use of antimicrobi-
als and the reasons (main diagnosis) for prescribing antimicrobials, 
on one hand, and carriage of penicillin-nonsusceptible pneumococci 
(PNSP), on the other, in pre-school children in Iceland.
Antimicrobial use 
in the community
Antimicrobial resistance 
in the community
Fig. 3. Main research question of the thesis.
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Fig. 4. Hypothesised associations between the main factors studied 
in this thesis.
Specific aims 
• To describe the total use of antimicrobials in the communities, 
specifically among pre­school children, by class of antimi-
crobials, amount prescribed and prescription rate in selected, 
well­defined communities.
• To describe potential links between antimicrobial treatment 
for acute otitis media, socio-demographic factors and parental 
views on the use of antimicrobials. 
• To describe the use of tympanostomy tube placements and pos-
sible association with the use of antimicrobials among children.
• To analyse associations between antimicrobial use and naso-
pharyngeal carriage of PNSP in children with regard to both 
individual use and total use in the community. 
• To describe clonal spread of PNSP in communities and to anal-
yse the interplay of factors contributing to this spread. 
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STUDY POPULATIONS
Demography of Iceland
Iceland is a volcanic island in the North Atlantic Ocean (Fig. 5), just 
south of the Arctic Circle, with an area of 103,000 km2 and 299,891 
inhabitants at the end of 2005. The population is limited to a narrow 
coastal belt, and most of the people live in and around the capital, 
Reykjavik, on the south-west coast. Beginning in the Caribbean and 
ending in the North Atlantic, the Gulf Stream plays an important role 
in the pole-ward transfer of heat and salt surrounding Iceland. The 
climate is characterised by a relatively small difference in tempera-
ture between summer and winter, an oceanic climate.
Characteristics of the study areas
This thesis is based on studies from five areas (Fig. 6). These are 
Hafnarfjordur and Gardabaer (HG, when both communities repre-
sent one study area with a common off-hours service in phase I, 
but H, when Hafnarfjordur alone represented the same study area in 
Fig. 5. The North-Atlantic countries.
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phases II and III), Vestmannaeyjar (V), Egilsstadir (E), Bolungarvik 
(B) and Hella and Hvolsvollur (HH, only included in phase I).
Hafnarfjordur (H) and the smaller neighbour town Gardabaer (G) 
are adjacent to the capital Reykjavik. The town of Vestmannaeyjar 
(V) is a fishing centre on an island off the south coast. Egilsstadir (E) 
in East Iceland, and the smaller town Hella/Hvolsvollur (HH) in the 
southern part are surrounded by large farming areas. Bolungarvik 
(B) is a small fishing town in north­west of Iceland. The climate in 
Vestmannaeyjar (V) is described as somewhat warmer and wind-
ier than in other parts of Iceland, whereas Egilsstadir (E) is more 
characterised by a climate closer to some parts of Scandinavia, with 
colder winters, less humidity and warmer summers than elsewhere 
in Iceland. Classical weather parameters for the study areas as well 
as the years of the three phases during the 10-year period are shown 
in Table 1 (The Icelandic Meteorological Office http://www.vedur.
is, last viewed February 2006). The weather parameters shown did 
not differ much between the research areas during the study period, 
except for more mean wind speed in Vestmannaeyjar than observed 
in the other study areas.
Fig. 6. Study areas in Iceland.
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Choice of study areas
The reasons for selecting study areas vary. They were selected to repre-
sent rural (B, E, HH and V) and urban (H, HG) areas. These areas are also 
geographically well­defined, evenly distributed around the country and 
have reliable registers of all inhabitants, based on the National Register 
“Statistics Iceland” (http://hagstofan.is/, last viewed in February, 2006). 
The primary healthcare centres in areas H, B and E had well-established 
teaching practices, and the content of care in these practices had also 
been well documented from previous research (Sigurdsson et al. 1989; 
Njalsson et al. 1996; Halldorsson et al. 2002; Petursson 2005 a ). 
The five study areas corresponded to seven communities, each 
served by one primary healthcare centre, where GPs and other staff 
are responsible for all primary healthcare, including on-call servic-
es night and day, throughout the year. The medical records in all 
these primary healthcare centres have long been computerised. The 
Table 1. Temperature, humidity and wind speed during the years 1993, 1998 and 
2003 in four research areas in Iceland; Hafnarfjordur (H), Vestmannaeyjar (V), 
Egilsstadir (E) and Bolungarvik (B) (ND = no data available).
Area Year Temperature, degrees Celsius. 
Mean (range)
Relative 
humidity
Mean wind 
speed. Me-
tres/second
 January July Jan. July Jan. July
H1 1993 -2.3 (-12.7 to 6.8) 10.1 (4.7 to 19.7) 76.9 75.0 6.7 4.6
1998 0.6 (-13.7to 8.8) 11.1 (5.4 to 18.0) 73.8 78.9 5.7 3.8
 2003 1.5 (-11.3 to 9.1) 12.3 (6.8 to 18.7) 76.7 79.5 4.7 2.6
V2 1993 -0.2 (-12.2 to 7.2) 9.3 (4.8 to 15.9) 76.2 80.2 13.0 9.0
1998 2.6 (-9.3 to 7.7) 10.4 (6.4 to 17.0) 77.6 88.3 9.4 6.6
 2003 3.1 (-4.4 to 8.2) 11.4 (7.1 to 20.0) 79.8 88.6 12.9 7.5
E 1993 -4.5 (-18.6 to10.0) 7.5 (3.5 to 14.5) 89.5 86.6 6.6 5.2
19983 -1.1 (-18.8 to 8.4) 8.4 (-0.9 to 25.2) 90.1 ND 6.7 ND
 20033 -2.7 (-19.9 to 7.2) 11.1 (2.5 to 22.1) ND ND ND ND
B 19934 -3.2 (-17.0 to 7.1) 7.0 (3.3 to 15.2) 73.6 84.7 7.7 5.0
1998 -0.3 (-11.2 to 8.0) 8.8 (2.5 to 17.0) 79.4 79.1 7.9 3.8
 2003 1.0 (-7.9 to 9.2) 10.3 (3.5 to 18.0) 78.8 80.7 5.7 4.4
1Reykjavík station, 2Stórhöfdi station (on Heimaey, Vestmannaeyjar), 3Egilsstada airport in July 
1998 and 2003, 4Galtarviti station (15 km from Bolungarvík) in 1993.
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healthcare centre in area H was the author’s own workplace during 
all phases of this study.
This study is an epidemiologic cross-sectional follow-up study. In 
analyses of individuals (randomised trials), the basic assumption is that 
there are no connections between the outcome for one person and that 
of any other person (Campell et al. 1999). When analysing GPs pre-
scription habits or practices, it is more likely that the outcome for many 
patients will have a similar pattern if they are treated by the one and the 
same physician. Furthermore, it is more likely that there is a consistent 
treatment pattern within the same practice or healthcare centre than be-
tween practices and healthcare centres (Diwan et al. 1992; Gabbay and 
le May 2004; Petursson 2005 a). The study areas were therefore feasible 
to examine differences in medical praxis in the primary healthcare in 
Iceland in connection with antimicrobial prescription habits.
Organisational structure of the healthcare service
The main organisational structure of the healthcare service was by 
and large similar during the 10-year study period. There is direct ac-
cess to all doctors in Iceland, and GPs therefore have no gate-keep-
ing role as they do in some other countries. The same otolaryngology 
specialist visited areas V, E and B bi-monthly during the years 1998 
and 2003, a fact which may be taken into consideration when deal-
ing with the results described in Papers III and IV. The study areas 
were served by a total of 19 GPs (18.2 positions) in 2003, of whom 
11 were the same individuals as in the 1998 study, and 8 were the 
same individuals as in the 1993 study. As areas H and G are suburbs 
of the capital Reykjavik, the inhabitants in these areas had easy ac-
cess to their GPs as well as to other specialists in Reykjavik. In this 
respect there was no change for H during the study period. However, 
some other changes took place in area H that may have affected the 
results of our study. After phase II, off-hours service for children was 
provided more often outside the H area, resulting in some decline in 
the continuity of care in area H and, consequently, probably some 
underestimation of antimicrobial prescribing. 
 
Details on data collection from the different areas
The cross-sectional investigations were carried out in three phases: 1992-
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1993, 1997-1998 and 2003. Sales statistics over 12 months, based on 
computerised data on prescriptions from the local pharmacies were col-
lected separately in the first phase from October 1992 to September 1993 
and in the second phase from May 1997 to April 1998. No prescription 
data on sales statistics were collected during the third phase of the study.
In the first phase, nasopharyngeal specimens were collected from 
October 1992 to November 1993, excluding the months of June, July 
and August. In phases II and III the collection was made during the 
months March to May in 1998 and 2003, respectively, as was the 
administration of questionnaires. In the third phase, otoscopy was 
performed if the child’s records indicated tympanostomy tubes. As 
most contacts with the participants in 1992-1993 were made in 1993 
(~90%), and all contacts in the second and third phases were made 
in 1998 and 2003, the three phases will hereafter be referred to as the 
1993, 1998 and 2003 studies, respectively.
Three communities Gardabaer (G) (population 7,493) and Hella 
and Hvolsvollur (HH) (population 3,150), were only included in the 
1993 study (I). This means that the cross-sectional follow-up in-
cludes four well­defined communities: Hafnarfjordur (H), Vestman-
naeyjar (V), Egilsstadir (E) and Bolungarvik (B). Gardabaer (G) was 
excluded from the 1998 and 2003 studies for practical reasons, and 
Hella and Hvolsvollur (HH) because no data from the local phar-
macy could be obtained in 1992-1993. An overview of the study 
population and participation is given in Table 2. 
Selection criteria for the study groups 
In all phases of the study, children receiving antimicrobials in the 
preceding two weeks were excluded as far as the analysis of naso-
pharyngeal specimen sampling was concerned, as shown in Tables 
2 and 3.  The 1993 study (I) referred mainly to children up to seven 
years of age (thus also including those less than one year of age) who 
were visited at day care centres on given days or went to the primary 
healthcare centres to visit a doctor for vaccination or because of an 
acute, unspecified upper respiratory infection (common cold), while 
the 1998 studies (II-III) and those in 2003 (IV-V) were supposed to 
include children representative of all 1- 6 years old children living in 
the study areas. In the 1998 studies (II, III), there was a computerised 
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Table 2. Study population from phases II (1998) and III (2003) and, for compar-
ison, from phase I (1993), where children from area HH and children <1 year of 
age were excluded from the results presented in Paper I. In the table a) includes 
the total sample, and b) excludes those who had been treated with antimicrobi-
als during the last two weeks, and for whom no nasopharyngeal sampling was 
analysed.
Area and year Population Children 
1-6 years 
old
Invited Participated 
(% of invited)
N (number) N % N % N % Mean 
age±SD
Hafnarfjördur (area H)
19931 25452 2670 11 527 3.6±1.5
1998, b) Paper II 18203 1989 11 401 20 301 75 4.2±1.8
1998, a) Paper III 18203 1989 11 442 22 331 75 4.1±1.8
2003, a) Paper IV 20675 2004 10 380 19 287 76 4.2±1.7
2003, b) Paper V 20675 2004 10 351 18 258 74 4.2±1.7
Vestmannaeyjar (area V)
1993 4883 529 11 100 4.6±1.0
1998, b) Paper II 4640 512 11 295 58 224 76 4.2±1.7
1998, a) Paper III 4640 512 11 321 63 244 76 4.2±1.7
2003, a) Paper IV 4416 406 9 396 98 324 82 4.4±1.6
2003, b) Paper V 4416 406 9 373 92 301 81 4.2±1.6
Egilsstadir (area E)
1993 3071 318 10 111 3.8±1.5
1998, b) Paper II 3076 300 10 190 63 167 88 4.0±1.8
1998, a) Paper III 3076 300 10 198 66 174 88 4.1±1.8
2003, a) Paper IV 2874 265 9 256 97 216 84 4.2±1.7
2003, b) Paper V 2874 265 9 247 93 207 84 4.2±1.7
Bolungarvik (area B)
1993 1176 123 11 53 3.8±1.5
1998, b) Paper II 1094 99 9 62 63 51 83 4.2±1.7
1998, a) Paper III 1094 99 9 66 67 55 83 4.2±1.7
2003, a) Paper IV 957 82 9 75 92 62 83 3.9±1.6
2003, b) Paper V 957 82 9 71 87 58 82 3.9±1.6
1Hafnarfjördur together with Gardabaer in the 1993 study
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random sample comprising children, 1-6 years of age from all the 
study areas; it was drawn from the National Registry, “Statistics Ice-
land”, while in 2003 the sample was a random sample of children, 1-
6 years old, from Hafnarfjordur and including all available children 
of those ages from the other  areas.
Overview of the data presented in the thesis
Table 3 summaries the different sources of data presented in this the-
sis. Table 2 gives an overview of the study areas, ages and numbers 
of participants in the three examination phases described in the dif-
ferent Papers. The lower number of the participants in Tables 2 and 
3, representing Papers II and V is due to the exclusion of 61 children 
from the nasopharyngeal bacteria sampling because of antimicrobial 
treatment during the preceding 14 days in the 1998 study, and 65 
children being excluded from the 2003 study for the same reason.
Table 3. Details on data collection from the different areas.
Type of data Areas Ages
Study 
population
Study 
year
Paper 
number
Prescription data 
from pharmacies
HG (1993), 
H (1998), V, 
E, and B
All ages 34,582 1993 I
27,013 1998 II
Prescription data 
from parents and 
medical records
HG (1993), 
H (1998, 
2003), V, E, 
and B, HH 
(only 1993)
0-6 years 9191 1993 I
1-6 years 804 (743) 1998 III (II)
1-6 years 889 (824) 2003 IV (V)
Data from naso-
pharyngeal bacteria 
sampling
HG (1993), 
H (1998, 
2003), V, E, 
and B, HH 
(only 1993)
0-6 years 9191 1993 I
1-6 years 743 1998 II
1-6 years 824 2003 V
Data from ques-
tionnaire on paren-
tal view
H, V, E, B 1-6 years 804 1998 III
1-6 years 889 2003 IV
Data on acute otitis 
media and tympa-
nostomy tubes
H, V, E, B 1-6 years 804 1998 III
1-6 years 889 2003 IV
1Of these, 791 children were 1-6 years old when area HH was excluded; they were therefore compa-
rable in age to the children studied in phases II and III in 1998 and 2003 (see Table 2.).
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METHODS
Antimicrobial sales statistics
In the 1993 and 1998 studies (I, II) computerised information on 
total sales of oral antimicrobials prescribed during one year for all 
inhabitants, adults as well as children, was collected from the local 
pharmacies (not hospital use) in the four areas HG (1993), H (1998), 
V, E and B. No data on prescriptions were available from the local 
pharmacy in area HH. Numbers of defined daily doses (DDD) were 
calculated per 1000 inhabitants per day (WHO 1992).
Microbiology and nasopharyngeal sampling for pneumococci
Nasopharyngeal samples were obtained with rayon tipped swabs and 
stored for a maximum of 48 hours until being processed in the mi-
crobiology laboratory of the University Hospital. They were then 
inoculated on blood and chocolate-blood agar and incubated aerobi-
cally and anaerobically in 1993 and 1998, but only anaerobically in 
2003. 
Pneumococci were identified by conventional methods and 
screened for penicillin resistance by the oxacillin disc diffusion test 
according the Kirby-Bauer method 1993 (Ruoff 1995; Woods and 
Washington 1995) and according to the NCCLS method and criteria 
in the studies performed in 1998 and 2003 (Jorgensen et al.1999). 
The minimal inhibitory concentration was determined by the agar 
dilution method 1993 (Woods and Washington 1995) and by E-test 
(Tenover et al. 1996) in 1998 and 2003, according to the manufactur-
er’s recommendations (AB Biodisk, Solna, Sweden). The pneumo-
cocci colonies were also screened for susceptibility to tetracycline, 
erythromycin, chloramphenicol and trimethoprim-sulfamethexazole. 
In 2003 clindamycin was added to this screening procedure. 
Penicillin non-susceptible isolates were also serotyped by co-ag-
glutination (Kronvall 1973) using antisera from the State Serumin-
stitute (Copenhagen, Denmark). Further details about the identifica-
tion of bacteria, the screening for antimicrobial resistance, laboratory 
methods and standards are given in Papers I, II and V.
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Information about infectious disease history and socio-demo-
graphic factors
In the 1993 study (I) parents completed a questionnaire. The question-
naire included questions about demographic factors, the number of 
children in the household, whether the children were enrolled in a day 
care centre, the number of oral antimicrobial prescriptions during the 
preceding year, including not only prescriptions made by their GP´s 
but also those made by other specialists, the date and name of the 
last antimicrobial agent, type of infection and whether the child had 
been taking prophylactic antimicrobials for three weeks or more in the 
preceding year. The information collected from parents was matched 
with that available from the medical records at the local healthcare 
centre. Parental information was used when medical records could not 
be traced, especially when children had been seen by other profession-
als outside the study areas (around 5% of the cases).  
In the 1998 and 2003 studies the parents of the participating chil-
dren received postal questionnaires, asking the same questions as in 
the 1993 study, with additional questions about both past and pres-
ent use of tympanostomy tubes. In 2003, there were also additional 
questions about smoking in the household. Parents were also asked 
to complete a questionnaire about their personal preferences regard-
ing antimicrobial treatment in the case of 1) unspecified upper respi-
ratory infections (common cold) and 2) acute otitis media. Parents 
answered the question whether it was always, sometimes or never 
appropriate to give antimicrobials in these two situations, or whether 
they did not know. They were then asked to agree, disagree or give 
no comment (or answer “do not know”) to the following two state-
ments; “Some pathogens are becoming resistant to antimicrobials” 
and “Inappropriate antimicrobial use can lead to antimicrobial resis-
tance problems with common pathogens”. 
Statistical methods
Carriage of penicillin-nonsusceptible or penicillin-susceptible pneu-
mococci was the most important single outcome variable in Papers I, 
II and V. Carriage of erythromycin-resistant pneumococci or eryth-
romycin-susceptible pneumococci was also an outcome variable in 
Paper V. Antimicrobial treatment or not for acute otitis media and 
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the presence or history of tympanostomy tube placements or not 
were the outcome variables in Papers III and IV. Recent (< 8 weeks) 
antimicrobial use for acute otitis media or not for children having 
tympanostomy tubes or not, adjusted for age, were also outcome 
variables in Papers III and IV. 
The Pearson chi-square test or Fisher´s exact test was used for 
univariate analysis of categorical variables and one-way ANOVA for 
continuous variables. The multivariate logistic regression method 
was used to estimate the risk for all variables potentially contribut-
ing to antimicrobial resistance (I, II and V), antimicrobial treatment 
for acute otitis media (III, IV), presence of tympanostomy tube(s) 
(III, IV), and parental willingness to accept antimicrobial treatment 
for the common cold (III) in order to control interdependence. Indi-
vidual regression coefficients were tested with the Wald statistic, and 
confidence intervals were calculated for the odds. All analyses were 
performed with the SPSS® program for Windows (Advanced Statis-
tics Release 6.0 (1993) and 8.0 (1998 and 2003) SPSS Inc, Chicago, 
IL). Linear regression analysis was used to estimate correlation coef-
ficient (r), and the 95% confidence interval for the slope of the mean 
number of antimicrobial courses for acute otitis media compared to 
the tympanostomy tube placement rate (cumulative rate) by areas 
(IV). Linear regression analysis was also used to estimate the cor-
relation between the mean number of total antimicrobial courses and 
the prevalence of parents finding it appropriate to sometimes treat 
common colds with antimicrobials (IV). 
The level of statistical significance was set at 0.05, and 95% con-
fidence intervals were given. Further information about statistical 
methods is given in the separate Papers, I-V. Statistical assistance 
was provided by Júlíus Björnsson and Örn Ólafsson, Landspitali 
University Hospital, Reykjavik.
Ethical considerations
The 1993 study was approved by the Ethics Committee of the Direc-
torate of Health. The 1998 and 2003 studies were approved by the 
National Bioethics Committee and National Data Protection Com-
mission, Iceland. Data on individuals were only collected if the par-
ents had given consent for the participation of their children.  
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RESULTS 
Sales statistics for antimicrobial use in communities (I, II)
The total antimicrobial use during one year in the communities, in-
cluding all ages, was gathered in the 1993 and 1998 studies. A total 
of 22,132 prescriptions were dispensed by local pharmacies in the 
1993 and 15,153 in 1998. The calculated amount used in terms of the 
number of defined daily doses (DDD) per 1000 inhabitants per day 
is shown in Table 4.
Table 4. Antimicrobial use 1993 and 1998 
according to sales statistics, measured as 
the number of defined daily doses (DDD) 
per 1000 inhabitants per day in the study 
areas.
Number of DDD/1000/day
Study area 1993 1998
H 13.61 14.2
V 19.9 17.2
E 16.7 12.3
B 13.6 11.2
1Together with Gardabaer in the 1993 study
Antimicrobial sales according to age, gender and time of year 
(1997-1998) 
When antimicrobial use is analysed as the rate of prescriptions in the 
1998 study (Fig. 7), the highest incidence of prescriptions is among 
pre-school children. Women used more antimicrobials than men and, 
as shown in Figs. 7 and 8. Most antimicrobial use was during the 
winter (Fig. 8).
Fig. 7. Incidence of antimicrobial prescriptions by age and gender in 
the 1998 study (information from annual drug-store sales statistics).
Fig. 8. Antimicrobial use as number of defined antimicrobial doses 
(DDD) per 1000 inhabitants per day by gender and month in the 
1998 study (information from annual drug-store sales statistics).
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Fig.7 (above) and Fig. 8 (below). See text on opposite page.
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Type of antimicrobial drug sales (1997-1998)
The types of drugs prescribed varied according to age. In the young-
est age group, amoxicillin and amoxicillin plus clavulanic acid were 
the most common drugs used, whereas tetracycline dominated in the 
teenage groups (Fig. 9). No big difference was observed between 
areas in the 1997-1998 study when types were analysed as a percent-
age of all antimicrobials prescribed. No difference was observed by 
gender and the type of drug prescribed.
Changes in antimicrobial sales for children between 1993 and 
1998 
In Paper II, antimicrobial sales for children < 7 years old between 
1992-1993 (6,223 prescriptions) (I) and 1997-1998 (3,347 prescrip-
tions) were compared for each area studied. The number of defined 
daily doses/1000 children/day and the number defined daily doses 
per prescription were calculated, for both the total use and each an-
timicrobial group specifically. Antimicrobial use had diminished in 
Fig. 9. Antimicrobial use according to age groups in the study areas 
1997-1998 (information from annual drug-store sales statistics).
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all study areas in terms of both as number of defined daily doses (14­
43%) and the number of antimicrobial treatment courses per year 
(9-50%). The reduction in antimicrobial use was greater for trime-
thoprim-sulfamethoxazole than for other antimicrobials, in one area 
(area V) dramatically or from 7.1 to 1.4 DDD/1000 children/day (II) 
(see also Fig. 2). Overall, there was no change in the number of de-
fined daily doses per prescription between these two periods (II).
Antimicrobial use among pre-school children in the sampled 
groups (I, III, IV)
The use of antimicrobials was commonest in the youngest children, 
as shown in Figure 10. The use was statistically lower in 1998, 1.21 
antimicrobial treatments per child per year (95% CI 1.09-1.32) and 
2003, 1.06 (0.95­1.17) than during the first study period, 1993, 1.51 
(1.39-1.63) but the difference between children of the same age was 
similar in the three studies.
Although the number of antimicrobial courses prescribed for pre-
school children per year, as observed in the sampled children 1-6 years 
Fig. 10. Yearly incidence of antimicrobial treatments per child in 
relation to age in 1993, 1998 and 2003.
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of age, diminished during the 10-year period by about one third, it 
varied between study areas (Fig. 11). This time trend was of statistical 
significance for all areas except for Vestmannaeyjar (area V).
Amoxicillin was most commonly the last antimicrobial drug pre-
scribed before children entered the study in all three studies (1993, 
1998 and 2003), as shown in Figure 12. In the 1993 study, the use 
of trimethoprim-sulfamethoxazole was common (I) but diminished 
dramatically in the 1998 study (II) and further still in the 2003 study 
(V), as also shown in Figure 2 (Total sales of antimicrobial mixtures 
in Iceland 1989-1997, based on sales statistics from the Ministry of 
Health and Social Security). The choice of antimicrobial drugs also 
varied considerably by study area. In 2003, broad-spectrum antimi-
crobials (amoxicillin+clavulanic acid, azithromyzin, erythromycin, 
trimethoprim-sulphamethoxazole) were used in only 23 out of 72 
cases (32%) in area E, where the total antimicrobial consumption 
was lowest, compared with 148 out of 189 cases (78%) in the high-
Fig. 11. Yearly incidence of antimicrobials among children 1-6 years 
of age in different study areas in the 1993, 1998 and 2003 studies.
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consumption area V (p<0.0001) (IV). In 2003 a new antimicrobial, 
azithromycin, had been introduced in the market. This was used 
more in area V (33.3%) than in the other areas and almost not at all 
in the area E (1.5%) (V).
Main diagnoses when prescribing antimicrobials for children 
Figure 13 shows the main reasons for prescribing antimicrobials for 
children 1-6 years of age just before their entry into the study when 
participating in the 1993, 1998 and 2003 studies.
As seen in the figure, acute otitis media was by far the commonest 
reason in all three studies, followed by tonsillitis. Very few children 
were prescribed antimicrobials for sinusitis in the 1993 study, while 
this percentage was 10% and 12% in the studies in 1998 and 2003, 
respectively.
Antimicrobial use for acute otitis media 
Figure 14 shows the percentage of children receiving antimicrobi-
al treatment for a diagnosis of acute otitis media in the previous 12 
months (yearly prevalence) by age in the three studies. Antimicrobial 
Fig. 12. Choice of last antimicrobial group prescribed before study 
entry among 1-6 year old children in the 1993, 1998 and 2003 stud-
ies.
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1993
Fig. 13. Main last diagnosis when prescribing antimicrobials for 
children, aged 1-6, in the 1993, 1998 and 2003 studies.
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Fig. 14. Yearly prevalence as the percentage of children receiving an-
timicrobial treatment for acute otitis media by age and study year.
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treatment was more common in the lower ages studied, 54% (95% 
CI 44-64%) for one-year-old children in the 2003 study. The yearly 
prevalence was statistically lower in the 1998 study for children 1-6 
years old, 35% (95% CI 31-38%) and in the 2003 study, 31% (95% CI 
28-34%) compared with the 1993 study, 48% (95% CI 45-52%).
Figure 15 shows the number of treatments for acute otitis media 
in the previous year by age (yearly incidence). The results are in 
agreement with those shown in Figure 10.
Over the study period, the yearly incidence of antimicrobial treat-
ment because of acute otitis media decreased from 1.02 (95% CI 
0.92-1.12) in the 1993 study to 0.70 (95% CI 0.61-0.79) in the 1998 
study and further but not significantly, down to 0.60 (95% CI 0.52­
0.68) in the 2003 study. In the 2003 study, the incidence was high-
est for two-year-old children, 1.35 (95% CI 1.03-1.68), 1.27 (95% 
CI 0.93-1.61) for one-year-old children, 0.65 (95% CI 0.50-0.80) 
for tree-year-olds, 0.37 (95% CI 0.26-0.47) for four-year-olds, 0.20 
Fig. 15. Yearly incidence of antimicrobial treatment for acute otitis 
media per child in relation to age and study year.
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(95% CI 0.11­0.28) for five­year­olds and 0.14 (95% CI 0.07­0.21) 
for six-year-old children. Figure 16 shows the number of treatments 
for acute otitis media during the preceding year in the three studies 
in the different areas. Similarly to what was shown in Figure 11, 
there was a significant decrease in all the areas except for Vestman-
naeyjar (area V).
Predictors for antimicrobial prescribing for acute otitis media  
The child’s age (younger age), history of tympanostomy tubes (past 
or present) and residence in area V, were independently associated 
with the number of antimicrobial treatments for acute otitis media 
(IV). In the 1998 study (III), this was the case only for younger age. 
Smoking in the family household did not influence the odds for 
whether children received antimicrobials for acute otitis media or 
not in the 2003 study. 
Fig. 16. Yearly incidence (95% confidence interval) of antimicrobial 
treatment for acute otitis media per child in different areas studied in 
1993, 1998 and 2003.
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Association between parental expectations and doctor’s prescrip-
tion habits for management of upper respiratory tract infections in 
children 
In both the 1998 and 2003 studies (III, IV), the vast majority of par-
ents (80-90%) in all areas agreed to the following two statements: 
“Some pathogens are becoming resistant to antimicrobials” and “In-
appropriate antimicrobial use can lead to antimicrobial resistance 
problems with common pathogens”.
Table 5 shows the results of the questionnaires about what the 
parents considered appropriate antimicrobial usage for the common 
cold and for acute otitis media in the total number of participants in 
the 1998 (III) and 2003 (IV) studies. 
Table 5. Parents’ views on appropriate antimicrobial treatment as reported in 
questionnaires from the 1998 and 2003 studies (percentage in brackets).
Year Always Sometimes Never Don’t know
Is it appropriate to give antimicrobial treatment for unspecified upper respira-
tory tract infections (common cold)?
1998 1 (0.1) 346 (43.4) 377 (47.3) 73 (9.2)
2003 0 (0) 394 (45.0) 420 (48.2) 59 (6.8)
Is it appropriate to give antimicrobial treatment for acute otitis media?
1998 66 (8.3) 686 (86.0) 13 (1.5) 33 (4.1)
2003 75 (8.5) 757 (86.3)   6 (0.7) 39 (4.4)
The vast majority of parents in all the areas were also of the opin-
ion that acute otitis media should only sometimes be treated with 
antimicrobials. Very few stated that antimicrobial treatment was al-
ways indicated for treating a common cold, while a similar percent-
age of parents stated “sometimes” and “never”. At the community 
level (IV), a significant correlation was found between the children’s 
total use of antimicrobials and the percentage of parents considering 
it sometimes appropriate to treat a common cold with antimicrobi-
als (r = 0.99, p = 0.01). In area E, where the prescription rate was 
lowest, it was also commonest for the parents to state that antimi-
crobial treatment was never necessary for treatment of a common 
cold, both 1998 and 2003 (III, IV). The response from parents to the 
questionnaire addressing issues of parental expectations and aware-
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ness, further indicated that parents who consider it inappropriate to 
treat unspecified upper respiratory tract infections with antimicrobi-
als significantly more often preferred that acute otitis media not be 
treated with antibiotics (III). They also more often considered it ap-
propriate to prescribe antimicrobials for unspecific upper respiratory 
tract infection if their child had previously received antibiotics for 
acute otitis media (III).
Tympanostomy tube placements (III, IV)
Figure 17 shows the cumulative prevalence of being subjected to 
tympanostomy tube insertion as reported in the 1998 and 2003 stud-
ies. About one third of the children had tympanostomy tube(s) cur-
rently or earlier. The curves for cumulative prevalence of tympanos-
tomy tubes during the first six years were similar in the 1998 and 
2003 studies.
From 1998 to 2003 there was an increase in tympanostomy tube 
__  __
_____
Fig. 17. Cumulative prevalence as a percentage (95% confidence 
interval) of use of tympanostomy tubes 1998 and 2003 among 1-6 
years old children in the study areas.
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placements in areas V (34.8 to 44.1%, p=0.034) and H (26.1 to 
36.8%, p=0.006), where antimicrobial prescription rates were high-
est, and a decrease in areas E (26.4 to 17.2%, p=0.049) and B (34.0 
to 24.6%, p=0.299), where the antimicrobial rates were lowest. In 
area E antimicrobial use had also diminished significantly  (IV). 
Table 6 shows the odds ratio for having tympanostomy tube(s), 
compared with those not having tympanostomy tube(s) for various 
variables studied. Odds ratios were significantly higher for residents 
of area V versus area E, day care attendance, and treatment with an-
timicrobials for acute otitis media, but not for gender or smoking in 
the family household (IV).
Table 6. Odds ratio by multivariate analysis, adjusted for age, for children 1-6 
years old having tympanostomy tube(s) at present (n=123) as opposed to not 
having tube(s) (n=736) in the 2003 study. 
Variable No. Odds ratio 95% CI p-value
Residence
Area V 314 1
Area E 214 0.35 0.17-0.64 0.0021
Area B 61 1.02 0.46-2.24 0.97
Area H 270 0.81 0.50-1.30 0.38
Gender
Female 407 1
Male 452 1.28 0.84-1.94 0.25
Day care
No 71 1
Yes 788 2.38 1.07-1.72 0.0317
Smoking in the family household
No 701 1
Yes 158 1.01 0.60-1.72 0.95
Number of antimicrobial treatments for acute otitis media during the last 12 
months
0 594 1
1-2 203 1.96 1.22-3.17 0.0059
>3 62 4.98 2.60-9.53 0.0001
Multivariate analysis (859 cases analysed, data missing in 30 cases) 
Overall significance: chi­square = 100.176, df = 9, p < 0.0001
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Association between tympanostomy tube placements and antimi-
crobial use 
Based on analyses by individuals, there was an association between 
having at present tympanostomy tube(s) and antimicrobial use be-
cause of acute otitis media in the last 12 months among children 1-6 
years old, as observed when studying these two factors in the 2003 
study (Table 6) (IV). There was also a significant association between 
the use of antimicrobials for acute otitis media and cumulative preva-
lence of tympanostomy tube placement as observed on the community 
level when plotting the data for the different areas studied 2003 (IV). 
In Figure 18, changes in the use of tympanostomy tubes over the last 
five years are plotted against changes in use of antimicrobials (as a 
percentage) for acute otitis media in the different areas involved. Even 
though the association was not statistically significant (p = 0.138), in 
area E, there was a concomitant and significant decrease both for tym-
panostomy tube placements in children and for antimicrobial treat-
ment of acute otitis media as mentioned earlier (IV).
Effects of tympanostomy tubes on recent antimicrobial drug con-
sumption 
In 2003, of a total of 123 children having tubes (at present), 49 (40%) 
had received oral antimicrobials at least once during the previous 
8 weeks, compared with 124 of 737 children (17%) without tubes 
(p<0.001). Considering only antimicrobial treatment for acute otitis 
media, 25 children (20%) in the tympanostomy group had recently 
received antimicrobials, compared with 74 children (10%) among 
those without tubes (p<0.001). Adjusting for age, the odds ratio for 
receiving antimicrobials recently was significantly higher for chil-
dren with tubes (p<0.001) (IV). In 1998, this difference was not sta-
tistically significant (III).
Antimicrobial resistance in pneumococci (I, II, V)
Carriage of penicillin-nonsusceptible pneumococci
In the 1993 study, including only children 1-6 years old, pneumo-
cocci were found in 426 (53.9%) of 791 children. In 36 (8.5% of all 
children carrying pneumococci), the pneumococci were penicillin-
nonsusceptible. In the 1998 study, pneumococci were found in 384 
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(51.7%) of 743 children, and in 31 (8.1% of all children carrying 
pneumococci), the pneumococci were penicillin-nonsusceptible. In 
the 2003 study, 525 of 824 children studied (63.7%) carried pneumo-
cocci, and 50 (9.5%) were penicillin-nonsusceptible. If only type-
able strains of pneumococci are taken into account, then 31 (5.9%) 
were penicillin-nonsusceptible in the 2003 study. 
A comparison between the three study periods concerning preva-
lence of PNSP is shown in Table 7. The carrying rate was highest 
in area V in the 1993 study (18.2%), in area E in the 1998 study 
(18.8%) and in area H in the 2003 study (13.0% or 10.6% if non-
typeable strains are excluded) (II, V).
 
Fig. 18. Differences in the use of tympanostomy tubes (cumulative 
prevalence) in relation to change (%) in the use of antimicrobials 
(yearly incidence) for acute otitis media between 1998 and 2003 for 
the different studies areas.
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Table 8 shows the numbers of children carrying pneumococci and 
percentages carrying PNSP in the 1993 study. Resistance was more 
common in the youngest children, those less than two years of age, 
compared with the children who were 2-6 years of age (I). This as-
sociation was confirmed by multivariate analysis. In the 1998 study, 
age was also significantly associated with the presence of PNSP in 
univariate analysis (II), while no significant association was ob-
served in the 2003 study (V).
Carriage of erythromycin-resistant pneumococci
Antimicrobial susceptible testing was done for all pneumococcal 
colonies, both penicillin-susceptible and penicillin-nonsusceptible. 
As shown in Table 9, resistance to trimethoprim-sulfamethoxazole 
is not so uncommon among penicillin-susceptible pneumococci and 
erythromycin resistance among penicillin-susceptible pneumococci 
Table 7. Prevalence of penicillin-nonsusceptible pneumococci as observed in 
the studies in 1993, 1998 and 2003.
Study year Total study 
group
Pneumococci
present
Penicillin-nonsusceptible 
pneumococci present
Number Number Number %1
1993 791 426 36 8.5
1998 743 384 31 8.1
2003 824 525 50 9.5
2003 824 525 31a) 5.9
2003 824 525 19b) 3.6
1Of all pneumococcal carriers, 
a) Typeable-stains, 2003
b) Non-typeable (non-encapsulated) strains, 2003
Table 8. Penicillin-resistant pattern for pneumococci in children in the 1993 
study by age groups.
Study year Total study 
group
Pneumococci
present
Penicillin-nonsusceptible 
pneumococci present
Number Number Number %1
<2 years 238 114 23 20.2
2-6 years 681 370 24 8.1
1Of all pneumococcal carriers, 
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increases significantly between 1998 (II) and 2003 (from 2% to 7.8%, 
p < 0.001) (V). They increased in areas H and V (p = 0.0004 and p < 
0.0001, respectively), but decreased in the other two areas (E and B, 
p = 0.05 and p = 0.6, respectively). However, the proportion of eryth-
romycin-resistance among PNSP decreased in 2003 but though not 
significantly (p<0.1), mainly because of increased rate of erythromy-
cin-susceptible PNSP, serotype 9V (in area H) and 14 (in area E) (V).
Penicillin-resistance among pneumococci and antimicrobial use 
When analysed for all areas combined, the prevalence of carrying 
PNSP remained similar during the years studied, but decreased for 
serotype 6B  (Fig. 19), at the same time as antimicrobial use dimin-
Fig. 19. Changes in antimicrobial use among 1-6 year old children in 
the four study areas and the carriage rate of penicillin-nonsusceptible 
pneumococci (PNSP) 1993, 1998 and 2003. Data from antimicrobial 
sales statistics in study areas for children < 7 years old, 1992-1993 
and 1997-1998, are also shown for comparison.
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Table 9. Number (No) of penicillin-susceptible (PSP) and nonsusceptible pneu-
mococci (PNSP), which are nonsusceptible (intermediate or resistant) to eryth-
romycin (ERY), tetracycline (TET) chloramphenicol (CHL) and trimethoprim-
sulfamethoxazole (SXT) according to disc diffusion tests, in 1993, 1998 and 
2003, in respective study areas.
Area Year ERY TET CHL SXT
No No % No % No % No %
H PSP 1993 256 0 0 1 3.0 0 0 62 24.4
  1998 163 1 0.6 1 0.6 0 0 46 28.8
  2003 134 13 9.7 2 1.5 0 0 34 25.4
PNSP 1993 24 20 83.3 22 91.7 13 54.2 24 100
  1998 11 7 63.6 8 72.7 8 72.7 11 100
  2003 20 10 50.0 10 50.0 4 20.0 20 100
V PSP 1993 45 2 4.4 2 4.4 0 0 17 37.8
  1998 117 0 0 0 0 0 0 25 20.7
  2003 199 21 10.6 3 1.5 0 0 50 25.1
 PNSP 1993 10 9 90.0 9 90.0 10 100 10 100
  1998 5 5 100 5 100 5 100 5 100
  2003 15 14 93.3 14 93.3 9 60.0 15 100
E PSP 1993 51 0 0 0 0 0 0 12 23.5
  1998 56 4 7.1 2 3.6 0 0 10 17.9
  2003 108 1 0.9 0 0 0 0 41 38.0
 PNSP 1993 1 1 100 1 100 1 100 1 100
  1998 13 13 100 13 100 13 100 13 100
  2003 12 8 66.7 7 58.3 0 0 12 100
B PSP 1993 38 0 0 0 0 0 0 6 15.8
  1998 17 2 11.8 2 11.8 0 0 12 70.6
  2003 34 2 5.9 0 0 0 0 2 5.9
 PNSP 1993 1 1 100 1 100 1 100 1 100
  1998 2 2 100 2 100 1 50.0 2 100
  2003 3 2 66.7 2 66.7 0 0 3 100
TOTAL PSP 1993 390 2 0.5 3 0.8 0 0 97 25.0
  1998 353 7 2.0 5 1.4 0 0 93 26.6
  2003 475 37 7.8 5 1.1 0 0 127 26.7
 PNSP 1993 36 31 86.1 33 91.6 25 69.4 36 100
  1998 31 27 87.1 28 90.3 27 87.1 31 100
  2003 50 34 68.0 33 66.0 13 26.0 50 100
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ished by about one third from 1993 to 2003. The association between 
changes in antimicrobial use and the carrying rate of PNSP, multire-
sistant, serotype 6B (Spain6B-2) over the 10 years in each area will be 
described below (Fig. 24).
Associations with PNSP-carrying in children carrying pneumococci 
Already at the time of the first study in 1993 (Paper I), the prevalence 
of PNSP was higher among children who had taken antimicrobials. 
Of 317 children participating in the 1993 study who had received 
antimicrobials during the preceding year, 44 (13.9%) carried PNSP 
compared with 3 out of 167 (1.8%) of those who had not received 
antimicrobials during the preceding year (p<0.001). Antimicrobial 
use was also found to be significantly associated with the carriage of 
PNSP in the 1998 and 2003 studies (II, V). This was confirmed with 
multivariate analysis of the data (I, II, V) as an increasing risk of 
PNSP carriage with an increasing number of antimicrobial treatment 
courses. When the data were examined specifically for treatment of 
acute otitis media in the 1998 (II) and 2003 studies (data not shown), 
this association also held true (p<0.001). 
Table 10 shows the results of a multivariate, backward, stepwise, 
logistic model including the factors discussed above, together with 
some other factors that had proved statistically significant in rela-
tion to antimicrobial resistance in univariate statistical analyses (II, 
V). Data from 1993 were recalculated to make them comparable. 
Excluding the number of antimicrobial treatments that were signifi-
cantly associated with PNSP carriage in all three analyses, age and 
residence were inconsistently found to be independent risk factors 
for carriage of PNSP. 
No single antimicrobial class could conclusively be shown to be 
more definitively associated with carriage of PNSP in all the three 
studies. However, some treatment groups were small. In the 1993 
study, trimethoprim­sulfamethoxazole was significantly associated 
with carriage of PNSP by univariate analysis (I). Children in area V 
had significantly higher odds than other children of carrying PNSP 
in 1993 by multivariate analysis (I), and the PNSP, multiresistant, se-
rotype 6B prevalence has remained surprisingly stable in this com-
munity between 1998 and 2003 (V). The most likely explanation was 
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much higher total use of antimicrobials, especially trimethoprim-sul-
famethoxazole and erythromycin in 1993 (I) and azithromycin in 2003 
(V) in this area.
The carriage rate of PNSP was also associated with the lapsed time 
since the last course of antimicrobials as shown in Figure 20. As seen 
in the figure, the prevalence of PNSP was higher in children who had 
taken antimicrobials recently (last 2-7 weeks).
The observation of an association between recent antimicrobial use 
and carriage of PNSP was confirmed in multivariate analysis of data 
from all phases of our studies. Recent antimicrobial use (2-7 weeks 
since last treatment) instead of the number of antimicrobial courses 
Table 10. Odds ratio (OR) of carrying penicillin-nonsusceptible pneumococci as 
opposed to penicillin-susceptible pneumococci by backward, stepwise, logistic 
regression method in the studies in 1993a), 1998b) and 2003c).
Variable Number OR 95% CI P value
Age, 1993a) 424 0.70 0.52-0.96 0.025
Residence, 1993a) Area H 279 1 (refer-
ence area)
Area V 55 2.62 1.00-6.81 0.048
Area E 52 0.23 0.03-1.81 0.163
Area B 38 0.31 0.04-2.43 0.266
Number of antimicro-
bial treatments in last 
12 months, 1993a) 424 1.32 1.11-1.58 0.002
Residence, 1998b) Area H 170 1 (refer-
ence area)
Area V 122 0.519 0.17-1.62 0.260
Area E 67 4.139 1.65-10.39 0.003
Area B 19 1.852 0.36-9.50 0.460
Number of antimicro-
bial treatments in last 
12 months, 1998b) 378 1.50 1.23-1.82 0.0001
Number of antimicro-
bial treatments in last 
12 months, 2003c) 506 1.28 1.11-1.48 0.007
a) Number of children in analysis, 1993 = 424, X2 = 35.87, df = 5, p < 0.0001.
b) Number of children in analysis, 1998= 378, X2 = 25.49, df = 4, p < 0.0001 (II).
c) Number of children in analysis, 2003= 506, X2 = 10.412, df = 1, p = 0.013 (V).
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in the preceding 12 months was the only variable constantly associ-
ated with PNSP carriage in all the analyses from the three studies (V). 
Figure 21 shows the odds ratio for different variables studied in 1993, 
1998 and 2003 by using the results of similar multivariate logistic 
models, including all possible risk factors for PNSP carriage against 
carriage of penicillin-susceptible pneumococci. The passage of 2-7 
weeks from the last antimicrobial treatment compared with > 8 weeks, 
was consistently the only significant risk factor for carriage of PNSP 
in all three analyses.
Risk of PNSP carriage after receiving antimicrobials for all chil-
dren (i.e., not only those carrying pneumococci) 
In our first study in 1993 (I), 580 children of 919 had received anti-
microbials over the previous 12 months, and 191 had received treat-
ment 2-7 weeks before sampling, of which 27 were carrying PNSP, 
as opposed to only 17 out of 389 children who had received antimi-
Fig. 20. Carriage rate of penicillin-nonsusceptible pneumococci 
(PNSP) of all children carrying pneumococci, 1-6 years of age, re-
lated to time from last antimicrobial treatment (2-7 weeks or 8-52 
weeks) or no treatment in the studies in 1993, 1998, and 2003.
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crobials 8-52 weeks before study entry (p<0.0001). Corresponding 
figures from the 1998 study (II) show that of 743 children, 372 had 
received antimicrobials in the previous 12 months; thereof 11 of 129 
children receiving antimicrobials in the previous 2-7 weeks carried 
PNSP, as opposed to only 8 out of 243 children receiving antimicro-
bials 8-52 weeks before sampling carrying PNSP (p=0.045). Cor-
responding figures for the 2003 study (V) show that of 824 children, 
357 children had received antimicrobials in the preceding 12 months. 
Of these 16 out of the 104 children that had received antimicrobials 
Fig. 21. Adjusted odds ratio (95% confidence interval) for carrying pen-
icillin-nonsusceptible pneumococci (PNSP) or not according to multi-
variate logistic regression analysis in studies in 1993, 1998 and 2003.
(Number of children in analysis 1993 = 426, X2 = 46.72, df = 8, 
p < 0.0001. Number of children in analysis 1998 = 384, X2 = 22.12, 
df = 9, p = 0.0085. Number of children in analysis 2003 = 510, X2 = 
31.47, df = 11, p = 0.0009)
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in the preceding 2-7 weeks carried PNSP, as opposed to only 18 out 
of 253 children receiving antimicrobial treatment 8-52 weeks before 
sampling carrying PNSP (p=0.027). 
Figure 22 shows the carriage of penicillin-susceptible (PSP) and 
PNSP of all children receiving antimicrobials (i.e., not only of those 
carrying pneumococci) for the three studies by the number of weeks 
from the last antimicrobial treatment. Relatively speaking the num-
ber of PSP strains are similar to the number of PNSP strains two to 
three weeks after antimicrobial treatment.
Fig. 22. Carriage rate (95% confidence interval) of penicillin­sus-
ceptible (PSP) (green) (n=648) and penicillin-nonsusceptible pneu-
mococci (PNSP) (red) (n=97) by all children receiving antimicrobi-
als during the 12 months prior to study entry (n=1315) for the 1993, 
1998 and 2003 studies, by the number of weeks from the last antimi-
crobial treatment.
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Fig. 23. Spread of different serotypes of penicillin-nonsusceptible 
pneumococcus (PNSP) as carrying ratio (%) of all pneumococci ob-
served in the studies in 1993, 1998 and 2003.
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Factors associated with carriage of erythromycin-resistant pneu-
mococci
All the variables tested for association with carriage of PNSP were 
also tested for association with carriage of erythromycin-resistant 
pneumococci with a multivariate, backward, stepwise, logistic re-
gression model in the 2003 study (V). As for PNSP carriage, the num-
ber of antimicrobial treatments was the only independent risk factor 
for carriage of erythromycin-resistant pneumococci, with an odds 
ratio of 1.18 for each treatment (95% CI 1.03-1.35), p=0.0157.
Spread of resistant strains 
In the 1998 study the carrying rate of PNSP, multiresistant, serotype 
6B, 7.5%, was similar to the 1993 study, 7.7% but decreased in the 
2003 study to 2.5% (p <0.001). On the other hand, new typeable 
PNSP strains (seroptypes 9V and 14) appeared in 2003 along with a 
new non-typeable (non-encapsulated) serotype, as shown in Fig. 23 
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(V). The new non-typeable PNSP serotype was found in all study 
areas. Serotype 9V was found only in area H and a new serotype 14 
only in area E.
Clonal spread of PNSP of multiresistant 6B strain (Spain6B-2) in 
different communities
When studying different areas separately, obvious differences be-
tween how the prevalence of PNSP of multiresistant serotype 6B 
(phenotypically identical according to antibiotic susceptibility test-
Fig. 24. The prevalence of penicillin-nonsusceptible pneumococci 
(PNSP) of multiresistant serotype 6B (the Spain6B-2 clone) as a car-
riage rate of all pneumococci and use of antimicrobials in the sample 
groups, as observed in the study areas in the 1993, 1998 and 2003 
studies (♦---♦). Data from antimicrobial sales statistics in the study 
areas for children < 7 years old, 1993 and 1998 are also shown for 
comparison (•---•).
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ing as the Spain6B-2 clone) changed in these areas were observed 
(II, V). The PNSP 6B strain was quite common in area V and area 
H in the south, near Reykjavik, the capital of Iceland, already in the 
1993 study but decreased in the next two studies (Fig. 24). This may 
be compared with what was observed in areas E and B in the east 
and west, remote areas, where the prevalence was low in the 1993 
study but increased considerably in 1998 and had disappeared again 
in 2003. As can also be seen in Figure 24, the use of antimicrobials 
was lower in the later studies, but there seems to be no obvious cor-
relation between total use of antimicrobials in the community for 
children and increase or decrease in the prevalence of the multiresis-
tant PNSP 6B strain (the Spain6B-2 clone).
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DISCUSSION
Starting-points when planning the studies
There were many reasons for focusing my research in primary 
healthcare in Iceland on upper respiratory tract infections and the 
use of antimicrobials drugs among children. Upper respiratory tract 
infection and especially acute otitis media, continues to be one of 
the most common childhood infections and source of morbidity in 
children (Söderström 1995; Rovers et al. 2004). Acute otitis media 
is one of the commonest reason for a child visiting a GP, and also 
the most common reason for antimicrobial prescription (McCaig 
and Hughes 1995; Arason et al. 1996; McCaig et al. 2002; Rovers 
et al. 2004). The prevalence of PNSP of multiresistant serotype 6B 
(now recognised as Spain6B-2) increased rapidly in Iceland after its 
first appearance 1989. The prevailing knowledge at that time indi-
cated a causal relationship between antimicrobial use and develop-
ment of resistant strains of pathogens not only in hospital settings 
(McGowan 1983) but also possibly in communities (Molstad et al. 
1988; Molstad and Hovelius 1989; Eliasson et al. 1990; Molstad et 
al. 1992; Reichler et al. 1992). GPs’ prescription pattern in different 
areas have been shown to differ, which might make a study of anti-
microbial prescription in relation to bacterial resistance pattern both 
interesting and important. 
When planning the study, it was known that the prescription of 
antimicrobials was commoner in Iceland than in the other Nordic 
countries. Acute otitis media in a child was found to be the most 
common reason for prescribing an antimicrobial for a child, and 
this was a reason for focusing the study on children with special 
reference to the treatment of acute otitis media. International rates 
of antimicrobial prescriptions and tympanostomy tube placements 
for otitis media vary greatly, which can be explained largely by the 
lack of uniform evidence-based guidelines (Schilder et al. 2004). Al-
though tympanostomy tube placement has been a well-established 
treatment option for chronic effusion in the middle-ear and recurrent 
episodes of acute otitis media, the prevalence rate of tympanostomy 
tube placements in Iceland during the planning of phase II of this 

study was not known at that time. It was therefore deemed of in-
terest to include a study of tympanostomy tubes in the study plan, 
with special focus on the potential association between frequent use 
of antimicrobials and the tympanostomy tube placement rate on the 
community level, especially in the third phase of the study where 
time trends could also be observed. 
Iceland should be a suitable country for studying the associations 
between antimicrobial use and the development of resistance in 
common pathogens like pneumococcus in the community. Prescrip-
tion patterns can easily be described, thanks to: computerised infor-
mation in the primary healthcare centres, computerised information 
from the local pharmacies and the organisation of healthcare in Ice-
land, where people, at least outside the capital of Reykjavik, visit 
their own primary healthcare centre and their own pharmacy. Be-
cause of the special geography of Iceland, areas are, to some extent, 
isolated from each other; this makes it easier to study changes in 
resistance patterns or to follow up newly recognised resistant clones. 
Furthermore, the prescription patterns of GPs in different areas has 
been shown to differ in Iceland, which might make a study of antimi-
crobial prescription in relation to bacterial resistance patterns even 
more interesting. 
Performance of the studies
This thesis is mainly based on the following basic examinations:
• Prescription studies on all antimicrobial sales, carried out in 
1992-1993 and 1997-1998, including all ages, and involving 
the pharmacies of the study areas. 
• Sampling of nasopharyngeal bacteria, cultivation for pneumo-
cocci with serotyping of PNSP strains and study of their resis-
tance pattern; this sampling included children up to 6 years old 
in 1993 and was confined to children 1­6 years old in 1998 and 
2003.
• Questionnaire about socio-demographic factors and history of 
previous use of antimicrobials and causes in the same chil-
dren and on the same occasions as mentioned in the preceding 
point. 
• Questionnaire to parents about personal preferences in relation 
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to antimicrobial treatment for upper respiratory tract infections 
1998 and 2003. 
• Questionnaire about previous and present history of tympa-
nostomy tube use in 1998 and 2003.
It was possible to carry out all these examinations according to 
plan. The co-operation with the local pharmacies was excellent, as 
was the co-operation with the GPs and other personnel at the in-
volved primary healthcare centres and the laboratory where pneu-
mococci cultivation was done.
The co-operation with the personnel at the day care centres as 
well as with the children and their parents was also very good, and 
in the studies based on random sampling or all available children 
(II­V), the participation rates were high, 75­90%. In the first phase, 
where sampling was from all available sick and healthy 0-6-year-old 
children, the participation rate was also high (15-38% of total popu-
lation under 7 years old).
In summary this means that the prerequisites and the performance 
of the different examinations were of high quality, facilitating the 
drawing of safe (accountable) conclusions when analysing the data.
Antimicrobial use 
The use of drugs by sales statistics, measured as number of defined 
daily doses (DDD) per 1000 inhabitants per day, is useful when com-
paring nations and whole communities (Medicines consumption in the 
Nordic countries http://www.nom-nos.dk/nomesco.htm , last viewed 
Mai 2006 ; Goossens et al. 2005). One defined daily dose is by defini-
tion the certain therapeutic amount (for example in milligrams) of a 
drug needed by an adult person per day. Although this calculation can 
be used to describe the amount (in milligrams) used in each age group, 
it does not give a clear picture when comparing therapeutic doses for 
children and adults. Therefore, the prescription rate (incidence rate) is 
better for demonstrating differences in consumption between children 
and adults as was demonstrated in Figure 7. 
As observed in a previous Icelandic study (Njalsson and McAu-
ley 1992), women use the healthcare centres more than men and 
use more drugs. This is also true regarding the use of antimicrobials 
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specifically, as shown in our study. It is, however, worth noting that 
this gender difference first becomes apparent in the early teenage 
years. This is in accordance with results from other studies showing 
that women have more episodes of respiratory tract infections than 
men, probably due to the fact that women have closer contact with 
children, both at home and in child-related work (Monto and Ullman 
1974; Söderström 1995). 
Seasonal variation with the highest peak of antimicrobial use in 
late winter has been reported from previous studies (Söderström 
1995; Goossens et al. 2005). It was also confirmed in our study. Viral 
infections like the common cold are far more common than bacterial 
infections (Benediktsdottir 1993; Monto 1994; Söderström 1995) 
and more common during the winter, but it can sometimes be hard 
to distinguish accurately between viral and bacterial infections clini-
cally (Heikkinen and Chonmaitree 2003). This can partly explain 
why antimicrobial prescriptions are so prevalent during the winter 
in Iceland like in other countries with heightened winter peaks with 
high yearly use of antibiotics (Goossens et al. 2005). This means also 
that the peak load of infections in people seeking healthcare service 
in Iceland is during late winter, and this was one of the reasons that 
we mainly collected the nasopharyngeal specimens March to May.
 A child with a bacterial upper respiratory tract infection often 
has a clinical picture of symptoms involving more than one site, in-
cluding the middle-ear, nose and throat. The higher prescription of 
antimicrobials for sinusitis in 1998 and 2003 than in 1993 possibly 
depends on a shift from stating acute otitis media as the main diag-
nosis to sinusitis when prescribing antimicrobials is deemed to be 
needed. In others studies, antibiotics are also frequently prescribed 
for children with unspecified upper respiratory tract infections and 
bronchitis, despite recommendations to the contrary (Howie 1983; 
Hamm et al. 1996; Schwartz et al. 1997; Nyquist et al. 1998; Wang et 
al. 1999). A frequent claim, which has not been adequately studied, 
is that restrictions in social security systems make people go to work 
even though they or their children suffer from infections. As a con-
sequence of this social pressure, children “have to” be treated with 
anti-infective drugs to be able to go to school or day care centres 
(Agenas et al. 1995; Jonsson and Haraldsson 2002).
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A phenomenological investigation in Iceland of why GPs pre-
scribe antimicrobials in cases when there are no clear signs of bacte-
rial infections, called “non-pharmacological prescriptions of antibi-
otics” concludes that the principal causes of such use of antibiotics 
are “the lack of stable doctor-patient relationships due to lack of con-
tinuity in medical care, pressure from patients in a stressful society, 
physician’s work pressure, the physician’s own personality, particu-
larly the earnings incentive and service mentality and, last but not 
least, the physician’s lack of confidence and uncertainty, resulting in 
use of antibiotic prescriptions as a coping strategy in an uncomfort-
able situation” (Petursson 2005 a).
Antibiotic utilisation among Icelandic children, age < 7 years, in 
our study 1998 (II), varied between areas in similar amount (from 
7.6 to 17.1 DDD/1000 children/day) as was shown in others studies 
the same year between various Danish and Swedish counties (from 
8.0 to 19.7 DDD/1000 children/day) (Melander et al 2000; Melander 
et al. 2003). “The observed variations in antibiotic prescribing may 
reflect different parental and/or prescribes attitudes towards use of 
antibiotics and they emphasise that antibiotic prescribing is influ-
enced by factors other than the prevalence of bacterial infections. 
Relationships between socio-economic position (educational level) 
and drug utilisation should not be generalised from one area to an-
other” (Melander et al. 2003).
The first part of the study was followed by an unstructured na-
tionwide campaign to reduce unnecessary antimicrobial use for up-
per respiratory tract infections, mainly in children. The interventions 
consisted of information and education of both the public through 
mass media and of physicians through meetings and the Icelandic 
Medical Journal. Prudent antimicrobial use was encouraged espe-
cially for acute otitis media. New antimicrobial prescription guide-
lines were prepared and made available on the Internet (1997) http://
lyf.landlaeknir.is/Brad_eyrnabolga_barna.htm (last viewed in Janu-
ary 2006). Simultaneously a greater reduction in antimicrobial sales 
for trimethoprim-sulfamethexazole statistics was observed than for 
other antimicrobials. Indirect effect of social (parental educational 
level) and climatological factors (on infection rate) on antimicrobial 
use are possible but unlikely in our study but are reported to be indi-
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rect force on antimicrobial use and resistance in Spain (Garcia-Rey et 
al. 2004). A  national ambulatory medical survey in North-America 
show dramatic decline (~40%) in the population based prescribing 
of antimicrobial agent to children and adolescents from 1990 to 2000 
and 47% decline because of otitis media specifically (McCaig et al. 
2002). The bad news is that during the 1990´s, a shift occurred from 
using targeted narrow-spectrum antimicrobials (the second compo-
nent of appropriate antimicrobial use) to broad-spectrum antimicro-
bials for children, from 23% to 40% (Steinman et al. 2003). The use 
of second-generation macrolides (including azithromyzin) among 
children has increased dramatically in North-America, even among 
younger children, for whom use for initial treatment of illness is not 
recommended (Stille et al. 2004). Changes in antimicrobial prescrib-
ing in our study and increasing use of broad-spectrum antimicrobials 
in some study areas along with high antimicrobial use will however 
be further discussed her below in connection with changes in the 
antimicrobial treatment options for acute otitis media over the study 
period and in the chapter “Amount and type of antimicrobials associ-
ated with resistance in the community”.
The incidence of antimicrobial treatments because of acute otitis 
media was found to be similar in our 2003 study as has been reported 
to the incidence of diagnosed acute otitis media for children in ear-
lier studies from the United States (Teele et al. 1989; Paradise et al. 
1997) and from Finland (Alho et al. 1991). There is more opportunity 
for the spread of respiratory infections and also a higher rate of acute 
otitis media among children in day care settings (Wald et al. 1988; 
Uhari et al. 1996; Rovers et al. 1999). In our studies, ~80% of all the 
children attended day care. The child’s age (younger age), residence 
in a high antimicrobial consumption area and history of tympanos-
tomy tubes (past or present), were independently associated with the 
number of antimicrobial treatments for acute otitis media (IV). In the 
1998 study (III), this was only the case for younger age and the high 
antimicrobial consumption area. 
The prescription of antimicrobials for children, particularly the 
prescriptions for acute otitis media, decreased considerably in the 
communities over the study period; in some areas the decrease is 
dramatic. The difference in prescriptions of antimicrobials was rath-
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er small between different areas at the beginning of our study period, 
but increased, and, at the end of the period, it was three times higher 
in the area where the prescription rate was highest, compared with 
the area where it was lowest. Not only is the prescription rate of 
antimicrobials different from one area to another in the end of our 
study but also the choice of an antimicrobial agent when prescribing 
an antimicrobial. Broad-spectrum antimicrobials, especially azithro-
mycin, were more often prescribed in areas where the total antimi-
crobial use was highest. Success in this aspect in some areas and not 
others is of special interest and may have complex explanations.
 A recent study addressed the phenomenon of varying clinical 
“mindlines” among primary healthcare practices in the United King-
dom (Gabbay and le May 2004). The authors found out that expe-
rienced GPs rarely use explicit evidence from research. They create 
shortcuts in their decision making, based on a combination of inputs 
and impulses from their professional surroundings, such as trusted 
colleagues and opinion leaders, written guidelines, material from pa-
tients, and pharmaceutical representatives. 
Parents in the area where antimicrobial consumption was lowest 
and narrow-spectrum antimicrobials were most often used, were less 
likely to be in favour of antimicrobial treatment (III, IV). The re-
sponse from parents to the questionnaire addressing issues of paren-
tal expectations and awareness, further indicated that parents who 
consider it inappropriate to treat unspecified upper respiratory tract 
infections with antimicrobials significantly more often preferred that 
acute otitis media not be treated with antibiotics (III). These varia-
tions in parental attitude together with a significant correlation at the 
community level between the children’s total use of antimicrobials 
and the percentage of parents considering it sometimes appropriate 
to treat a common cold with antimicrobials (IV), may be important 
observations in this study as primary care physicians maintain that 
parental pressure and expectations in relation to antimicrobial drug 
prescriptions represent an important barrier to restrictive prescription 
practices (Macfarlane et al. 2002; Garbutt et al. 2003; Siegel et al. 
2003; Petursson 2005 b). The high percentage of parents considering 
it sometimes appropriate to treat a common cold with antimicrobials 
in our studies is in accordance with results from study conducted in 
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the United States where misconception about the appropriate treat-
ment for colds was concluded to be predictive of increased health 
service utilization (Lee et al. 2003). Other studies have shown a 
tendency to reduce antimicrobial treatments for acute otitis media 
in children in tandem with parents’ acceptance of the reduction, 
through educational intervention with parents, watchful waiting and 
safety-net antibiotic prescription (Little et al. 2001; Smabrekke et 
al. 2002; Siegel et al. 2003; McCormick et al. 2005). It seemed that 
the prescribing doctor’s habits were adopted by the parents when 
dealing with children with upper respiratory tract infections in our 
studies (III, IV). It is reasonable to believe that parents’ views re-
flect the information given in mass media and during discussions 
with the healthcare personnel (nurses as well as GPs). This is in ac-
cordance with the observation that healthcare practices can function 
like “families”, where habits or indirect rules are created (Gabbay 
and le May 2004). Variations in parental attitude toward antimicro-
bial treatment may therefore be important and are possibly part of 
the above-mentioned “mindlines”.
Possible causative explanation of success in diminishing antimi-
crobial use in some areas but not others may be explained by pos-
sible correlation between non-antimicrobial drug use for acute otitis 
media specifically and lower risk of relapsing episodes of acute otitis 
media later and therefore decreasing need for antimicrobials as will 
be discussed below in the next chapters in connection with changes 
in the microflora of the nasopharynx after antimicrobials use.
Tympanostomy tube placements
Our feeling that tympanostomy tubes were common was confirmed 
in our studies, and we also found that it was more common than in 
other countries (Paradise et al. 1997; Coyte et al. 2001; Desai et 
al. 2002; Schilder and Rovers 2003). In a recent Finnish otitis me-
dia vaccine trial study, children were followed up to 24 months of 
age (Palmu et al. 2004). Tympanostomy tube placement and/or ad-
enoidectomy were performed in 24.1% and 20.6% of the children in 
the control and trial group, respectively (not significant difference). 
Tympanostomy tube placement, though, was much less common in 
the south of Sweden, where ~10% of children had a history of tym-
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panostomy tube insertion (Melander et al. 1998). This contrasts also 
somewhat to results from the United States, where the incidence of 
acute otitis media among children seems to be similar to that in Ice-
land but the rate of tympanostomy tube placements is generally much 
lower (<5%) and may therefore need further explanation (Teele et al. 
1989; Paradise et al. 1997; Thompson et al. 1999). However, rates 
of ~30% for surgery are reported in the United States in some areas 
(Myer and France 1997). Other studies have shown substantial area 
variation or an almost 10-fold difference between the areas with the 
highest and lowest rates (Coyte et al. 2001). Small-area variation in 
surgical rates of tympanostomy tube placements in United States has 
raised concerns about access to care, appropriateness of treatment, 
and the quality and cost of care (Coyte et al. 2001). In our studies, 
variation in the tympanostomy rate between areas was not so big in 
the beginning of our studies, but more interestingly, the rate changed 
over-time even though there were not so many changes in GP posi-
tions in the areas, and the same otolaryngologists served in the ar-
eas over the entire study-period. Therefore an explanation other than 
small-area variation is more likely to explain our results, like other 
non-causative explanation like intervention in the recommended in-
dication for tympanaostomy tube placements and/or causative ex-
planation like changes in the rate of chronic or recurrent otitis media 
in the areas or both as was mentioned above and will be discussed 
further in the chapter “Associations between acute otitis media, anti-
microbial use and tympanostomy tube placements” below.
Antimicrobial use and carriage of antimicrobial-resistant pneu-
mococcus
As mentioned in the introduction, the first case of PNSP in Iceland 
was observed in 1988 (Kristinsson et al. 1992) and in the following 
years most of them proved to be a multiresistant serotype 6B strain, 
probably coming from Spain, where this clone, now registered as 
Spain6B-2, had previously been observed (Soares et al. 1993). Later 
on it was shown that the prevalence of this strain increased rapidly. 
When our study started, the cultivation of bacterial sampling from 
hospital series (patients) indicated a PNSP prevalence rate of about 
20%, almost all of them (~80%) being multiresistant serotype 6B 
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(Kristinsson 1995). The prevalence in the community was not known 
at that time. 
Comparative and analytical studies have demonstrated a relation-
ship between high antibiotic consumption and increasing penicil-
lin-resistance among pneumococci. In few reported epidemiological 
studies for whole communities like in our studies (I, II, V) and some 
others (Melander et al. 1998), this correlation was found not only for 
antimicrobial use by whole communities (comparative and indirect re-
lationship) like in some others studies (Melander et al. 2000; Granizo 
et al. 2000; Dias and Caniça 2004; García-Rey et al. 2004; Goossens 
et al. 2005) but also for individual antimicrobial use (analytical and 
causative relationship). It is therefore of interest to observe the big 
differences in the prevalence of antimicrobial resistance among pneu-
mococci from time to time in the separate areas with interplay of other 
possible risk factors for individual carrying in our studies, especially 
because the increase in the prevalence of PNSP 1993 and 1998 was 
almost solely due to an increase in one particular strain, multiresistant 
serotype 6B which was shown to be phenotypically identical by antibi-
otic susceptibility testing as the Spain6B-2 clone and may be explained 
by a novel clonal spread into “virgin” communities and possible herd 
immunity could therefore be better defined as will be discussed later 
in the chapter “Clonal spread in the community”. 
Studies of the individual relationship between antimicrobial use 
and resistance in pneumococci have produced conflicting results, 
reflecting differences in the study design, setting, and measures of 
association used (Lipsitch 2001). In previously published studies the 
carriage rate of resistant pneumococci has usually been calculated 
with the total number of children carrying pneumococci as the de-
nominator. In all our three cross-sectional studies, the risk of carry-
ing PNSP was 4­5 times greater during the first 7 weeks after each 
antimicrobial course for children actually carrying pneumococci. 
Antimicrobial treatment does though not appear to increase an indi-
vidual’s absolute risk of carrying PNSP after treatment in some stud-
ies. However, it may increases a patient’s relative risk of carriage of 
PNSP (Lipsitch 2001). In French prospective studies, antimicrobial 
treatment did not increase the risk of an individual child carrying 
PNSP even though the proportion of PNSP increased (i.e., only for 
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those carrying pneumococci) (Cohen et al. 1997; Varon et al. 2000). 
This was mainly explained by a significant decrease in the number of 
individuals carrying penicillin-susceptible pneumococci after hav-
ing received antimicrobials and thereby relatively higher PNSP rate 
(relative risk) among those still carrying pneumococci. 
Because of the above-mentioned observations, we recalculated 
the data from all three studies for all children, i.e., not only those car-
rying pneumococci. The results were nevertheless identical to those 
that had been obtained before i.e., higher (absolute) risk of PNSP 
carriage for all children recently after antimicrobial treatment. Our 
results are therefore not congruent with the results from the French 
prospective studies. We conclude that current antimicrobial use en-
courages the uptake of resistant pneumococci and subsequent colo-
nisation or “selective acquisition of (foreign) nonsusceptible strains” 
from the outer ecosystem (from the community). In addition, PNSP 
not previously detected by our methods may proliferate and become 
abundant and detectable after antimicrobial treatment (unmasking of 
dormant and/or nonsusceptible strains present in very low numbers 
from the mucosa). This may be supported by the fact that in our last 
study, carriage of 2-3 strains was not uncommon (sometimes both 
penicillin-susceptible and nonsusceptible) (V). Detection of multiple 
pneumococcal carriages by our culture methods is though not pos-
sible unless the strains exhibit different colonial morphologies.
In vitro studies show that low doses of beta-lactam antimicrobi-
als can increase the growth of both intermediate and resistant pneu-
mococci in cultures on agar plates (Negri et al. 1994). Therapeu-
tic regimens containing beta-lactam antibiotics should therefore be 
able to select for PNSP, especially if given in low dosages. Clinical 
studies from France also support this theory (Guillemot et al. 1998). 
Modifying (increasing) the dose and duration of antibiotic therapy 
may therefore potentially limit the spread of resistant pneumococci 
as shown in another study (Schrag et al. 2001). Although it was not 
part of our prospective epidemiological study we confirmed that 
prescribed antibiotic dosages did not change between the first two 
phases of the study (II) and such change was unlikely between the 
second and third phases when antimicrobial use decreased much less 
than between the first phases. 
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In a Swedish study, a median duration of PNSP carriage (MIC, > 
or = 0.5 mg/L) was 19 days (range 3-267 days), but it was 10 days 
longer in infected than in asymptomatic contact cases (Ekdahl et al. 
1997). A significant risk factor for prolonged carriage was repeated 
treatment courses for acute otitis media. Other significant risk factors 
for prolonged carriage were the occurrence of first episode of acute 
otitis media before the age of one year, the carriage of PNSP by other 
family members, and the obtainment of a first positive culture during 
the winter months (Ekdahl et al. 1997). In our studies most children 
carried PNSP 28-42 days after the last antimicrobial treatment.
A rapid selection of PNSP isolates during or after (II) antibiotic 
treatment for acute otitis media specifically has also been shown 
in other studies (Dagan et al. 1998 a; Brook and Gober 2005; Mc-
Cormick et al. 2005). The clinical outcome of antibiotic treatment 
of acute otitis media may depend on antibiotic-mediated bacterial 
eradication and the spread of resistant clones could be facilitated by 
failures to eradicate resistant strains and subsequent re-colonisation 
of the mucosal membranes after discontinuation of therapy (Dagan 
et al. 2001 b). Conversely, eradication of susceptible pneumococcus 
in the nasopharyngeal flora by antimicrobials means that new strains 
will emerge thereafter and hence may also increase the likelihood of 
new episodes of acute otitis media (recurrent otitis media) and possi-
bly increase the risk of having tympanostomy tube later as described 
later on page 68-69.
Amount and type of antimicrobials associated with resistance in 
the community
Although the prevalence of resistant strains can be related to the 
community use of antimicrobials, in most countries, it is often not 
possible to quantify this use. Accordingly, it has not been possible 
to define acceptable levels of antibiotics usage. In our study we 
have tried to quantify the use, especially among Icelandic children, 
from the prevalence of prescriptions, the number of defined daily 
doses/1000/day and the number of defined daily doses per prescrip-
tion by antimicrobial class and residence (II). At the same time, we 
measured the resistance rate among pneumococci, and its relation to 
antibiotic usage. On the other hand, it was not our aim to analyse the 
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safety thresholds of use for either each antibiotic class or the total 
use.
Low dosage and long duration of antimicrobial treatment has 
been demonstrated to increase the risk of PNSP carriage (Guillemot 
et al. 1998). Comparison of the number of DDD/prescription in 1993 
and 1998 studies shows that this is not likely to be the explanation 
for differences in PNSP rate in the study areas (II). 
Our data suggest that some antimicrobial agents may be more 
active in inducing PNSP carrier state because of selective antimi-
crobial pressure. For example, only trimethoprim-sulfamethoxazole 
was significantly associated with carriage of PNSP in our first study 
(I). Other authors have also shown an association between trime-
thoprim-sulfamethoxazole and carriage of PNSP (Dagan et al. 1998 
b; Melander et al. 1998)
An explanation similar to that for increased carriage risk of PNSP 
by selective antimicrobial pressure after recent antimicrobial treat-
ment may also apply to carriage of erythromycin-nonsusceptible 
strains of pneumococci (V). Much higher use of macrolides, espe-
cially azitromycin, in 2003 than in 1998 may be one explanation for 
this development. Even though the continued high use of antimi-
crobials in one area (area V) could perhaps explain why the PNSP 
of multiresistant serotype 6B (the Spain6B-2 clone) is still present 
in 2003, it is tempting to conclude that rapidly increasing use of 
azithromycin (one third of all prescriptions in 2003 and much higher 
than in the other areas) has established a favourable selective envi-
ronment for this clone, which is also macrolide-nonsusceptible. This 
environment may also have led to the marked increase in the number 
of erythromycin-resistant but penicillin-susceptible pneumococci in 
that area. In fact, the long half-life and low serum concentrations of 
azithromycin have been associated with increased resistance rates 
of not only macrolide-nonsusceptible but also penicillin-nonsus-
ceptible pneumococci (Kastner and Guggenbichler 2001; Dias and 
Caniça 2004). This is in accordance with what is now observed in 
many other countries as the hidden epidemic of macrolide-resistant 
pneumococci (Klugman and Lonks 2005). 
Our study (comparative and analytical covering 10 years) is one 
of the first clearly showing that there is an causative association be-
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tween antimicrobial use and antimicrobial resistance patterns in dif-
ferent communities, something which had previously been shown in 
hospital settings (McGowan 1983) and day-care settings (Reichler 
et al. 1992). A recent French study showed also that intensive educa-
tional strategies aimed at optimizing antibiotic use could significant-
ly reduce the rate of PNSP colonization in areas with high resistance 
rates (Guillemot et al. 2005). 
Results from studies in Sweden, Spain and Portugal dealing with 
the association between antimicrobial use and carriage of antimi-
crobial-resistant pneumococci are congruent with results from our 
studies in most aspects (Melander et al. 1998 a; Melander et al. 1998 
b; Melander et al. 2000; Granizo et al 2000; Dias and Caniça 2004; 
García-Rey et al. 2004). Other older Swedish studies showed the 
emergence and persistence of ß-lactamase-producing bacteria (Hae-
mophilus influenzae and Moraxella catharralis) in the upper respira-
tory tract in children treated with ß-lactam antibiotics (Molstad et 
al. 1988; Molstad and Hovelius 1989; Eliasson et al. 1990). This re-
sistance pattern also appeared to be a long-term ecological effect of 
differences in the level of use of antibiotics between different com-
munities in Sweden (Molstad et al. 1992). 
Clonal spread in the community
The first observation of a PNSP, multiresistant, serotype 6B in Iceland 
was in 1989 and in the following years proved to be strain recognised 
as the Spanish Icelandic clone, i.e., Spain6B-2 as mentioned earlier. 
Before the first phase of the study, this clone was the first to spread in 
the heavily populated metropolitan areas near Reykjavik, the capital 
of Iceland, and then spread to remote areas. Despite means for the 
fast transport of people, the transfer of new pneumococcal clones is 
highly time-dependent (Melander et al. 1998 b; Arason et al. 2002 
a). In this study, special attention has been given to not only the fast 
spread of this clone in the community through high antimicrobial use 
but also its disappearance (V). The disappearance, however, was not 
explained, as might be expected, by direct (individual) association 
between antimicrobial use and carriage risk of PNSP in children, as 
discussed above. The effect of possible interaction of antimicrobial 
use and herd immunity may have been the missing explanatory link 
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in the first phase of the study. We have therefore studied the possible 
interplay of known individual risk factors for PNSP carriage in the 
communities, such as antimicrobial usage interacting with factors 
like time and the distance between study areas in the second and 
third phases of the study. The increase of PNSP of multiresistant se-
rotype 6B studied in this study, shown to be phenotypically identical 
by antibiotic susceptibility testing to the Spain6B-2 clone, in “virgin” 
communities (E and B) in the second phase explains the fitness of 
that particular clone to spread even in communities with low antimi-
crobial use. The prevalence has decreased in all of the study areas 
(V) and, as far as I know, in Iceland as a whole. For this particular 
penicillin-resistant pneumococcal strain (clone), it can be postulated 
that the period from the onset to the end of an epidemic in small 
communities with low antimicrobial use is less than 10 years. In ad-
dition to herd immunity, it is likely that the extent of antimicrobial 
use will play a role in determining the peak prevalence (how fast 
this clone will spread through the community by high carrying rate 
by the individuals) and the subsequent endemic prevalence and be-
haviour. This led us to construct a theoretical model for a plausible 
explanation of the appearance and disappearance of this special bac-
terial clone, which is shown in Figure 25 b. It is reasonable to believe 
that other or new antimicrobial-resistant pneumococcal clones will 
behave in a similar manner.
Strains failing to produce a polysaccharide capsule have com-
monly been isolated from carriage and disease contexts in some oth-
er studies (Hanage et al. 2006). Some studies seem to indicate that 
most non-typeable pneumococci may have diverse genetic back-
grounds compared to typeable pneomococci and may have evolved 
as a distinct group of pneumococcal isolates (Sa-Leao et al. 2006; 
Hanage et al. 2006). The non-typeable pneumococci in our 2003 
study (V) all had a rough appearance and are therefore probably non-
encapsulated, although this has not been confirmed with molecular 
investigations. Such rough (non-encapsulated) strains had not been 
observed in the previous two studies. It is unlikely that such rough 
strains were missed in the previous studies since all the agar plates 
were read by the same two senior biomedical laboratory scientists. 
Their appearance therefore probably indicates the introduction of a 
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novel clone. Probably the new non-typeable strains (clone) have ap-
peared and spread successfully in the day care centres. This increase, 
however, has not been noted in specimens from infected patients in 
Iceland (Kristinsson K.G., personal communication), probably con-
sistent with the lack of virulence of these strains. The significance of 
penicillin non-susceptibility in the non-typeable (non-encapsulate) 
pneumococci is not clear. 
Fig. 25. a) Prevalence of penicillin-nonsusceptible pneumococci 
(PNSP) of multiresistant serotype 6B (recognised as the Spanish-
Icelandic clone, Spain6B-2), as a percentage of all children carrying 
pneumococci, observed in areas H, V, E and B in the studies in 1993, 
1998 and 2003. b) A theoretical model (epidemiological curves) for 
the spread and disappearance of Spain6B-2 clone in four communi-
ties in Iceland 1993-2003 (The form of the curves indicate that the 
time scale for the emergence of resistance under constant selective 
pressure is typically much shorter than the decay time (Austin et al. 
1999)).
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New typeable (encapsulated) as well as non-typeable (non-encapsu-
lated) PNSP have become established in recent years in the study areas. 
The choice of antimicrobial class may influence the selective environ-
ment, favouring this particular resistant clone and stabilising the older 
ones. Also, in the near future, herd immunity may change through the 
impact of new pneumococcal conjugate vaccines (if used), which will 
probably reduce the acquisition of vaccine-type strains but increase the 
risk of non-vaccine serotype strain acquisition in the population. 
Associations between acute otitis media, antimicrobial use and 
tympanostomy tube placements
In the first part of our 1993 study, evaluation of risk factors for car-
riage of PNSP demonstrated that antimicrobial use was an important 
risk factor. Our results indicated that the use of trimethoprim-sul-
phamethoxazole might be worse than the use of other antimicrobials 
(I). This was followed by a nationwide campaign to reduce unneces-
sary antimicrobial use for upper respiratory tract infections, mainly 
in children as described earlier (Kristinsson 1999). These efforts re-
sulted in a 35% reduction in the use of liquid antimicrobials for oral 
use by children from 1992 to 1997. This is in congruence with even 
bigger changes in one study area (area E), where the antimicrobial 
prescription for acute otitis media diminished by about 2/3 over the 
10-year period, and broad-spectrum antimicrobials were only used 
in 32% of cases compared to 78% in the high-consumption area (IV). 
The most likely explanation, in my opinion, is a change in antimi-
crobial prescription habits for acute otitis media among the GPs in 
that particular area rather than diminished prevalence of the natural 
onset of acute otitis media in that area but not the others as discussed 
above in relation to total antimicrobial use. How conservative treat-
ment strategy may possibly diminish the prevalence of acute otitis 
media will be discussed better in connection to the changes in the 
rate of tympanostomy placements for children here below (dimin-
ished rate of children who may develop chronic effusion or relapsing 
acute otitis media and who may need tympanostomy tubes later). 
An important question is also whether tympanostomy tubes will pro-
tect against new middle-ear infections, diminishing the need for antimi-
crobials later. Our results indicate that the wide-use of tympanostomy 
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tubes does not support this view. This does not exclude the possibility 
that a subgroup of infection-prone children with chronic middle-ear ef-
fusion might benefit from placement of tympanostomy tubes.
An association was observed between individual previous pre-
scriptions of oral antibiotics for acute otitis media among children 
with tubes. Furthermore, there was an association between overall 
community antimicrobial use for acute otitis media and the cumula-
tive prevalence of tympanostomy tube placement among children 
in the community (IV). Of special interest was that the prevalence 
of tympanostomy tubes decreased in areas with decreasing use of 
antimicrobials for acute otitis media (IV). This observation, how-
ever, was only statistically significant in one area, between 1998 and 
2003, although similar time trend changes were also observed for the 
other areas. This was also in accordance with parental attitude to-
ward restrictive antimicrobial prescription policy. This phenomenon 
may have different underlying explanations.
One possible causative correlation may be explained partly by the 
fact that children having tubes had got recent oral antimicrobials for 
acute otitis media more often than children not having tympanos-
tomy tubes. This may be due to the fact that otorrhea is a common 
problem in children with tympanostomy tubes (Ah-Tye et al. 2001). 
This may lead to prescriptions of oral antibiotics due to suspicion of 
acute otitis media. In our study, we did not analyse the use of topi-
cal antibiotics, such as ear-drops, that are also frequently used and 
recommended as a first line therapy in clinical guidelines for this 
problem. 
The possibility of a positive causative correlation between an-
timicrobial drug (over) use for acute otitis media, further episodes 
of acute otitis media and tympanostomy tube placement later may 
be explained in connection with changes in the microflora of the 
nasopharynx by antimicrobias. Three different scenarios can be pos-
tulated: 
1. The majority of pneumococcal acute otitis media events may 
develop in association with newly acquired carriage of pneu-
mococcus (Gray et al. 1980; Syrjanen et al. 2005). Eradica-
tion of susceptible pneumococcus in the nasopharyngeal flora 
by antimicrobials means that new strains will emerge thereaf-
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ter and hence may increase the likelihood of new episodes of 
acute otitis media. 
2. A rapid selection of PNPS isolates during antibiotic treat-
ment for acute otitis media as has been shown in some studies 
as mentioned earlier (Dagan et al. 1998 a; Brook and Gober 
2005) or after treatment (Arason et al. 2002 a; McCormick et 
al. 2005) (See discussion on pages 60-62). 
3. Frequent use of antimicrobial drugs probably leads to change 
in the bacterial flora in the community by promoting the emer-
gence of resistant bacteria. This and no. 2 is associated with 
a decreased rate of successful eradication of pathogens from 
middle­ear fluid, which is associated with clinical failure, 
chronic middle-ear effusion and risk of relapsing acute ear 
symptoms (Reichler et al 1992; Dagan 2000; Brook and Gober 
2005; Libson 2005) (See also discussion in the next chapter). 
Another explanation for the correlation between antimicrobial 
use for acute otitis media and prevalence of tympanostomy tubes 
on community level may be non-causative. Differences in medical 
practice both for antimicrobial prescribing and threshold indica-
tions for tympanostomy placements among otitis-prone children and 
changes overtime because of intervention strategies to lower anti-
microbial use in some practices as described earlier is one possible 
explanation of the correlation (Gabbay and le May 2004; Petursson 
2005 a). It must also be kept in mind, although an unlikely explana-
tion concerning our results in a small country that the incidence of 
respiratory tact infections may vary.
Acute otitis media in relation to antimicrobial-resistant bacteria
Our results specifically show rapid selection of PNSP isolates after 
antimicrobial treatment because of acute otitis media, as has also 
been shown in other studies during treatment (Dagan et al. 1998 a; 
Brook and Gober 2005). This may increase the risk of treatment-
resistant episodes of acute otitis media and chronic effusion in the 
middle-ear (Reichler et al. 1992; Dagan 2000; Brook and Gober 
2005; Libson 2005) as mentioned above. One study in the 1970s, 
showed that when acute otitis media was treated with a broad-spec-
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trum antibiotic, it relapsed more often than after a course of narrow-
spectrum antibiotic (Howard et al. 1976). The incidence of recurrent 
acute otitis media increased three-fold in Finland from 1978/1979 
to 1994/1995, at the same time as penicillin-V was replaced with 
broad­spectrum antibiotics as the first­line drug without any obvious 
change in microbial ecology that would justify the shift (Joki-Erkki-
la et al. 2000). However, I can not draw any safe conclusion from our 
studies concerning the question of whether resistant bacteria increase 
the risk of new episodes of acute otitis media more often, compared 
with the risk of a new episode due to non-resistant bacteria. 
Tympanostomy tubes and bacterial antimicrobial resistance
The potential association between tympanostomy tube placements 
and antimicrobial resistance was not specifically studied. However, 
it may be concluded, in agreement with what was stated above about 
the associations between antimicrobial use and resistance and about 
antimicrobial use and tympanostomy tubes placements in the study 
areas, that there is probably a indirect association between tympa-
nostomy tube placements and the prevalence of bacterial antimicro-
bial resistance in the community (see discussion above). Our results, 
however, do not support a conclusion that frequent use of tympanos-
tomy tubes protects against antimicrobial resistance.
Limitations in the study design
I have mentioned some strengths of our studies, one being that it is 
based on subjects from different well­defined communities, allowing 
conclusions, based on the population level as well as differences in 
clinical practice in Iceland. However, the study samples are limited 
as they are focused on pre-school children, and also limited to anti-
microbial use, mostly because of diagnosed upper respiratory tract 
and middle-ear infections by GPs in primary healthcare settings. 
Diagnosis of precise acute otitis media can be hard to define and 
differ also by national perspectives and specialty (Rosenfeld 2002). 
A child with a bacterial upper respiratory tract infection often has a 
clinical picture of symptoms involving more than one site, including 
the middle-ear, nose and throat. One diagnosis (acute otitis media) 
may therefore be used more often than others as a primary reason for 
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antimicrobial prescription among GPs in ordinary clinical settings 
when prescribing antimicrobials is deemed to be needed. Further-
more, only bacteria from the nasopharynx have been cultured, and 
the culturing of bacteria has focused on pneumococci. This makes it 
impossible to conclude anything about adults, other infections, and 
bacteria other than pneumococci and the resistance patterns of bac-
teria other than pneumococci. On the other hand, this focus on a 
specified population, specified infections and a specific bacterium 
may also be a strength as confounding factors can be expected to be 
less important. 
 In our studies we used antibiotic susceptibility testing together 
with serotyping to characterise the bacterial isolates of pneumococci 
as a phenotypes. Although it is probably true that PNSP of multiresis-
tant serotype 6B are members of the Spain6B-2 clone, antibiotype and 
serotype alone are not enough to draw a definitive conclusion. Molec-
ular methods, such as pulsed­field gel electrophoresis and multilocus 
sequence typing for DNA fingerprinting would be the only methods 
suitable for drawing a definitive conclusion about the clonal origin of 
the multiresistant 6B strain to the Spain6B-2 clone. The non-typeable 
pneumococci in the 2003 study (V) all had a rough appearance and 
are therefore probably non-encapsulated, although this has not been 
confirmed with molecular investigations. A clonal origin for this non­
typeable pneumococci is therefore also hard to define.
Summary of associations studied
Figure 4 shows some potential associations analysed in this thesis. 
These potential associations have been discussed, and Figure 26 
summarises this discussion. 
Recent antimicrobial use is the most consistent and important risk 
factor for the carriage of resistant pneumococci at each time (I, II, 
V), and the choice of antimicrobial class may influence the selective 
environment, favouring particular resistant clones (I, V). It seems 
that age was strongly associated with the carriage of PNSP in the 
first study but not at all in the third one. Neither did gender (I, II V), 
number siblings (I, II, V), day care (I, II, V), history of tympanos-
tomy tubes (II, V), presence of an upper respiratory tract infection (I) 
and smoking in the household of the index child (V). 
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An association was observed between individual previous pre-
scriptions of oral antibiotics for acute otitis media and younger age, 
living in a high antimicrobial consumption area and among children 
with tubes (IV), between day care attendance and children having 
tubes (IV) and between overall community antimicrobial use for 
acute otitis media and the cumulative prevalence of tympanostomy 
tube placement among children in the community (IV). 
Parents’ expectations of antimicrobial prescriptions for their child 
because of acute otitis media were associated with former antimicro-
bial use (III) and by living in area with high antimicrobial utilization 
(III, IV).
A bidirectional arrow means that our studies provide some direct 
(causative) or indirect (non-causative) support for such a relation-
ship, and a bracketed arrow means that there is a probable associa-
tion, although one not covered by our studies. 
As far as I know, this is the first time that such associations for 
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Fig. 26. Conclusions concerning potential associations and their di-
rections.
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these subjects have been studied in the general population. However, 
I am well aware that our data can never allow final conclusions con-
cerning causal relationships between the factors studied.
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SUMMARY OF AIMS, MAIN RESULTS 
AND CONCLUSIONS
Some specific aims were stated in the introductory chapter. They 
are repeated below along with the relevant main findings from our 
studies.
• To describe the total use of antimicrobials in the communities, 
specifically among pre-school children, by class of antimicrobi-
als, amount prescribed and prescription rate in selected, well-de-
fined communities. 
 Repeated cross-sectional studies have enabled us to observe pos-
sible trends over time regarding antimicrobial use over a 10-year 
period. Prudent antimicrobial use was encouraged, especially 
for upper respiratory tract infections and acute otitis media. The 
number of antimicrobial courses prescribed to pre-school chil-
dren diminished markedly, especially for acute otitis media, but 
varied between study areas, indicating that in areas where the pre-
scription rate is high, GPs prescribe broad-spectrum antimicrobi-
als relatively more often than narrow-spectrum antimicrobials. 
• To describe potential links between antimicrobial treatment for 
acute otitis media, socio-demographic factors and parental views 
on the use of antimicrobials.
 The child’s age and residence were independently associated with 
the number of treatments for acute otitis media. Parents’ expecta-
tions of antimicrobial prescriptions for common colds were as-
sociated with the doctor’s handling of upper respiratory tract in-
fections. It is concluded that antimicrobial prescriptions may be 
more common in areas where parents have such expectations. 
• To describe the use of tympanostomy tube placements and pos-
sible association with the use of antimicrobials among children.   
 The cumulative prevalence of tympanostomy tube placements 
among pre-school children is very high in Iceland (over 30%). 
An association was observed on the community level between 
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the prescription of oral antimicrobials, specifically for acute oti-
tis media, and the cumulative prevalence of tympanostomy tube 
placements. Of special interest was the observation that the prev-
alence of tympanostomy tubes decreased significantly in areas 
where the use of antimicrobials for acute otitis media decreased, 
and increased where the use of antimicrobials was highest. The 
possibility of a causative, positive correlation between antimicro-
bial drug (over)use for acute otitis media, future episodes of acute 
otitis media and tympanostomy tube placement later, warrants 
further investigation. Differences in routine medical practice may 
be a possible non-causative explanation of the correlation. 
• To analyse associations between antimicrobial use and nasopha-
ryngeal carriage of PNSP in children with regard to both indi-
vidual use and total use in the community. 
 There was a strong association between antimicrobial use on an 
individual level and the nasopharyngeal carriage of PNSP in all 
three phases of our studies. The results indicate that this asso-
ciation cannot be solely explained by (selective) antimicrobial 
pressure on penicillin-susceptible strains. It is proposed that “se-
lective acquisition” of (foreign) non-susceptible strains from the 
outer ecosystem together with unmasking of dormant and/or non-
susceptible strains present in very low numbers from the inner 
ecosystem could also be a possible explanation. Nevertheless, the 
interplay between antimicrobial use on a community level and 
clonal spread of non-susceptible pneumococci is harder to ex-
plain (see next paragraph).
 
• To describe the clonal spread of PNSP in communities and anal-
yse the interplay of factors contributing to this spread. 
 The PNSP strain of multiresistant type 6B (phenotypically iden-
tical by antibiotic susceptibility testing to the Spain6B-2 clone) 
appeared and disappeared over a 10-year period in the communi-
ties, both in communities with high and low antimicrobial use. 
This probably reflects the strain’s fitness to spread where herd im-
munity of the population is lacking. We conclude that the spread 
of resistant clones within well­defined areas seems to follow a 
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classical “rise and fall” epidemiological pattern. The extent of an-
timicrobial use may determine both the peak prevalence and the 
subsequent endemic prevalence in the community. The choice of 
antimicrobial class may influence the selective environment, fa-
vouring particular resistant clones.
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CLINCAL IMPLICATIONS
The prescription of antimicrobials for children has decreased con-
siderably in some of the study communities, particularly prescrip-
tions for acute otitis media. In some areas the decrease is dramatic. 
I believe that GPs in some of the areas studied greatly changed their 
prescription patterns for antimicrobials immediately after the first 
phase of this study in 1993 because of the study’s findings regarding 
the risk of development of bacterial resistance in the community. 
Antimicrobial use for acute otitis media, however, is still about 
50% of all antimicrobial prescribing today for children in Iceland. In 
some areas the parents are well informed about the consequences of 
uncritical antimicrobial use, and in these areas the parents are also 
more prepared to wait before starting antimicrobials for their children. 
This indicates the importance of getting information to parents about 
the appropriate management of infectious diseases, especially in cases 
of mild symptoms because of acute otitis media. 
The use of tympanostomy tubes is commoner in Iceland than in 
other comparable countries. Our studies indicate that the use of tym-
panostomy tubes does not lead to less use of antimicrobials, either 
in children as a whole or, specifically, in the children with a current 
history of tympanostomy tubes. Our results also demonstrate an asso-
ciation between the use of antibiotics and use of tympanostomy tube 
placements. However, it is impossible to say whether this association 
is due to causal effects or differences in the routine medical practice or 
both. These observations may warrant further discussion on optimal 
treatment to achieve a consensus on such treatment of middle-ear in-
fections and other upper respiratory tract infections.
For small communities the spread of resistant clones appears to be 
the main reason for rapid and significant changes in pneumococcal 
resistance rates. Herd immunity against new strains of PNSP seems 
to appear within a certain period, even where the consumption of an-
timicrobials is high. The extent of antimicrobial use may determine 
both the peak prevalence and the subsequent endemic prevalence in 
the community. Recent antimicrobial use by direct (selective) anti-
microbial pressure on susceptible strains, “selective acquisition” of 
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(foreign) non-susceptible strains from the community and unmasking 
of dormant non-susceptible strains present from the inner ecosystem, 
is the most consistent and important risk factor for carriage of these 
resistant strains. 
Associated with a decreased rate of successful eradication of patho-
gens from middle­ear fluid because of antimicrobial resistance among 
them is a tendency toward chronic middle-ear effusion and risk of 
relapsing acute ear symptoms. The positive effect of decreased anti-
biotic use on antibiotic resistance may outweigh the possible benefit 
of earlier symptom resolution attributed to antibiotic treatment in the 
case of mild acute otitis media. 
Eradication of the susceptible pneumococcus in the nasopharyn-
geal flora and interference on the natural balance of microbial spe-
cies in the nasopharynx by antimicrobials means that new strains will 
emerge thereafter and hence may also increase the likelihood of new 
episodes of acute otitis media.  
“Preventing recurrent acute otitis media is a goal of child health-
care. The objective is to reduce the frequency of pain and fever be-
cause of otitis media, shorten the duration of hearing loss, reduce the 
costs of physician visits, surgery and drugs, reduce parent anxiety and 
prevent long­term sequelae” (Giebink 2000). Identification of risk fac-
tors for acute otitis media and antimicrobial-resistant pneumococcal 
colonisation of the nasopharynx together with the possible use of the 
new protein-polysaccharide conjugate pneumococcal vaccine against 
the most potential pathogenic strains of pneumococci, although it has 
not yet been used in Iceland, provides new opportunities for prevent-
ing and managing acute otitis media and other pneumococcal diseases 
among children in the future. Efforts to improve the judicious use of 
antimicrobials for acute otitis media should focus on improving di-
agnostic accuracy. There is also a need to use qualitative methods to 
prepare information and to understand factors influencing behavioral 
change among antimicrobial prescribers.
Our results indicate that the uncritical use of antibiotics increases 
the risk of developing antimicrobial resistance. Therefore, prudent use 
of antimicrobials is recommended.
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ABSTRACT
The�effects�of�community-wide�interventions�to�reduce�resistance�rates�are�poorly�understood.�This�study�eval-
uated�the�effect�of�reduced�antimicrobial�usage�on�the�spread�of�penicillin-nonsusceptible�pneumococci�(PNSP)
in�four�communities�in�Iceland.�The�study�was�performed�after�interventions�to�reduce�antimicrobial�usage
and�compared�to�an�identical�study�performed�5�years�before.�A�randomized�sample�of�953�children�was�cho-
sen�from�all�2,900�1-�to�6-year-old�children�living�in�four�well-defined�communities.�The�main�outcome�mea-
sures�were�nasopharyngeal�carriage�of�PNSP�and�individual�and�community�use�of�antimicrobials.�Pneumo-
cocci�were�carried�by�51.7%�of�the�743�children�enrolled,�and�8.1%�of�the�pneumococci�were�PNSP�as�opposed
to� 8.5%� in� the� previous� study.� The� antimicrobial� use� of� participants� had� been� reduced� from� 1.5� to� 1.1
courses/year�and�the�overall�use�among�children�,7�years�old�living�in�the�study�areas�from�13.6�to�11.1�de-
fined�daily�dosages/1000�children�per�day.�The�prevalence�of�PNSP�increased�in�the�two�areas�furthest�away
from�the�capital�area�despite�reduced�consumption.�The�major�risk�factors�for�carriage�of�PNSP�remained
the�same.�Interventions�can�be�effective� in�reducing�antimicrobial�use.�Pandemic�multiresistant�clones�can
also�spread�fast� in�small�communities�with� low�antimicrobial�use,�where�their�appearance�may�be�delayed
compared�to�highly�populated�urban�areas.�Clonal�spread�and�herd�immunity�are�important�factors�to�be
considered�in�the�evaluation�of�intervention�effects.
187
INTRODUCTION
COMPARATIVE AND ANALYTICAL STUDIES have�demonstrateda�relationship�between�high�antibiotic�consumption�and�in-
creasing�drug�resistance.�This�correlation�has�been�found�both
for� individual�antimicrobial�use1,13 and�antimicrobial�use� by
whole�communities.1,15–17 However,�the�effect�of�reduced�an-
timicrobial�consumption�on�the�prevalence�of�resistance�has�not
been�clearly�documented�on�a�community�wide�scale.
The� incidence� of� penicillin-nonsusceptible� pneumococci
(PNSP)� increased�rapidly�in� Iceland�from� 19896 until� 1993,
when�it�had�reached�20%�in�pneumococcal�infections.7 Most�of
the�PNSP�belonged�to�a�single�multiresistant�serotype�6B�clone
(the�Spanish-Icelandic�clone,�Spain-26B).18 A�study�performed
in�1993�to�evaluate�risk�factors�for�carriage�of�PNSP�demon-
strated�that�antimicrobial�use�was�an�important�risk�factor,�and
suggested�that�the�use�of� trimethoprim-sulfamethoxazole�and
macrolides�might�be�worse�than�use�of�other�antimicrobials.1
This�was�followed�by�a�nationwide�campaign�to�reduce�unnec-
essary�antimicrobial�use�for�upper�respiratory�tract�infections,
mainly�in�children.9 The�interventions�consisted�both�of�infor-
mation�and�education�of�the�public�through�mass�media�and�of
physicians�through�meetings�and�the�Icelandic�Medical�Jour-
nal. New�antimicrobial�prescription�guidelines�were�prepared
and�made�available�on�the�Internet.�Prudent�antimicrobial�use
was� encouraged,�especially�for�upper�respiratory�tract� infec-
tions.�These�efforts�resulted�in�a�35%�reduction�in�the�use�of
liquid�antimicrobials�for�oral�use�by�children�from�1992�until
1997�(data�from�the�Ministry�of�Health).�Subsequently�the�over-
all� incidence�of�PNSP� in�pneumococcal�infections�in� Iceland
declined�to�12%�in�1997.2,9
There�are�many�factors�other�than�antimicrobial�use�that�can
play�a�role�in�the�spread�of�PNSP.8 The�interplay�between�these
risk�factors�may�be�complex�and�is�poorly�understood.�Studies
evaluating�this�interplay�in�the�community�are�urgently�needed
to�assist�public�health�officials�in�designing�effective�interven-
1Department�of�Family�Medicine,�University�of�Iceland,�Solvangur,�Hafnarfjordur,�Iceland.
2Department�of�Clinical�Microbiology,�Landspitali�University�Hospital,�Reykjavik,�Iceland.
3Directorate�of�Public�Health,�Reykjavik,�Iceland.
tion�strategies�to�curtail�the�rapidly�increasing�resistance�rates.
The�confined�Icelandic�community�is�ideal�for�such�studies.�To
get�a�better�understanding�of�the�interplay�of�risk�factors�and
time,�the�aim�of�this�study�was�to�analyze�the�effect�of�dimin-
ished�antimicrobial�use�on�individual�risk�factors�and�the�preva-
lence�of�PNSP�in�the�same�communities�as�were�studied�in�Ice-
land�in�1993.1
MATERIALS�AND�METHODS
Study�population�and�design
Four�of�five�geographical�areas�that�had�been�studied�in�a
comparative�study�in�19931 could�be�re-examined�in�1998.�At
the�end�of�1997�(December�1,�1997),�these�areas�had�a�total
population�of�27,013,�including�2,900�children�from�1�to�6�years
old,�e.g., Hafnarfjordur�(H),�18,203�inhabitants,�1,989�children
1–6�years�old.�Corresponding�figures�for�the�other�areas�were:
Vestmannaeyjar�(V),�4,640�and�512;�Egilsstadir�(E),�3,076�and
300;�and�Bolungarvik�(B),�1,094�and�99.�Area�H�is�a�town�ad-
jacent�to�the�capital�(Reykjavik),�area�V�a�fishing�town�on�an
island�of�the�south�coast,�area�E�a�town�surrounded�by�a�large
farming�area,�and�area�B�a�fishing�town�(Fig.�1).�The�popula-
tion�density�and� living�standards�are� similar�in�all� the� study
towns.�The�study�population�was�chosen�to�allow�a�representa-
tive�comparison�with�the�1993�study�performed�in�these�areas.
After�computer�randomization�of�all�1-�to�6-year-old�children
identified�from�the�National�Registry�of�these�areas,�953�chil-
dren�(33%�of�the�children�of�that�age)�were�selected�for�par-
ticipation�(H,�20%;�V,�58%;�E,�63%;�and�B,�62%).�Seventeen
general�practitioners,�of�whom�14�were�the�same�as�in�the�1993
study,�served�these�areas.
The�sites�were�visited�in�April�and�May,�1998�(same�time�of
the�year�as�in�the�1993�study).�After�informed�parental�consent,
a�nasopharyngeal�specimen�was�taken�from�each�child.�Parents
were�asked�to�bring�their�child�to�the�local�health�center�or�the
sample�was�obtained�at�the�relevant�day�care�center.�The�par-
ents�were�also�asked�the�following�questions�regarding�antimi-
crobial�use�of�their�child:�number�of�antimicrobial�courses�in
the�preceding�year;�the�date�and�type�of�the�last�antimicrobial
agent�used;�type�of�infection�and�whether�the�child�had�been
taking�prophylactic�antibiotics�$3�weeks�during�the�preceding
year.�The�same�information�was�also�collected�from�the�med-
ical�records�at�the�local�health�center.�Children�that�had�received
antimicrobial� treatment� in� the� preceding�2� weeks� were� ex-
cluded,�as�in�the�previous�study.
The�National�Bioethics�Committee�and� the�National�Data
Protection�Commission,�Iceland,�approved�the�study.
Microbiology
Nasopharyngeal�samples�were�obtained�with�a�rayon-tipped
swab�(Mini-tip�Culturette®,�Becton�Dickinson�and�Co.,�Sparks,
MD),�stored�for�maximum�of�24�hr�before�they�were�inoculated
on�two�blood�agars�(Difco,�Detroit,�MI)�one�containing�gen-
tamicin�(5�mg/L)�and�incubated�anaerobically�and�the�other�in-
cubated�aerobically�with�added�CO2.�Colonies�were�identified
with� conventional�methods,�and�pneumococci�were� screened
for�penicillin�resistance�by�the�oxacillin�disc�diffusion�test19 and
the�MIC�of� nonsusceptible�isolates�determined�by� the�E-test
(AB�Biodisk,�Solna,�Sweden)�according�to�the�manufacturer’s
recommendations.�Susceptibility�to�erythromycin,�tetracycline,
chloramphenicol,�and�trimethoprim-sulfamethoxazole�was�de-
termined�by�disc�diffusion�tests�according�to�the�NCCLS�meth-
ods� and� criteria.5 Penicillin� nonsusceptible� isolates� were
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FIG.�1. Map�of�Iceland�showing�the�major�roads,�Reykjavik,�Akureyri,�and�the�study�sites.
serotyped�by�co-agglutination11 using�antisera�from�the�State
Seruminstitute�(Copenhagen,�Denmark).�Antimicrobial�suscep-
tibilities�to�other�antimicrobials�were�tested�by�disc�diffusion
tests�using�the�NCCLS�methods�and�criteria.5
Antimicrobial�sales
Information�on�total�antimicrobial�sales�(adults�and�children)
was�collected�from�computerized�records�of�the�local�pharma-
cies�in�the�study�areas�for�the�12�months�preceding�the�study
visits�(May,�1997,�to�April,�1998).�The�sales�were�assumed�to
represent�the�antimicrobial�use�and�calculated�in�number�of�de-
fined�daily�doses�per�1,000�inhabitants�per�day�(DDD/1000�in-
habitants�per�day).21 In�addition,�the�antimicrobial�sales�for�the
age�group�0–6�years�were�analyzed�separately�by�looking�at�the
amount�prescribed�of�the�major�antimicrobial�classes�and�the
amount�in�each�prescription�(calculated�as�the�mean�number�of
DDDs�per�prescription).
Statistical�analysis
The�single�outcome�variable�was�carriage�of�PNSP�penicillin-
susceptible�pneumococci�(PSP).�The�variables�of�sex,�age,�area
of�residence,�siblings,�day�care�attendance,�the�last�antimicro-
bial�agent�used,�2–7�or�8–52�weeks�from�last�antimicrobial�treat-
ment,�the�number�of�courses�in�the�preceding�12�months,�and
use�of�prophylactic�antibiotics�were�examined�for�association
with�the�outcome�variable.�The�Fisher’s�exact�tests�were�used
for� univariate�analysis�of� categorical�variables�and� one-way
analysis�of�variance�(ANOVA)�for�continuous�variables.
Multivariate� logistic� regression� by� backward� stepwise
method�was�used�to�estimate�the�risk�of�carrying�PNSP�to�con-
trol� interdependence.� Individual�regression�coefficients�were
tested�with�the�Wald�statistic,�and�confidence�intervals�calcu-
lated�for�the�odds.�The�multivariate�analyses�were�performed
with�the�SPSS® program�for�Windows�(Advanced�Statistics�Re-
lease�8.0,�SPSS�Inc,�Chicago,�IL).�The�level�of�statistical�sig-
nificance�was�taken�as�0.05.
RESULTS
Nasopharyngeal�carriage�
Of�the�953�children�invited�to�participate,�743�(78%)�partic-
ipated�(H,�301,�75%;�V,�224,�76%;�E,�167,�88%;�and�B,�51,
83%)�and�384�(52%)�carried�pneumococci.�The�pneumococcal
carriage�rate�varied�from�37%�to�58%�(H,�58%;�V,� 54%;�E,
41%;�and�B,�37%).�The�mean�age�for�the�whole�group�was�4.2
years�(95%�CI�4.1–4.3)�and�the�age�ranged�from�1�to�6�years
[V,� 4.2� (4.0–4.5);� B,� 4.2� (3.8–4.7);� E� 4.1� (3.8–4.4);� H� 4.2
(4.0–4.4)].
The�proportion�of�pneumococci�that�was�nonsusceptible�to
penicillin�was�8.1%�and�all�of�the�nonsusceptible�strains�except
two�were�multiresistant�and�of�serotype�6B�(i.e.,�phenotypically
identical�to� the�Spanish–Icelandic�clone).18,20 These�multire-
sistant�strains�were�found�in�all�study�areas�and�their�penicillin
MICs�were� the�following:�one�strain,�0.125�mg/L,� 21�strains
0.5�mg/L,�six�strains�1.0�mg/L,�and�one�strain�2.0�mg/L.�The
two� other� strains� were� only� found� in� area� H;� one� was� of
serogroup�9�(MIC�1�mg/L)�and�the�other�of�serogroup�19�(MIC
0.5� mg/L),� both� resistant� to� trimethoprim-sulfamethoxazole.
There�was�a�marked�difference�between�the�resistance�rates�of
the�study�areas,�with�rates�ranging�from�4.1%�to�18.8%.�The
rates�had�also�changed�significantly�from�the�1993�rates�(Table
1),�with�reduced�resistance�rates�in�the�two�areas�located�in�the
southwest�(H�and�V),�but�an�increased�rate�in�the�two�areas�fur-
thest�away�from�the�capital�area�(B�and�E).�PNSP�were�found
in�all�day�care�centers�in�area�E.�The�PSP�were�all�susceptible
to�chloramphenicol�and�nonsusceptibility�to�erythromycin�and
tetracycline�remained�uncommon�in�these�strains�(Table�2).�All
PNSP�were�nonsusceptible�to�trimethoprim-sulfamethoxazole,
and�approximately�one-quarter�of�the�PSP.
Antimicrobial�use
By�the�whole�population�in�the�study�areas: In�1998,�a�total
of�15,153�antimicrobial�prescriptions�were�dispensed�to�the�in-
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TABLE 1. CARRIAGE OF PNEUMOCOCCI (PNC)�AND PNSP�AND THE NUMBER OF
ANTIMICROBIAL (AM)�COURSES PER YEAR IN THE STUDY GROUPS
No. No. No. AM�courses�per
Area Year children PNC�(%) PNSP (%) year�(95%�CI) Total PEN AMP ERY SXT PEN AMP ERY SXT
H 1993 527 280�(53.1) 24�(8.6)a 1.5�(1.4–1.7) 11.9 2.2 7.0 0.5 2.2 3.7 4.4 2.7 2.4
1998 301 174�(57.8) 11�(6.3)a 1.0�(0.8–1.1) 9.9 1.3 7.3 0.5 0.8 3.7 4.4 2.5 2.8
V 1993 100 55�(55.0) 10�(18.2)a 1.7�(1.2–2.1) 23.2 3.5 9.7 2.9 7.1 3.6 4.2 3.0 2.4
1998 224 122�(54.5) 5�(4.1)a 1.4�(1.1–1.6) 17.1 1.8 13.0 0.9 1.4 4.5 4.3 2.7 2.5
E 1993 111 52�(46.8) 1�(1.9)a 1.3�(1.0–1.6) 13.4 2.4 7.0 0.5 3.5 4.6 3.9 3.3 2.3
1998 167 69�(41.3) 13�(18.8)a 0.9�(0.7–1.1) 7.6 1.2 5.2 0.2 1.0 3.7 4.4 2.8 2.4
B 1993 53 39�(73.6) 1�(2.6)a 1.5�(1.0–2.0) 9.6 2.5 4.3 0.6 2.2 3.2 4.1 2.7 2.1
1998 51 19�(37.3) 2�(10.5)a 1.0�(0.6–1.4) 8.3 0.5 5.9 0.0 1.9 5.0 3.4 — 2.0
Total 1993 791 426�(53.9) 36�(8.5)a 1.5�(1.4–1.6) 13.6 2.5 7.3 0.8 3.0 3.7 4.3 2.9 2.4
1998 743 384�(51.7) 31�(8.1)a 1.1�(1.0–1.2) 11.1 1.3 8.3 0.5 1.0 3.9 4.3 2.6 2.6
ap , 0.01.
The�corresponding�figures�from�the�1993�study�are�shown�for�comparison.�The�use�of�the�main�antimicrobial�classes�(in�de-
fined�daily�dosages�[DDD];�penicillin�[PEN],�ampicillin�[AMP],�trimethoprim-sulfamethoxazole�[SXT],�and�erythromycin�[ERY])
by�children�,7�years�old�living�in�the�study�areas�is�shown�on�the�right-hand�side,�together�with�the�mean�number�of�DDDs�per
perscription.
DDD/prescriptionDDD/1000�children�,7�yrs/day
habitants�of� the� target�areas�by� the� local� pharmacies,�corre-
sponding�to�14.2�DDD/1000�inhabitants�per�day�in�area�H,�17.2
in�area�V,�12.3�in�area�E�and�11.5�in�area�B.�Of�these,�3,347
(22.1%)�were�for�children�under�7�years�old.�Compared�to�the
1993�study,�antimicrobial�consumption�had�diminished�in�all
study�areas�both�as�measured�in�defined�daily�doses�(14–43%)
and�as�number�of�antibiotic�treatment�courses�per�year�(9–50%).
The�greatest�reduction�was�seen�in�area�E�(Table�1).�Children
in�area�V�still�consumed�around�50%�more�antimicrobials�than
children�in�the�other�areas.�The�reduction�in�antimicrobial�use
was�greater�for�trimethoprim-sulfamethoxazole�than�for�other
antimicrobials.�In�three�of�the�areas�(H,�V,�and�B),�there�was�a
slight�increase�in�the�use�of�broad-spectrum�penicillins�(mainly
amoxycillin� and� amoxycillin�with� clavulanic�acid).�Overall,
there�was�no�change�in�the�number�of�DDDs�per�prescription,
and�there�were�only�relatively�small�changes�within�the�areas
with�one�exception.�In�area�B,�there�was�almost�a�50%�increase
in� the�average�amount�prescribed�for�narrow�spectrum�peni-
cillins�(mainly�phenoxymethylpenicillin)�(Table�1).
By� the� study�population�alone: The�mean�number�of� an-
timicrobial�courses�per�child�in�the�study�population�was�1.1
during�the�year�preceding�the�sampling�(95%�CI�1.0–1.2).�This
was� a� 26.7%�reduction�compared�to� comparable�data�of� the
1993�study�(Table�1).�Forty�percent�of�the�children�(298)�had
received�antimicrobials�at�least�once�during�the�preceding�year,
compared�to�65%�in� 1993.�In� both�1993�and�1998,�the�con-
sumption�was�lowest�in�area�E�and�highest�in�area�V.�Acute�oti-
tis�media�was�still�by�far�the�most�common�reason�for�antimi-
crobial� prescriptions,� constituting� 55%� of� all� antimicrobial
prescriptions�(65%�in�1993).�The�number�of�treatments�for�oti-
tis�media�per�child�had�diminished�from�1.0�(95%�CI�0.9–1.1)
in�1993�to�0.6�(0.5–0.7)�in�1998.�In�1993�trimethoprim-sulf-
amethoxazole�was�the�most�commonly�recently�prescribed�an-
timicrobial� agent� (50.1%)� but� not� in� 1998� (11.8%)� (p 5
0.0001).
Factors�associated�with�carriage�of�PNSP
By�univariate�analysis,�young�age�(p 5 0.013),�geographical
location�(area�E;�p 5 0.003),�prophylactic�antimicrobial�treat-
ment�(p 5 0.008),�antimicrobial�treatment�for�otitis�media�(p 5
0.001),�total�number�of�antimicrobial�treatment�courses�(p ,
0.0001),�and�,8�weeks� from� last� antimicrobial�course�(p 5
0.002),�were�significantly�associated�with�PNSP�carriage.�The
PNSP� carriage�rate�was� 21.6%� (11/51)� 2–7� weeks� after� an-
timicrobial�treatment�compared�to�5.6%�(8/142)�8–52�weeks�af-
ter�treatment�(p 5 0.002)�or�6.3%�(12/191)�if�no�treatment�had
been� received�(p 5 0.001).�The� same� risk� factors�were� also
identified�in�the�1993�study,�but�not�the�same�geographical�lo-
cations.�Factors�that�were�not�found�to�be�significantly�associ-
ated�with�PNSP�carriage�were�gender,�number�of�siblings,�day
care�attendance,�and�antimicrobial�courses�for�tonsillitis�and�si-
nusitis.�The�numbers�were�too�small�to�assess�the�risk�of�indi-
vidual�antimicrobial�classes.
To�control�for�confounding�factors,�all�significant�variables
from�the�univariate�analysis�were�used�in�a�multivariate�back-
ward� stepwise�logistic�regression�model.�Number� of� antimi-
crobial�treatments�and�geographical�area�(area�E)�were�the�only
independent�risk�factors�for�carriage�of�PNSP�(Table�3).
DISCUSSION
The�nationwide�campaign�to�reduce�unnecessary�antimicro-
bial�use�for�upper�respiratory�tract�infections�in�children�that
took�place�between�1993�and�1998�was�associated�with�a�sig-
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TABLE 2. NUMBER OF PNEUMOCOCCI NONSUSCEPTIBLE (RESISTANT OR INTERMEDIATE)�TO ERYTHROMYCIN (ERY),
TETRACYCLINE (TET),�CHLORAMPHENICOL (CHL),�AND TRIMETHOPRIM-SULFAMETHOXAZOLE (SXT),�
ACCORDING TO DISC DIFFUSION TESTS,�IN 1993�AND 1998,�IN THE RESPECTIVE AREAS
No. No. No. No.
Area Year ERY (%) TET (%) CHLO (%) SXT (%)
H PSP 1993 0 0 1 3.0 0 0 62 24.4
1998 1 0.6 1 0.6 0 0 46 28.8
PNSP 1993 20 83.3 22 91.7 13 81.3 24 100
1998 7 63.6 8 72.7 8 72.7 11 100
V PSP 1993 2 4.4 2 4.4 0 0 17 37.8
1998 0 0 0 0 0 0 25 20.7
PNSP 1993 9 90.0 9 90.0 10 100 10 100
1998 5 100 5 100 5 100 5 100
E PSP 1993 0 0 0 0 0 0 12 23.5
1998 4 7.1 2 3.6 0 0 10 17.9
PNSP 1993 1 100 1 100 1 100 1 100
1998 13 100 13 100 13 100 13 100
B PSP 1993 0 0 0 0 0 0 6 15.8
1998 2 11.8 2 11.8 0 0 12 70.6
PNSP 1993 1 100 1 100 1 100 1 100
1998 2 100 2 100 1 50.0 2 100
Total PSP 1993 2 0.5 3 0.8 0 0 97 25.0
1998 7 2 5 1.4 0 0 93 26.6
PNSP 1993 31 86.1 33 91.6 25 69.4 36 100
1998 27 87.1 28 90.3 27 87.1 31 100
nificant�reduction�in�antimicrobial�use�by�children�in�the�study
areas�(from�13.6�to�11.1�DDD/1000�children�,7�years�old�per
day)�and�in�the�study�populations�(1.5–1.1�antimicrobial�courses
per�year).�This� reduction�was�mainly�due� to� reduced�use�of
trimethoprim-sulfamethoxazole�and�fewer�prescriptions�for�oti-
tis�media�(from�1.0�to�0.6�prescriptions�per�year).�Despite�this
reduction�in�antimicrobial�use,�the�proportion�of�PNSP�carriage
only�declined�to�8.1%,�from�the�corresponding�figure�of�8.5%,
obtained�in�the�comparable�study�performed�in�1993.1 This�is
in�contrast�with�the�much�greater�reduction�in�the�incidence�of
PNSP�observed�in�specimens�submitted�from�patients�from�the
whole�of�Iceland�(i.e., 20–13%),�where�the�majority�(.80%)
of�the�specimens�came�from�the�capital�area.8 In�the�1993�study,
one�of�the�main�risk�factors�for�carrying�PNSP�was�recent�an-
timicrobial�use,1 yet�5�years�later�there�was�an�increasing�PNSP
prevalence�in�the�two�areas�that�not�only�had�the�lowest�use�of
antimicrobials�but�also�one�of�these�areas�had�the�greatest�re-
duction�in�their�use.�The�other�important�risk�factors�were�young
age�and�living�in�an�area�with�high�antimicrobial�consumption,
but�the�age�distribution�of�the�children�in�these�populations�did
not�change�between�the�study�periods.�Therefore,�an�important
variable�is�likely�to�be�missing�from�the�risk�factor�analysis�in
the�previous�study.�Risk�factors�for�PNSP� carriage�that�have
been�demonstrated�by�other�investigators�(day�care�center�at-
tendance,�prior�hospitalization,�otitis-prone�condition,�otitis�me-
dia�not�responsive�to�antimicrobials,�white�race,�low�dose,�and
long�duration�of�antimicrobial�prescriptions)10 cannot�account
for�these�differences.
How�can�the�apparent�contradiction�between�the�known�risk
factors�and�the�change�in�prevalence�of�resistance�in�these�com-
munities�be�explained?�Important�factors�such�as�the�spread�of
novel�bacterial�clones�to�communities�with�little�or�no�herd�im-
munity�to�the�new�clones�has�not�been�evaluated�in�previous
community-wide�studies�on� antimicrobial�resistance.�Despite
fast�means�of�transport�for�people,�the�transfer�of�new�pneu-
mococcal� clones� is� highly� time� dependent.14 International
clones�are�likely�to�appear�first�in�highly�populated�urban�ar-
eas�and�then�spread�from�there�to�rural�areas�and�distant�and
smaller�urban�areas.�Reaching�remote�rural�areas�should�take
even�longer�time.�The�Spanish–Icelandic�serotype�6B�pneumo-
coccal�clone�first�appeared�in�Iceland�in�1989�and�was�almost
exclusively�isolated�from�patients�living�in�the�capital�area�dur-
ing�the�first�2�years.�Subsequently�it�appeared�and�spread�in�the
town�of�Akureyri,�which�is�the�largest�urban�area�outside�the
capital�area�(389�km�by�road;�see�Fig.�1)�(K.G.�Kristinsson,�un-
published�data).�The�PNSP�6B�prevalence�in�areas�E�and�B�was
very�low�in�1993�(1.9�and�2.6%;�one�strain�in�each�area)�com-
pared�to�the�other�study�areas�and�they�are�also�furthest�away
from�the�capital�area�(see�Fig.�1).�It�is�very�likely�that�it�took
the�Spanish–Icelandic�clone�longer�to�reach�areas�B�and�E�than
the�other�areas.
Another� important� observation� is� the� high� prevalence
reached�by�the�Spanish–Icelandic�clone�in�area�E�(18.8%),�an
area�with�low�and�declining�use�of�antimicrobials.�This�demon-
strates�that�this�clone�can�also�spread�fast�in�communities�with
low�antimicrobial�consumption,�which�probably�reflects�its�fit-
ness�and�little�or�no�herd�immunity�of�the�population�in� that
area.
Low�dosage�and�long�duration�of�treatment�has�been�demon-
strated�to� increase�the�risk�of�PNSP� carriage.4 To� see�if� this
could�account�for�some�of�the�changes�in�PNSP�prevalence,�we
calculated�the�number�of�defined�daily�dosages�prescribed�per
prescription.�Comparison�of�the�number�of�DDD/prescription
(Table�1)�shows�that�this�is�not�likely�to�be�the�explanation�in
the�study�areas.�Infection�control�measures�are�also�important
in�reducing�resistance�rates12 and�have�been�shown�to�be�ef-
fective�in�reducing�antimicrobial�prescriptions�and�resistance�in
day�care�centers.3 Infection�control�was�not�part�of�the�Icelandic
intervention.
One�of�the�major�strengths�of�this�study�is�the�use�of�ran-
dom� sampling� in� unselected�populations,�high� participation
rates,�and�the�quality�of�the�data�in�general.�The�number�of�par-
ticipants�was�just�over�one-quarter�of�all�1-�to�6-year-old�chil-
dren�living�in� the�study�areas�and� the�actual�sales�of�all�an-
timicrobial�agents�in�the�study�areas�together�with�the�individual
use�of�antimicrobials�by�the�participants�was�available�for�study.
The�study�confirmed�the�risk�factors�for�carrying�PNSP�demon-
strated�in�the�1993�study,�i.e., antimicrobial�use,�time�from�last
antimicrobial�treatment,�age,�and�living�in�a�high�prevalence
area.�Again,�day�care�center�attendance�was�not�a�risk�factor.
This�is�probably�because�only�17%�of�the�participants�were�not
attending�day�care�centers�and�their�siblings�and/or�friends�are
therefore�highly�likely�to�be�attending�day�care�centers,�enabling
efficient�transmission�from�the�day�care�centers.�The�reduced
antimicrobial�use�is�likely�to�have�contributed�to�the�reduced
prevalence�of�PNSP�in�areas�H�and�V�and�limited�the�increase
in�areas�B�and�E.
Iceland�has�a�small�homogenous�population�and�some�parts
are�sparsely�populated.�Apart�from�that,�it� is�very�similar� to
other�western�European�countries.�The�main�results�of�this�study
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TABLE 3. RISK (ODDS RATIO)�OF CARRYING PNSP�AS OPPOSED TO PSP�
BY BACKWARD STEPWISE LOGISTIC REGRESSION METHOD
Variable Number OR 95%�CI p value
Residence
Area�H 170 1�(reference�area)
Area�V 122 0.519 0.17–1.620 0.2600
Area�E 67 4.139 1.65–10.39 0.0030
Area�B 19 1.852 0.36–9.500 0.4600
Number�of�antimicrobial 378 1.50 1.23–1.820 0.0001
treatments
Overall�significance:�x2 5 25.49,�df�5 4,�p�, 0.0001.
demonstrating�the�fitness�of�a�particular�pneumococcal�clone�in
its�ability�to�spread�fast�in�communities�with�little�or�no�herd
immunity�should�therefore�also�be�applicable�to�other�countries.
The� importance�of�such�fitness�is�obvious�if� such�clones�are
multiresistant�and/or� virulent�and�also� for� future�vaccination
strategies.�Interventions�can� be� effective�in� reducing�antimi-
crobial�use�in�small�communities�such�as�in�Iceland,�but�they
may�not�lead�to�immediate�reductions�in�prevalence�of�resistant
strains.�Longitudinal�epidemiological�intervention�studies�car-
ried�out�in�different�areas�and�assessing�all�known�and�likely
risk�factors�are�needed�to�assist�public�health�officials�further
in�designing�the�most�effective�strategies�to�reduce�resistance
rates.� Future� studies� on� the� epidemiology�of� pneumococcal
clones�and�the�effects�of�interventions�must�consider�the�effect
of�distance,�time,�and�herd�immunity.
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Tympanostomy tube placements,
sociodemographic factors and parental
expectations for management of acute otitis
media in Iceland
VILHJALMUR A. ARASON, MD, JOHANN A. SIGURDSSON, MD, PHD, KARL G. KRISTINSSON, MD, PHD AND
SIGURDUR GUDMUNDSSON, MD, PHD
Background.Widespread antimicrobial use is a
risk factor for development of antimicrobial re-
sistance. Antimicrobial treatment of acute otitis
media (AOM) may not always be necessary. Little
is known about the influence of parental expec-
tations on physicians’ decision-making in rela-
tion to treatment of AOM. Evidence is insuffi-
cient as to whether tympanostomy tube
placement reduces antibiotic consumption.
Methods.We randomly selected 1030 children 1
to 6 years old living in 4 geographic areas in
Iceland to be invited to participate in the study.
Information about sociodemographic factors, an-
timicrobial prescriptions and their indications
during the preceding 12 months, tympanostomy
tube placements and parental views on antimi-
crobial use and bacterial resistance were ob-
tained from a questionnaire completed by the
parents and medical records.
Results. The incidence of AOM episodes result-
ing in antimicrobial prescription for 804 children
recruited into the study was 0.7 (95% confidence
interval, 0.6 to 0.8) per child per year, highest
among children age 1 year, i.e. 1.8 prescriptions
(95% confidence interval, 1.4 to 2.2). The cumula-
tive incidence of tympanostomy tube placements
was �30%. Antimicrobial use during the preced-
ing 8 weeks for children with and without tubes
did not differ (P � 0.36). Fifteen percent of chil-
dren with tubes had received antimicrobials dur-
ing the preceding 8 weeks at last once for AOM
compared with 14% of those without tubes (P �
0.97). Parents in the area where antimicrobial
consumption was lowest were less likely to ac-
cept antimicrobial treatment than parents in the
other areas (P � 0.005). Parents of children who
had previously received antimicrobials for AOM
were more likely to accept antimicrobials (P �
0.04).
Conclusions. Parental expectations to antimi-
crobial treatment and awareness about resis-
tance development appear to influence treat-
ment strategies for AOM. The high rate of
tympanostomy tube placement in preschool chil-
dren does not result in reduced antimicrobial
consumption.
INTRODUCTION
Antimicrobial overuse is one of the major causes for
the development of antimicrobial resistance among
common pathogens.1 A strong association between the
overall antimicrobial use and carriage of penicillin-
resistant pneumococci has been documented in Icelan-
dic children.2 During the years 1993 to 1998 an Icelan-
dic public information campaign accompanied by
targeted information to physicians resulted in a 30%
reduction of the total antimicrobial prescriptions rate
for acute otitis media (AOM) in children.3 A reduced
prevalence of penicillin resistance among pneumococci
followed in the wake of the campaign.4
AOM was the single most common (65%) diagnosis
resulting in antimicrobial prescription for Icelandic
children in 19932 which is in agreement with studies
from other countries.5, 6 Previously we demonstrated
an association between antimicrobial consumption and
prevalence of penicillin-nonsusceptible pneumococci in
relation to AOM.3 There are several randomized clini-
cal trials7, 8 and metaanalyses9, 10 that indicate that
antimicrobial treatment of AOM may not always be
necessary or that treatment may have only a limited
effect. Despite successful efforts to reduce antibiotic
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consumption in Iceland, there could be a potential for
further reduction of antibiotic prescriptions for AOM.
Physicians considering an antimicrobial prescription
may consider not only clinical symptoms and signs but
also social factors and parental expectations.11–14 The
aim of this study was to investigate factors contribut-
ing to antibiotic prescriptions for AOM in preschool
children, including sociodemographic factors, parental
expectations and awareness to resistance development,
as well as the impact of former antimicrobial usage by
the index child. We also evaluated whether tympanos-
tomy tubes placement reduces antibiotic consumption
among children.
METHODS
Study population and design. Children in four
geographic areas in Iceland were included in the study
(Fig. 1). At the end of 1997 these areas had a total
population of 27 013 inhabitants, of whom 2900 were
children from 1 to 6 years old, according to the National
Registry. These areas were served by 17 general prac-
titioners. The areas were: Hafnarfjordur (H), 18 203
inhabitants, including 1989 children 1 to 6 years old;
Vestmannaeyjar (V) with 4640 inhabitants, including
512 children; Egilsstadir (E), with 3076 inhabitants,
including 300 children; and Bolungarvik (B), with 1094
inhabitants and 99 children. After computer random-
ization of all 2900 eligible children, 1030 children (36%
of the total) were selected, and their parents received a
letter inviting them to participate in the study together
with their child (H, 20%; V, 58%; E, 63%; and B, 62%).
Informed parental consent was obtained from all par-
ticipants.
Data were collected in April and May 1998. Parents
of participating children received postal question-
naires, addressing sociodemographic factors, number
of children in the household and day-care attendance.
Antimicrobial use was measured as the number of oral
antimicrobial courses during the preceding year. The
date of the last antimicrobial prescription was noted,
together with the type of agent prescribed and the
clinical indication (diagnosis) for the prescription. Past
or present use of tympanostomy tubes was recorded.
The information collected from parents was matched
with information available from the medical records at
the local health center.
Parents were also asked to complete a questionnaire
about their personal preferences in relation to antimi-
crobial treatment in the case of (1) unspecified upper
respiratory infections (common cold) and (2) acute
otitis media. Parents answered the question whether it
was always, sometimes or never appropriate to give
antimicrobials in these two situations, or whether they
did not know. They were then asked to agree, disagree
or give no comment (or answer “do not know”) to the
following two statements: “Some pathogens are becom-
ing resistant to antimicrobials” and “Inappropriate
antimicrobial use can lead to antimicrobial resistance
problems among common pathogens.”
The study was approved by the National Bioethics
Committee and the National Data Protection Commis-
sion, Iceland.
Statistical analysis. The Pearson chi square test
was used for univariate analysis of categorical vari-
ables. Multivariate logistic regression was used to
estimate the odds if a child had been given treatment
by antimicrobials because of AOM or not, adjusted to
age, gender, residence, having siblings or not and
day-care attendance to control interdependence. The
multivariate logistic regression was also used to deter-
mine the odds if a child had received tympanostomy
tubes or not, adjusted for residence and gender and for
the odds if a child had received antimicrobials during
the preceding 8 weeks or not, adjusted for age, and if
the child had tympanostomy tube inserted or not.
Furthermore the logistic regression method was used
for the odds that a parent would express the opinion
that it is never appropriate to give antimicrobial treat-
ment for colds (unspecified upper respiratory tract
infection) rather than sometimes, adjusted for resi-
dence, the child having siblings or not, parental view
that AOM should be treated with antimicrobials or not
and whether a child had received antimicrobial treat-
ment for otitis media during the last 12 months or not.
Individual regression coefficients were tested with the
Wald statistic, and 95% confidence intervals (95% CI)
were calculated for the odds. The statistical analyses
were performed with the SPSS program for Windows
(Advanced Statistics Release 8.0; SPSS Inc, Chicago,
Ill.). The level of statistical significance was taken as
0.05.
RESULTS
Eight hundred four children and their parents par-
ticipated in the study. The mother was the responder inFIG. 1. The study areas in Iceland.
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92% of cases. This represented a response rate ranging
from 75 to 88% of the total random sample of the study
areas (Table 1). A total of 439 (54.6%) had received
antimicrobial treatment at least once during the pre-
ceding 12 months. The total incidence of antibiotic
treatments for any reason was 1.21 per child per year
(95% CI 1.09 to 1.32). This number was significantly
higher in area V, 1.51 (95% CI 1.26 to 1.75) than in area
E, 0.89 (95% CI 0.60 to 1.09). In area H the incidence
was 1.16 (95% CI 0.99 to 1.33), and in area B it was
1.15 (95% CI 0.72 to 1.57).
Antimicrobial prescriptions for acute otitis
media. The yearly incidence of disease episodes diag-
nosed as AOM and resulting in oral antimicrobial
treatment was 0.70 (95% CI 0.61 to 0.79) per child,
constituting 58% of total antimicrobial prescriptions
for any reason. The rate was highest, 1.79 (95% CI 1.40
to 2.18) per child, among children 1 year of age and
lowest among the 6-year-olds, i.e. 0.25 (95% CI 0.15 to
0.36) per child. Analyzed by areas the incidence was: E,
0.57 (95% CI 0.41 to 0.74); B, 0.65 (95% CI 0.32 to 0.99);
H, 0.69 (95% CI 0.56 to 0.83); and V, 0.81 (95% CI 0.62
to 1.00).
The types of antimicrobial agent used in the most
recent treatment for AOM were amoxicillin or ampicil-
lin in 111 cases (50.7%), amoxicillin plus clavulanic
acid in 56 cases (25.6%), trimethoprim-sulfamethox-
azole in 35 cases (16.0%), penicillin in 11 cases (5,0%),
erythromycin in 1 case (0.5%) and other classes (or not
known) in 5 cases (2.3%).
The yearly incidence of clinical episodes other than
AOM resulting in antimicrobial prescriptions were:
tonsillitis, 0.18 (95% CI 0.15 to 0.21); acute sinusitis,
0.10 (95% CI 0.08 to 0.13); bronchitis, 0.07 (95% CI 0.05
to 0.09); pneumonia, 0.07 (95% CI 0.05 to 0.09); skin
infections, 0.05 (95% CI 0.04 to 0.07); and urinary tract
infections, 0.04 (95% CI 0.02 to 0.06).
Sociodemographic risk factors for antimicro-
bial prescription for acute otitis media. Young age
(1 to 3 years old) was significantly associated with more
antimicrobial prescriptions for AOM than in children
ages 4 to 6 years old (Table 2). Gender, number of
siblings, residence and day-care attendance did not
influence the odds of receiving antimicrobials for AOM.
Use of tympanostomy tubes. Information about
tympanostomy tube usage was obtained for 735 chil-
dren. Among these 213 or 29% (95% CI 26 to 33%) had
at some point received tympanostomy tube in one or
both ears. Twenty-three percent (95% CI 16 to 31%) of
1-year-old children had already received tubes (Fig. 2).
The percentage of children who had received tubes was
26% in Areas E and H, 34% in Area B and 35% in Area
V (P � 0.113). Adjusted for area of residence, the odds
for boys to receive tympanostomy tubes (128 of 377)
was 1.56 as compared with girls (88 of 358) (P � 0.01).
Of 88 children currently having tympanostomy tubes,
31 (35%) had received oral antimicrobials at least once
during the previous 8 weeks compared with 162 of 645
children (25%) not having tympanostomy tubes (P �
0.059). When adjusted also for age the odds if child
received antimicrobials or not was not statistically
significant (P � 0.36).
Thirteen children with tympanostomy tubes (15%)
had received oral antimicrobials for AOM during the
preceding 8 weeks (mean, 3.77 weeks; 95% CI 2.11 to
5.43), compared with 90 children (14%) without tubes
(mean, 3.76 weeks; 95% CI 3.24 to 4.27) (P � 0.97).
Parental expectations and awareness in rela-
tion to antimicrobial treatment. Parents in Area E,
TABLE 1. Study population
Area Participants Boys Girls Mean Age ofParticipants
Hafnarfjordur 331 (75)* 173 (52.3) 158 (47.7) 4.07 � 1.75†
Vestmannaeyjar 244 (76) 131 (53.7) 113 (46.3) 4.20 � 1.67
Egilsstadir 174 (88) 83 (47.7) 91 (52.3) 4.04 � 1.78
Bolungarvik 55 (83) 28 (50.9) 27 (49.1) 4.23 � 1.72
Total 804 (78) 415 (51.6) 389 (48.4) 4.11 � 1.73
* Numbers in parentheses, percent enrolled of those invited.
† Mean � SD.
TABLE 2. Adjusted odds ratio for children who have been
treated with antimicrobials for acute otitis media in the
preceding 12 months (N � 277) as opposed to not (N � 519)
by multivariate analysis (796 cases analyzed, data missing
in 8 cases)
Variable No. OddsRatio 95% CI P*
Age
1–3 yr 386 1
4–6 yr 410 0.24 0.17–0.33 0.0001
Gender
Male 409 1
Female 387 1.25 0.92–1.71 0.156
Siblings
No 128 1
Yes 668 1.04 0.69–1.58 0.844
Residence 0.558
Area H 327 1
Area V 242 1.21 0.83–1.74 0.332
Area E 172 0.89 0.59–1.35 0.581
Area B 55 1.16 0.62–2.17 0.636
Day care
No 145 1
Yes 651 1.01 0.68–1.50 0.972
* Overall significance: chi square, 88.8; df, 7; P � 0.0001.
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where antibiotic consumption was lowest, answered
significantly more often than parents in other areas
that it was never appropriate to give antimicrobial
treatment for unspecified upper respiratory tract infec-
tion (Table 3). The statement “some pathogenic bacte-
ria are becoming resistant to antimicrobials” was an-
swered by 798 parents, of whom 719 agreed (89.4%), 2
(0.2%) disagreed, 33 (4.1%) were passive and 44 (5.5%)
did not know. Similarly 797 parents gave their opinion
on the statement “inappropriate antimicrobial use can
lead to resistance development among common patho-
gens” and 644 (80.1%) agreed, 4 (0.5%) disagreed, 76
(9.5%) were passive and 73 (9.1%) did not know. The
response from parents to the questionnaire addressing
issues of parental expectations and awareness further
indicated that parents who consider it inappropriate to
treat unspecified upper respiratory tract infections
with antimicrobials significantly more often preferred
that AOM not be treated with antibiotics (Table 4).
They also more often considered it appropriate to
prescribe antimicrobials for unspecific upper respira-
tory tract infection if their child had previously re-
ceived antibiotics for AOM. Tympanostomy tube usage
for their child did not influence parental opinion in
relation to this matter.
DISCUSSION
AOM is the most common clinical diagnosis under-
lying antimicrobial prescriptions for Icelandic pre-
school children. Physician treatment strategies for this
condition are likely to have a significant impact on the
total antibiotic consumption in the community. The
study indicates that antimicrobial consumption in a
community can be influenced by efforts that aim at
increasing parental interest and awareness in relation
to antibiotic use. As has been shown in a recent
study,15 involving patients more actively in evaluating
the need for antimicrobial treatment in situations in
which convincing evidence for a clear benefit is lacking,
may lead to reduced drug consumption.
Parents of children who had previously been treated
for AOM with antimicrobials were more likely to con-
cur with antimicrobial therapy, even for the common
cold. This may be caused by positive reinforcement
given that the child might have improved from upper
airway infections on a previous occasion while taking
an antimicrobial agent. Similar findings have been
reported for treatment of sore throat.16
A major benefit of this study is the comparison
between geographically well-defined areas. The impact
of day-care attendance is hard to evaluate on the basis
of this study, given that �80% of 1- to 6-year-old
children in Iceland attend day care. Other studies
have, however, demonstrated that day care appears to
have a clear impact on the number of treatment cours-
es.17
There was a surprisingly high use of tympanostomy
tubes among the participating children. This number is
much higher than in the south of Sweden where �10%
of children had a history of tympanostomy tube inser-
tions.18 Use appears to be even less in the United
States where a recent study found that 1.8% of 1-year-
old children and 4.2% of 2-year-old children had tym-
panostomy tube placement.19 The explanation for these
FIG. 2. Cumulative prevalence in percentage (� 95% CI) of
preschool children in Iceland who have received tympanostomy
tube placements.
TABLE 3. Results from parent’s questionnaire about appropriate antimicrobial usage for upper respiratory tract infections
for children
Question 1*: Is It Appropriate to Give Antimicrobial
Treatment for AOM?
Question 2†: Is It Appropriate to Give Antimicrobial
Treatment for Unspecified Upper Respiratory Tract Infection
(Common Cold)?
Always Sometimes Never Don’t know Always Sometimes Never Don’t know
Area H 27 (8.3)‡ 286 (87.5) 3 (0.9) 11 (3.4) 0 (0.0) 154 (47.2) 148 (45.4) 24 (7.4)
Area V 28 (11.5) 197 (81.1) 4 (1.6) 14 (5.8) 1 (0.4) 121 (49.8) 95 (39.1) 26 (10.7)
Area E 9 (5.2) 152 (87.9) 5 (2.9) 7 (4.0) 0 (0.0) 50 (28.9) 109 (63.0) 14 (8.1)
Area B 2 (3.6) 51 (92.7) 1 (1.8) 1 (1.8) 0 (0.0) 21 (38.2) 25 (45.5) 9 (16.4)
Total 66 (8.3) 686 (86.0) 13 (1.6) 33 (4.1) 1 (0.1) 346 (43.4) 377 (47.3) 73 (9.2)
* Pearson chi square, 13.01; df 9; P � 0.159.
† Pearson chi square, 32.27; df 9; P � 0.0001.
‡ Numbers in parentheses, percent.
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differences is not clear. Availability of physicians did
not appear to influence treatment strategies in general,
including selection of children for tympanostomy tube
placements. The numbers of ear, nose and throat
physicians and general practitioners in Iceland were
7.3 and 56.7/100 000 inhabitants, respectively, which is
comparable with conditions in Sweden, where the cor-
responding figures have been 6.6 and 59.1/100 000.20
The main indications for tympanostomy tube place-
ments are persistent fluid in the middle ear and recur-
rent AOM. This study focuses on causes of antimicro-
bial treatment in children, especially the diagnosis of
AOM, with and without tympanostomy tubes. It did
not specifically address the criteria for insertion of
tympanostomy tubes, but we assume that the indica-
tions are comparable with those in the US, Canada and
Scandinavia, given that all ear, nose and throat spe-
cialists in Iceland and most of remitting general prac-
titioners have completed their postgraduate training
abroad, usually in the above-mentioned countries.
Tympanostomy tube placement was not associated
with reduced antimicrobial use for AOM in the present
study. This does not exclude the possibility that a
subgroup of infection-prone children with chronic mid-
dle ear effusion might benefit from the placement of
tympanostomy tubes.
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Population-based surveillance for hospitalized
and ambulatory pediatric invasive
pneumococcal disease in Santiago, Chile
ROSANNA LAGOS, MD, ALMA MUN˜OZ, MD, MARI´A TERESA VALENZUELA, MD, INGRID HEITMANN, MD AND
MYRON M. LEVINE, MD, DTPH
Background. Nine- and 11-valent pneumococ-
cal conjugate vaccines under development may
control pediatric pneumococcal disease in non-
industrialized countries. Because these vaccines
are expensive, population-based surveillance of
pneumococcal disease in children <36 months of
age was undertaken in Santiago, Chile to provide
health authorities with reliable data on the bur-
den of invasive pneumococcal disease and caus-
ative serotypes, including those in outpatients
with high fever.
Methods. Automated blood culture machines
were introduced into 9 hospitals that admit 85%
of all hospitalized children in Santiago. Acutely
ill pediatric febrile ambulatory patients are at-
tended at 8 emergency rooms (ERs) and 36 ur-
gent primary care services. After a 12-month
pilot study in 3 ERs, health authorities collected
blood cultures from children <36 months of age
with high fever seen in the ER as standard prac-
tice. Streptococcus pneumoniae isolates were se-
rotyped.
Results. Blood cultures of 18 (1.2%) of 1503
outpatients 6 to 35 months of age with high fever
in the pilot study yielded S. pneumoniae. In the
ensuing 24 months 236 children <36 months old
were hospitalized with invasive pneumococcal
disease (incidence, 33.9 cases/105 children), and
188 bacteremias were detected among ambula-
tory ER patients with high fever (incidence, 27.0
cases/105 children). Although serotypes were
similar among hospitalized and ambulatory
cases (except 18C, which was more common in
the latter), case fatality was 9.5% in hospitalized
(21 of 236) vs. 0% in ambulatory cases (0 of 188)
(P � <0.0001). High level resistance to penicillin
(25.8% vs. 10.1%) and cefotaxime (19.5% vs. 6.2%)
was observed more often among pneumococcal
isolates from hospitalized than among ambula-
tory cases (P < 0.001).
Conclusions. ER surveillance detected approx-
imately one case of pneumococcal bacteremia
among febrile ambulatory patients for each hos-
pitalized invasive case. Because 71% of cases
were caused by vaccine serotypes (and 87% by
vaccine serogroups), 9- and 11-valent pneumo-
coccal conjugate vaccines could prevent most
invasive pediatric pneumococcal disease in
Chile.
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ORIGINAL ARTICLE
Otitis media, tympanostomy tube placement, and use of antibiotics
Cross-sectional community study repeated after five years
VILHJALMUR A. ARASON1, JOHANN A. SIGURDSSON1, KARL G. KRISTINSSON2,
LINN GETZ1 & SIGURDUR GUDMUNDSSON3
1Department of Family Medicine, University of Iceland, Solvangur, Hafnarfjordur, 2Department of Clinical Microbiology,
Landspitali University Hospital, Reykjavik, 3Directorate of Public Health, Reykjavik, Iceland
Abstract
Objective. To investigate potential links between antimicrobial drug use for acute otitis media (AOM) and tympanostomy
tube placements, and the relationship between parental views and physician antimicrobial prescribing habits. Design. Cross-
sectional community study repeated after five years. Subjects . Representative samples of children aged 1�/6 years in four well-
defined communities in Iceland, examined in 2003 (n�/889) and 1998 (n�/804). Main outcome measures. Prevalence of
antimicrobial treatments for AOM, tympanostomy tube placements, and parental expectations of antimicrobial
treatment. Results. Tympanostomy tubes had been placed at some time in 34% of children in 2003, as compared with
30% in 1998. A statistically significant association was found between tympanostomy tube placement rate and antimicrobial
use for AOM in 2003. In the area where antimicrobial use for AOM was lowest in 1998, drug use had further diminished
significantly. At the same time, the prevalence of tympanostomy tube placements had diminished from 26% to 17%. Tube
placements had increased significantly, from 35% to 44%, in the area where antimicrobial use for AOM was highest. Parents
in the area where antimicrobial consumption was lowest and narrow spectrum antimicrobials were most often used were less
likely to be in favour of antimicrobial treatment. Conclusions. Comparison between communities showed a positive
correlation between antimicrobial use for AOM and tympanostomy tube placements. The study supports a restrictive policy
in relation to prescriptions of antibiotics for AOM. It also indicates that well-informed parents predict a restrictive
prescription policy.
Key Words: Acute otitis media, antimicrobial use, drug prescription, epidemiology, Iceland, intervention, parental
expectations, tympanostomy tube placement
Acute otitis media (AOM) is the single most
common diagnosis resulting in antimicrobial pre-
scription for children in the Western world [1�/4],
including Iceland. Nevertheless antimicrobial treat-
ment of AOM is debatable. Several randomized
clinical trials [5,6] and meta-analyses [7,8] indicate
that it may often be unnecessary, yet severe infec-
tions such as acute mastoiditis can complicate
AOM. Comparison of the incidence of mastoiditis
in the USA where AOM has usually been treated
with antimicrobials and the Netherlands where
AOM is usually not treated with antimicrobials,
however, reveals a negligible difference [9]. A
restrictive antibiotic policy for AOM therefore
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In Iceland, 30% of pre-school children have had
tympanostomy tube placements for recurrent or
chronic otitis media. It is unclear whether this is
due to high disease prevalence or medical over
treatment.
. We found a positive correlation between
tympanostomy tube placements and rate of
antimicrobial drug prescription for acute
otitis media.
. In regions with diminishing use of antimi-
crobials, a decrease in tympanostomy place-
ments could be observed over time.
Scandinavian Journal of Primary Health Care, 2005; 23: 184�/191
(Received 30 December 2004; accepted 19 April 2005)
ISSN 0281-3432 print/ISSN 1502-7724 online # 2005 Taylor & Francis
DOI: 10.1080/02813430510031298
appears justifiable. Such a policy is further sup-
ported by the documented link between high con-
sumption of antimicrobials and development of
antimicrobial resistance among common pathogens
[1,10,11]. A strong association between antimicro-
bial use for AOM and carriage of penicillin non-
susceptible pneumococci in children has been
demonstrated [12]. Further knowledge about the
short- and long-term impact of different treatment
strategies for otitis media is important.
Tympanostomy tube placement is a well estab-
lished treatment option for chronic effusion in the
middle ear and recurrent episodes of AOM [13], yet
the consequences of this intervention are not clear
[14�/16]. The cumulative prevalence of tympanost-
omy tube placement among Icelandic pre-school
children has been shown to be 30% [2], which is
much higher than reported in other countries [17].
Furthermore, children with tympanostomy tubes
received as many antimicrobial courses as children
without tubes.
The aim of the present study was to investigate
potential links between antimicrobial treatment for
AOM and tympanostomy tube placements and
evaluate the impact of sociodemographic factors
and parental views on physician prescribing habits.
We approached these research questions by con-
ducting a cross-sectional investigation in four well-
defined areas with a five-year interval.
Material and methods
Study population and design
Eligible participants included all children 1 to 6
years of age living in the four Icelandic communities
Hafnarfjo¨rdur (H), Vestmannaeyjar (V), Egilsstadir
(E), and Bolungarvik (B). All eligible children in V,
E, and B were invited to participate, whilst a random
sample was invited in area H (Table I). The study
areas were served by a total of 19 general practi-
tioners (GPs) (18.2 positions), of whom 11 were the
same individuals as in the 1998 study. The organiza-
tional structure of the healthcare service was similar
for both study periods, except in area H which is a
suburb of Reykjavik. Emergency appointments were
more often provided by doctors outside area H in
2003 than in 1998, resulting in somewhat declining
continuity of care in area H. The same ear, nose, and
throat specialists were responsible for bi-monthly
visits to each of the areas V, E, and B during the
years 1998 and 2003. Inhabitants in area H had easy
access to such specialists in Reykjavik. Informed
parental consent was obtained for all participants.
The parents received a questionnaire regarding
sociodemographic factors, number of children and
smoking habits in the household, and day care
attendance. Antimicrobial use was measured as the
number of oral antimicrobial courses during the
preceding year, according to parents’ recollection.
The date of the last antimicrobial prescription was
noted, together with the type of agent prescribed and
the clinical indication (diagnosis) for the prescrip-
tion. A history of past or present use of tympanost-
omy tubes was recorded. Information gathered from
parents was matched with information from the
medical records at the local health centre. Parents
were furthermore asked to complete a questionnaire
about their personal views in relation to antimicro-
bial treatment, similar to the 1998 study [2]. The
study was approved by the National Bioethics
Committee and the National Data Protection Com-
mission, Iceland.
Statistical analysis
The statistical methods have been described in detail
elsewhere [2]. Fisher’s exact test and the Pearson
chi-square test were used for univariate analysis of
categorical variables. Linear regression analysis was
used to estimate correlation coefficient (r) and 95%
confidence interval for the slope of mean number of
antimicrobial courses for AOM compared with
tympanostomy tube placement rate by areas and
mean number of total antimicrobial courses com-
pared with the prevalence of parents finding it
appropriate sometimes to treat common cold with
antimicrobials. Multivariate logistic regression mod-
els were used to estimate odds ratio. Individual
regression coefficients were tested with the Wald
statistic and 95% confidence intervals were calcu-
lated for the odds. The statistical analyses were
performed with the SPSS† program for Windows
(Advanced Statistics Release 8.0, SPSS Inc,
Chicago, Ill.). The level of statistical significance
was taken as 0.05.
Results
Participation
In total, 889 children participated (see Table I),
representing a response rate from 76 to 84 percent.
According to the questionnaires most of the children
attended day care centres (84�/94%). The child’s
mother provided the parental information in 90% of
cases.
. Parental knowledge about appropriate use of
antimicrobial drugs was found to be related
to physician prescribing habits.
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Prescription of antibiotics
A total of 48% of the participating children had
received oral antimicrobial treatment at least once
during the preceding 12 months, compared with
55% in 1998 (p�/0.007). The mean number of
antibiotic treatments per year was 1.06 (1.21 in
1998, Table II). The usage was significantly higher
in area V compared with the other areas on both
occasions. The proportion of antimicrobial prescrip-
tions for AOM was about the same (57%) as in 1998
(58%). The number of treatment courses for the
indication AOM was also highest in area V, i.e. 0.88
courses per year per child (Table II). In area E,
where the antimicrobial prescription rate was lowest
(0.57) in 1998, it had decreased significantly to 0.27
in 2003.
The choice of antimicrobial drug also varied
considerably by study areas. Broad-spectrum anti-
microbials (amoxicillin�/clavulanic acid, azitromyzin,
erythromycin, trimethoprim-sulphamethoxazole), were
used in only 23 of 72 cases (32%) in area E where
the total antimicrobial consumption was lowest but
in 148 of 189 cases (78%) in the high-consumption
area V (pB/0.0001).
Predictors of prescriptions for antibiotics for otitis media
As shown in Table III, the child’s age, residence, and
history of tympanostomy tubes (past or present)
were independently associated with the number of
antimicrobial treatments for AOM. In our 1998
study, this was the case only for age. Smoking did
not influence the odds if the child received anti-
microbials for AOM or not.
Predictors of tympanostomy tube placements
Information about tympanostomy tube usage was
obtained for 880 children. A total of 298 (34%)
reported tympanostomy tube insertions in one or
both ears at some time point (cumulative preva-
lence), and among these, as many as 22% (95% CI
14�/31%) of one-year-old children. Boys, as in 1998,
had received tympanostomy tubes significantly more
often (178/467) than girls (120/413) (p�/0.018).
The percentage of children who had received tubes
varied significantly from 17% in area E to 44% in
area V in 2003 (see Table II, pB/0.0001).
From 1998 to 2003, there had been a significant
increase in tympanostomy tube placements in areas
Vand H (where antimicrobial prescription rates were
highest), and a decrease in areas E and B (not
significant in area B) (see Table II). In area E, a
concurrent and significant decrease took place in
tympanostomy tube placements among children and
antimicrobial prescriptions (total use as well as for
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the indication AOM specifically). According to
multivariate analysis, adjusted for age, a child having
tympanostomy tube(s) was more likely to have had
recurrent antimicrobial treatment and to live in
the area where antimicrobials were most frequently
used (area V, Table IV). Day care attendance was
also a predictor of having tubes. A significant
correlation was found at the community level
Table II. Total number of antimicrobial treatment courses during the 12 months prior to enrolment, number of treatment courses for
AOM, and number (%) of children 1�/6 years of age having had tympanostomy tube placement.
Area Year
No. of treatment courses
per child per year
(95% CI)
No. of treatment courses for
AOM per child per year
(95%CI)
No. (%) of children having
had tympanostomy tube
placement
p-value* for changes in
tympanostomy tube
placement rate between
1998 and 2003
H 1998 1.16 (0.99�/1.33) 0.69 (0.56�/0.83) 81/310 (26.1)
2003 1.05 (0.86�/1.23) 0.57 (0.43�/0.71) 103/280 (36.8) 0.006
V 1998 1.51 (1.26�/1.75) 0.81 (0.62�/1.00) 79/227 (34.8)
2003 1.48 (1.27�/1.69) 0.88 (0.71�/1.04) 143/324 (44.1) 0.034
E 1998 0.89 (0.60�/1.09) 0.57 (0.41�/0.74) 39/148 (26.4)
2003 0.53 (0.41�/0.65) 0.27 (0.19�/0.36) 37/215 (17.2) 0.049
B 1998 1.15 (0.72�/1.57) 0.65 (0.32�/0.99) 17/50 (34.0)
2003 0.72 (0.46�/0.98) 0.41 (0.20�/0.62) 15/61 (24.6) 0.299
Total 1998 1.21 (1.09�/1.32) 0.70 (0.61�/0.79) 216/735 (29.4)
2003 1.06 (0.95�/1.16) 0.60 (0.52�/0.68) 298/880 (33.9) 0.060
Corresponding figures from the 1998 study are included.
Table III. Mean number of antimicrobial treatment courses per year for AOM and adjusted odds ratios (OR) for children treated with
antimicrobials for AOM in the preceding 12 months (n�/270), as opposed to not (n�/593).
Variable
Mean number of treatment courses
per year for AOM (95%CI) OR 95% CI p-value
Age
1�/3 yrs 1.06 (0.90�/1.21) 1
4�/6 yrs 0.23 (0.18�/0.28) 0.18 0.12�/0.25 0.0001
Gender
male 0.61 (0.50�/0.72) 1
female 0.59 (0.47�/0.70) 1.01 0.73�/1.40 0.99
Siblings
No 0.82 (0.57�/1.08) 1
Yes 0.55 (0.47�/0.63) 0.79 0.52�/1.20 0.25
Residence
Area V 0.88 (0.71�/1.04) 1
Area E 0.27 (0.19�/0.36) 0.32 0.20�/0.51 0.0001
Area B 0.41 (0.20�/0.62) 0.44 0.22�/0.88 0.019
Area H 0.57 (0.43�/0.71) 0.50 0.34�/0.74 0.0003
Day care
No 0.89 (0.58�/1.20) 1
Yes 0.57 (0.49�/0.66) 0.86 0.50�/1.47 0.56
Tympanostomy
tube, now or before
Yes 0.94 (0.75�/1.13) 1
No 0.43 (0.36�/0.50) 0.49 0.35�/0.70 0.0001
Smoking in the house
No 0.59 (0.50�/0.68) 1
Yes 0.64 (0.45�/0.82) 0.92 0.61�/1.41 0.69
Multivariate analysis (863 cases analysed, data missing for 26 cases). Overall significance: chi-square�/165,79, df�/10, p�/0.0000.
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between tympanostomy tube placement rate and
antimicrobial use for AOM (r�/0.97, p�/0.032)
(Figure 1).
Effects of tympanostomy tubes on recent antimicrobial
drug consumption
Of 123 children having tubes, 49 (40%) had received
oral antimicrobials at least once during the previous
8 weeks, as compared with 124 of 737 children
(17%) without tubes (pB/0.001). Considering only
antimicrobial treatment for AMO, 25 children
(20%) in the tympanostomy group had recently
received antimicrobials, compared with 74 children
(10%) among those without tubes (pB/0.001).
Adjusting for age, the odds ratio for receiving
antimicrobials was significantly higher for children
with tubes (pB/0.001). In 1998, this difference was
not statistically significant.
Parental views on antimicrobial drug treatment
Table V gives the results of the questionnaires
regarding appropriate antimicrobial usage for upper
respiratory infections in children. Data from 1998
are provided for comparison. At the community
level, a significant correlation was found between the
children’s total antimicrobial use and the rate of
parents considering it sometimes appropriate to treat
common cold with antimicrobials (r�/0.99, p�/
0.01).
Discussion
Four communities in Iceland have been studied with
an interval of five years with regard to use of
antimicrobial drugs, prevalence of tympanostomy
tube placements, and prevalence of penicillin non-
susceptible pneumococci, in particular to see how
these factors interact with each other. Our earlier
studies have highlighted the risk of recent antimi-
crobial usage on carriage of penicillin non-suscep-
tible pneumococci [1,12] as well as an unusually
high prevalence of tympanostomy tube placements
in Iceland [2]. In the present paper we observed not
only an association between antimicrobial prescrip-
tion rates for AOM and prevalence of tympanostomy
tube placements at the community level, but also
changes with time between 1998 and 2003 in
relation to antimicrobial usage. In the area where
antimicrobial consumption was lowest in 1998,
antimicrobial use for AOM as well as tympanostomy
tube placements decreased significantly. In the two
areas where antimicrobial use was highest in 1998,
antimicrobial use remained high, and the tympa-
nostomy tube placement rate increased significantly.
Changes in the delivery of acute healthcare services
in area H from 1998 to 2003 weakened the quality of
the local data where a higher antimicrobial prescrip-
tion rate could be expected.
There was a significant association between the
number of antimicrobial prescriptions for AOM in
children and tympanostomy tube placements on the
Table IV. Odds ratio (OR) adjusted for age for children having tympanostomy tubes (n�/123), as opposed to not (n�/736).
Variable No. OR 95%CI p-value
Residence
Area V 314 1
Area E 214 0.35 0.17�/0.64 0.0021
Area B 61 1.02 0.46�/2.24 0.97
Area H 270 0.81 0.50�/1.30 0.38
Number of antimicrobial treatments for AOM, last 12 months
0 594 1
1�/2 203 1.96 1.22�/3.17 0.0059
]/3 62 4.98 2.60�/9.53 0.0001
Gender
Female 407 1
Male 452 1.28 0.84�/1.94 0.25
Smoking in the family house setting
No 701 1
Yes 158 1.01 0.60�/1.72 0.95
Day care
No 71 1
Yes 788 2.38 1.07�/5.28 0.0317
Multivariate analysis (859 cases analysed, data missing in 30 cases). Overall significance: chi-square�/100.176, df�/9, p�/0.0000.
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level of both the individual and the community. This
phenomenon may have different underlying expla-
nations. One possibility is that frequent use of
antimicrobial drugs might change the bacterial flora
in the community, by promoting the emergence of
resistant bacteria [1,12]. This could in turn increase
the risk of treatment-resistant episodes of bacterial
infections including AMO [18], chronic effusion in
the middle ear, and subsequent tympanostomy tube
placement. A second possibility may be due to the
fact that otorrhea is a common problem in children
with tympanostomy tubes [19]. This may lead to
prescriptions of antibiotics due to suspicion or fear of
AOM and may at least partly explain why children
with tubes in the present study had more often
received recent oral antimicrobial treatment.
On the other hand, the observed difference of
practice may have a complex set of explanations.
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Figure 1. Correlation between tympanostomy tube placement rate (cumulative prevalence) and antimicrobial use for acute otitis media (last
12 months) among 1- to 6-year-old children in Iceland, 2003.
Table V. Results from parents’ questionnaires regarding appropriate antimicrobial usage for upper respiratory tract infections for children,
number and percentage (%), compared with results from the 1998 study.
Question/area Year Always Sometimes Never Don’t know
Question 11 Is it appropiate to give antimicrobial treatment for acute otitis media?
Area H 1998 27 (8.3) 286 (87.5) 3 (0.9) 11 (3.4)
2003 30 (10.7) 231 (82.5) 3 (1.1) 16 (5.7)
Area V 1998 28 (11.5) 197 (81.1) 4 (1.6) 14 (5.8)
2003 33 (10.2) 274 (85.1) 1 (0.3) 14 (4.3)
Area E 1998 9 (5.2) 152 (87.9) 5 (2.9) 7 (4.0)
2003 11 (5.1) 194 (90.7) 1 (0.5) 8 (3.7)
Area B 1998 2 (3.6) 51 (92.7) 1 (1.8) 1 (1.8)
2003 1 (1.6) 58 (95.1) 1 (1.6) 1 (1.6)
Total 1998 66 (8.3) 686 (86.0) 13 (1.6) 33 (4.1)
2003 75 (8.6) 757 (86.3) 6 (0.7) 39 (4.4)
Question 22 Is it appropriate to give antimicrobial treatment for unspecified upper respiratory tract infection (common cold)?
Area H 1998 0 (0.0) 154 (47.2) 148 (45.4) 24 (7.4)
2003 0 (0) 122 (44.0) 137 (49.5) 18 (6.5)
Area V 1998 1 (0.4) 121 (49.8) 95 (39.1) 26 (10.7)
2003 0 (0) 186 (57.9) 114 (35.5) 21 (6.5)
Area E 1998 0 (0.0) 50 (28.9) 109 (63.0) 14 (8.1)
2003 0 (0) 64 (30.2) 131 (61.8) 17 (8.0)
Area B 1998 0 (0.0) 21 (38.2) 25 (45.5) 9 (16.4)
2003 0 (0) 20 (32.8) 38 (62.3) 3 (5.1)
Total 1998 1 (0.1) 346 (43.4) 377 (47.3) 73 (9.2)
2003 0 (0) 392 (45.0) 420 (48.2) 59 (6.8)
11998, Pearson chi-square 13.01, df 9, p�/0.159; 2003, Pearson chi-square 15.05, df 9, p�/0.090. 21998, Pearson chi-square 32.27, df 9,
p�/0.0001; 2003, Pearson chi-square 46.65, df 9, p�/0.0001.
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The incidence of respiratory tract infections may
vary between areas. There may also be a tendency to
under-diagnose AOM in some areas and over-
diagnose AOM in others. Furthermore, the various
areas may have different treatment traditions/cul-
tures in relation to the clinical problem in question.
A recent study by Gabbay and Le May addressed the
phenomenon of varying clinical ‘‘mindlines’’ among
primary health care practices in the UK [20].
Parents in areas where antimicrobial drug usage
was lowest and broad-spectrum antimicrobials
most rarely prescribed appeared to be better in-
formed about the benefits of restrictive use of
antimicrobial drugs for upper respiratory tract
infections. These variations in parental attitude
may be important as primary care physicians main-
tain that parental pressure and expectations in
relation to antimicrobial drug prescriptions represent
an important barrier to a restrictive prescribing
practice [2,21�/27].
Our results demonstrate an association between
the use of antibiotics, parental views about antimi-
crobial treatment, and use of tympanostomy tube
placements. However, it is impossible to say whether
the associations between antimicrobial use for AOM
and tympanostomy tube placements are due to
direct causal effects or because of differences in
medical practice. The possibility of a direct positive
correlation between antimicrobial drug (over) use
for AOM, future episodes of AOM, and tympanost-
omy tube placement later warrants further investiga-
tion.
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ABSTRACT
The relative effects of risk factors on the prevalence of resistant pneumococcal clones are hard to determine.
Our aim was to evaluate the effect of risk factors on the prevalence of resistant pneumococci in Iceland in
2003 and compare these data with results of identical studies performed in 1993 and 1998. A randomized sam-
ple of 1,107 children was chosen from all 2,532 children 1 to 6 years old living in four communities. Pneu-
mococci were carried by 64% of the 824 children enrolled and 9.5% were penicillin nonsusceptible (PNSP),
as opposed to 8.1% (1998) and 8.5% (1993), and multiresistant strains of serotype 6B were 2.5% compared
to 7.5% and 7.7% (p � 0.001). Antimicrobial use had declined in 10 years from 1.5 to 1.0 courses/child per
year. The only significant risk factor for carriage of PNSP and erythromycin-resistant pneumococci was an-
timicrobial consumption. The multiresistant type 6B strains disappeared from the areas with the lowest an-
timicrobial use but maintained unchanged prevalence in the area with the highest use. The number of ery-
thromycin-resistant, penicillin-susceptible strains of all pneumococci (37/475, 7.8%) increased significantly
from the previous studies (7/353, 2.0%, 1998, and 2/390, 0.5%, 1993). This observation is associated with in-
creased use of macrolides, especially azithromycin, in one of the study areas. Spread of novel resistant clones
appears to be the main reason for rapid and significant changes in pneumococcal resistance rates. The choice
of antimicrobial class appears to influence the selective environment favoring particular resistant clones.
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INTRODUCTION
COMPARATIVE AND ANALYTICAL STUDIES have demonstrateda relationship between high antimicrobial consumption 
and increasing antimicrobial drug resistance in pneumo-
cocci.1,2,12,13,18 However, the effects of reduced antimicrobial
consumption and herd immunity on the prevalence of resistance
have been harder to document.2 This requires long-term longi-
tudinal epidemiological studies of risk factors for carriage of
resistant pneumococci and prevalence of resistant clones.10
There is an increasing need to analyze available data to con-
struct mathematical models that can be used as tools to predict
the likely outcomes of various antibiotic policy options.3,15 The
incidence of penicillin-nonsusceptible pneumococci (PNSP) in-
creased rapidly in Iceland from 19897 until 1993, when it had
reached 20% in pneumococcal infections.8 Most of the PNSP
belonged to a single multiresistant clone of serotype 6B (the
Spanish-Icelandic clone, Spain-26B).19 An unstructured nation-
wide campaign to reduce antimicrobial use followed. The cam-
paign was led by key opinion leaders and involved all of the
mass media together with meetings with health professionals.
Subsequently, the overall antimicrobial use for children reduced
by about one third.2,9
Our studies to evaluate risk factors for PNSP carriage in 1993
and 1998 demonstrated the importance of antimicrobial use,
clonal spread, and herd immunity.1,2 The relative importance
of antimicrobial use compared to clonal spread and herd im-
munity on PNSP carriage is not known.
This is the third cross-sectional study of risk factors and
PNSP carriage in the same communities, giving three snapshots
over a 10-year period. Our aim is to analyze the relative effects
of various risk factors, clonal spread, and herd immunity.
1Department of Family Medicine, University of Iceland, Solvangur, Hafnarfjordur, Iceland.
2Department of Clinical Microbiology, Landspitali University Hospital, Reykjavik, Iceland.
3Directorate of Public Health, Reykjavik, Iceland.
4Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
MATERIALS AND METHODS
Study population and design
Four geographical areas that had been studied in compara-
tive studies in 1993 and 1998 were reexamined in 2003 by com-
parable methods.1,2 At the end of 2002 (December 1, 2002)
these areas had a total population of 28,922, including 2,757
children from 1 to 6 years old, i.e., Hafnarfjordur (H), 20,675
inhabitants, 2,004 children 1–6 years old. Corresponding fig-
ures for the other areas were Vestmannaeyjar (V), 4,416, 406,
Egilsstadir (E), 2,874, 265, and Bolungavik (B), 957, 82. Area
H is a town adjacent to the capital Reykjavik, area V is a fish-
ing town on an island of the south coast, area E is a town sur-
rounded by a large farming area, and area B is a fishing town
on the northwest coast. The population density and living stan-
dards are similar in all the study towns. All eligible children,
according to the Icelandic National Registry, were invited to
participate in V (396), E (256), and B (75), whereas a random
sample of 380 children was invited to participate in area H.
Eighteen general practitioners, of whom 11 were the same as
in the 1998 study, served these areas.
The sites were visited in April and May, 2003. After in-
formed parental consent, a nasopharyngeal specimen was taken
from each child. The parents answered a postal questionnaire
regarding the use of antimicrobials by their child: number of
antimicrobial courses in the preceding year; the date and type
of the last antimicrobial agent used; type of infection and
whether the child had been taking prophylactic antibiotics �3
weeks during the preceding year. They were also asked about
the presence of tympanostomy tubes (TT) (presently and in the
past) and if someone smoked in the same household. Informa-
tion on antibiotic and tympanostomy use was also collected
from the medical records at the local health center. Children
that had received antimicrobial treatment in the preceding 2
weeks were excluded, as in the previous studies.
The National Bioethics Committee and the National Data
Protection Commission approved the study.
Microbiology
Nasopharyngeal samples were obtained with rayon-tipped
swabs (Mini-tip Culturette®, Becton Dickinson and Co., MD),
stored for a maximum of 24 hr before they were inoculated on
blood agar (Difco, Detroit, MI) containing gentamicin (5 mg/L)
and incubated anaerobically. Typical colonies were identified
with conventional methods, and pneumococci were screened
for penicillin resistance by the oxacillin disc diffusion test.20 If
colonial appearance suggested the presence of more than one
pneumococcal strain, each of the colonies was tested separately.
The MIC of nonsusceptible isolates was determined by the E-
test (AB Biodisk, Solna, Sweden) according to the manufac-
turer’s recommendations. Isolates having a penicillin MIC of
�0.094 mg/L were defined as nonsusceptible. Susceptibility to
erythromycin, tetracycline, chloramphenicol, clindamycin, and
trimethoprim-sulfamethoxazole was determined by disc diffu-
sion tests according to the Clinical and Laboratory Standards
Institute (CLSI) methods and criteria.4 Penicillin nonsuscepti-
ble isolates were also serotyped by co-agglutination11 using an-
tisera from the State Seruminstitute (Copenhagen, Denmark).
Statistical analysis
Carriage of penicillin-nonsusceptible as opposed to -suscep-
tible pneumococci or erythromycin-resistant as opposed to ery-
thromycin-susceptible pneumococci were the single outcome
variables. Each case could only be associated with a single
strains, so where there was carriage of a typeable PNSP strain
with a nontypeable (nonencapsulated) strain, the nontypeable
strain was excluded from the analysis because it is much less
likely to be associated with infections. Similarly, we excluded
penicillin-susceptible strains in dual carriage with PNSP strains.
Analysis of possible association with the outcome variable was:
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TABLE 1. ANTIMICROBIAL (AM) USAGE IN NUMBER OF COURSES PER YEAR, CARRIAGE OF PNEUMOCOCCI AND PNSP AND THE
NUMBER OF DIFFERENT PNSP STRAINS IN THE STUDY GROUPS
AM courses
Number of per year Non-
Area Year Children (�95% CI) 6B (%6B) 9V 14 19F 23 typeable
H 1993 527 1.5 (1.4–1.7) 280 53.1 24 8.6 21 7.5 1 2
1998 301 1.0 (0.8–1.1) 174 57.8 11 6.3 9 5.2 1 1
2003 258 1.0 (0.8–1.1) 154 59.7 20 13.0 4 2.6 10 2 4
V 1993 100 1.7 (1.2–2.1) 55 55.0 10 18.2 10 18.2
1998 224 1.4 (1.1–1.6) 122 54.5 5 4.1 5 4.1
2003 301 1.4 (1.2–1.6) 214 71.1 15 7.0 9 4.2 6
E 1993 111 1.3 (1.0–1.6) 52 46.8 1 1.9 1 1.9
1998 167 0.9 (0.7–1.1) 69 41.3 13 18.8 13 18.8
2003 207 0.5 (0.4–0.6) 120 60.0 12 10.0 0 0 5 7
B 1993 53 1.5 (1.0–2.0) 39 73.6 1 2.6 1 2.6
1998 51 1.0 (0.6–1.4) 19 37.3 2 10.5 2 10.5
2003 58 0.7 (0.4–1.0) 37 63.8 3 8.1 0 0 1 2
Total 1993 791 1.5 (1.4–1.6) 426 53.9 36 8.5 33 7.7 1 2
1998 743 1.1 (0.0–1.2) 384 51.7 31 8.1 29 7.5 1 1
2003 824 1.0 (0.9–1.1) 525 63.7 50 9.5 13 2.5 11 5 2 0 19
aPNC, Pneumococcal carriers.
Number of
PNCa(%)
Number of
PNSP (%)
Type of PNSP
sex, age, area of residence, siblings, day-care attendance, type
of the last antimicrobial agent used, weeks from last antimi-
crobial treatment, number of courses in the preceding 12
months, use of prophylactic antibiotics, use of tympanostomy
tubes at the time of sampling or before, and tobacco smoking
in the same household. The Pearson chi-square tests were used
for univariate analysis of categorical variables and one-way
analysis of variance (ANOVA) for continuous variables.
As in the earlier studies of 1993 and 1998, the multivariate
logistic regression method was used to estimate the risk for all
known variables of carrying PNSP to control interdependence.
Individual regression coefficients were tested with the Wald sta-
tistic, and confidence intervals calculated for the odds. The mul-
tivariate analyses were performed with the SPSS® program for
Windows (Advanced Statistics Release 8.0, SPSS Inc, Chicago,
IL). The level of statistical significance was 0.05. Confidence
intervals are given as 95% confidence intervals.
RESULTS
Nasopharyngeal carriage
Overall carriage: Of the 1,107 children invited, 848 (77%)
participated (H, 74%; V, 78%; E, 82%, and B 79%). Twenty
four were excluded from nasopharyngeal culturing because they
had received antimicrobials in the 2 preceding weeks. Thus,
824 children were studied. The mean age for the whole group
was 4.3 years (SD� 1.7) (H, 4.2; V, 4.4; E, 4.2, and B, 3.9).
A total of 525 carried pneumococci (63.7%) and average car-
riage rate in the communities varied from 59.7% to 71.1%
(Table 1).
Carriage of PNSP: The proportion of PNSP was 9.5%, but
only 5.9% if nontypeable strains are excluded (Table 1). Mul-
tiresistant serotype 6B strains (n � 13) (phenotypically identi-
cal to the Spanish-Icelandic clone) were only found in two 
areas (Table 1). Fifty four children carried at least two pneu-
mococcal strains. In two instances, children carried two PNSP
strains where one was nontypeable and therefore excluded from
statistical analyses and Table 1. Similarly, we excluded 9 peni-
cillin-susceptible strains in dual carriage with PNSP nontype-
able strains and 12 penicillin-susceptible strains in dual carriage
with PNSP typeable strains. Thirty-one children carried two or
more penicillin-susceptible pneumococci. Two children carried
only penicillin-susceptible nontypeable pneumococci. All of the
PNSP were resistant to trimethoprim-sulfamethoxazole and all
type 6B, type 19F, and nontypeable strains were multiresistant.
All except the serotype 6B strains were susceptible to chlo-
ramphenicol. The serotype 9V and 14 strains were susceptible
to erythromycin, tetracycline, and clindamycin but the nonty-
peable and serotype 6B strains were not. The penicillin MICs
were as follows: serotype 6B, nine strains 0.25 mg/L, three 0.38
mg/L, and one 0.75 mg/L; serotype 9V, one 0.125 mg/L, two
0.25 mg/L, four 0.38 mg/L, and four 0.5 mg/L; serotype 14,
three 0.5 mg/L, one 0.75 mg/L, and one 1.0 mg/L; serotype
19F, one 0.25 mg/L and one 0.5 mg/L; nontypeable (nonen-
capsulated) strains, five 0.094, one 0.19 mg/L, eight 0.25 mg/L,
three 0.38 mg/L, and one 0.5 mg/L. There was a marked dif-
ference in the PNSP rates between the study areas (7.0–13.0%,
Table 1), which had decreased from 1998 in two areas but in-
creased in the other two. The number of serotype 6B strains
had decreased in all areas except area V and the rate of typeable
PNSP had also decreased in all areas (Fig. 1). Nontypeable
(nonencapsulated) PNSP strains had not been observed in the
two previous studies.
Carriage of erythromycin-resistant pneumococci: The num-
ber of erythromycin-resistant and penicillin-susceptible strains
increased significantly from the previous study in 1998 in ar-
eas H and V (p � 0.0004 and p � 0.0001, respectively), but de-
creased in the other two areas (E and B, p � 0.05 and p � 0.6,
respectively) (see Table 2). However, the proportion of ery-
thromycin resistance among PNSP remained similar.
Antimicrobial use: The mean number of antimicrobial
courses per child in the study population was 1.0 during the
year preceding the sampling (CI 0.9–1.1; 33.3% reduction from
1993 and 9.1% from 1998, Table 1 and Fig. 1). Forty six per-
cent of the children (n � 379) had received antimicrobials at
least once during the preceding year, compared to 65% in 1993
and 40% in 1998. The consumption was lowest in area E and
highest in area V. As previously, acute otitis media was the
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TABLE 2. ERYTHROMYCIN SUSCEPTIBILITY OF PENICILLIN-
SUSCEPTIBLE AND NONSUSCEPTIBLE PNEUMOCOCCI, IN 1993,
1998, AND 2003, IN THE RESPECTIVE AREAS (NUMBER OF
ERYTHROMYCIN-RESISTANT PNEUMOCOCCI)
Number
Area Year Number of ERYa %
H PSPb 1993 256 0 0
1998 163 1 0.6
2003 134 13 9.7
PNSP 1993 24 20 83.3
1998 11 7 63.6
2003 20 10 50.0
V PSP 1993 45 2 4.4
1998 117 0 0
2003 199 21 10.6
PNSP 1993 10 9 90.0
1998 5 5 100
2003 15 14 93.3
E PSP 1993 51 0 0
1998 56 4 7.1
2003 108 1 0.9
PNSP 1993 1 1 100
1998 13 13 100
2003 12 8 66.7
B PSP 1993 38 0 0
1998 17 2 11.8
2003 34 2 5.9
PNSP 1993 1 1 100
1998 2 2 100
2003 3 2 66.7
Total PSP 1993 390 2 0.5
1998 353 7 2
2003 475 37 7.8
PNSP 1993 36 31 86.1
1998 31 27 87.1
2003 50 34 68.0
aERY, Erythromycin.
bPSP, Penicillin-susceptible pneumococci.
most common reason for antimicrobial prescriptions (56%). An-
timicrobial use by age was 1.82 courses per one year old child
per year (CI 1.36–2.28), 1.94 (1.56–2.33) for 2 years old, 1.17
(0.96–1.38) for 3 years old, 0.76 (0.58–0.94) for 4 years old,
0.46 (0.32–0.61) for 5-year-old, and 0.35 (0.23–0.48) for 6-
year-old children. The choice of antimicrobial class differed
markedly between areas. Amoxicillin was the most commonly
prescribed antimicrobial agent overall 29% (37% in 1998 and
20.8% in 1993), and in all areas except area V (E, 43%; B,
32%; H, 39%, and V, 17%). The penicillins (amoxicillin, amox-
icillin � clavulanic acid, and phenoxmethylpenicillin) ac-
counted for 62% overall (B, 82%; H, 75%; E, 77%; and V,
46%). Other antimicrobials accounted for less than 15% in all
areas except area V. The main antimicrobial used in area V was
azithromycin (33.3%), which was rarely used in the other ar-
eas (E 1.5%, B 13.6%, and H 9.7%).
Factors associated with carriage of PNSP
Antimicrobial use: Antimicrobial use was the most significant
risk factor for carrying PNSP by univariate analysis (Table 3).
Children carrying PNSP had received on average 1.78 
antimicrobial courses during the preceding 12 months (CI
1.24–2.32) compared to 0.95 courses (CI 0.82–1.09) for children
carrying penicillin-susceptible pneumococci (Table 3) and 0.93
(CI 0.75–1.10) for no carriage. The PNSP carriage rate was 26.7%
(16/60) 2–7 weeks after antimicrobial treatment compared to 7.3%
(34/465) �8 weeks after treatment (p� 0.001). On the other hand,
the overall pneumococcal carriage was similar for children that
had received antimicrobial treatment 2–7 weeks before sampling
time (60/104, 58%) as opposed to �8 weeks before sampling time
(465/720, 64%)(p� 0.1906). There was no significant difference
in the recorded risk factors between children carrying typeable
PNSP versus nontypeable PNSP (Table 4).
Age: The mean age for children carrying pneumococci was
lower, 4.12 years (CI 3.98–4.26), than for children not carrying
pneumococci, 4.49 years (CI 4.29–4.69), but not significantly
lower for PNSP carriage. The PNSP carriage rate was highest
for 2-year-children, 18% (16/89); 8.3% for 1 year, 9% for 3
years, 7.4% for 4 years, 6.1% for 5 years, and 8.3% for 6-year-
old children. The carriage of specific serotypes/groups of PNSP
was not related to particular age groups, except that carriers of
nontypeable pneumococci were significantly older than carriers
of serotype 14 (mean age 4.08 years (95% CI 3.22–5.00) as op-
posed to 2.82 (2.57–3.08). The mean age was 3.95 years
(2.70–5.19) for type 6B and 3.41 (2.50–4.31) for type 9V.
Tympanostomy tubes: Information on tympanostomy tube
use was available for 817 children; thereof 279 (34%) children
either currently had tubes or had had tubes before. Information
on current use was available for 782, and of these as many as
111 (14.2%) had tympanostomy tubes at the time of sampling.
Presence of tympanostomy tubes was neither associated with
carriage of pneumococci nor PNSP (Table 3).
Smoking: Pneumococcal carriage was slightly higher in chil-
dren from smoking households as opposed to nonsmoking
households, but the difference was not significant (100/522 for
carriers vs. 48/297 for others, p � 0.30). There was no associ-
ation between smoking in the household settings and PNSP car-
riage (Table 3).
Other factors: Children attending day care were more likely
to carry pneumococci 489/752 than children not attending day
care 35/70 (p � 0.0138), but pneumococcal carriage was nei-
ther associated with gender nor to number of siblings.
Factors that were not found to be significantly associated
with PNSP carriage (Table 3) were gender, number of siblings,
and day-care attendance.
Multivariate analysis: To control for confounding factors, all
significant variables from the univariate analysis were used in
a multivariate backward stepwise logistic regression model
(number of children in analysis� 506, �2 � 10.412, df � 1,
p � 0.013). The number of antimicrobial treatments was the
only independent risk factor for carriage of PNSP, odds ratio
1.28 for each treatment (95% CI 1.11–1.48), p � 0.007. Figure
2 shows the odds ratio by using a similar multivariate logistic
model for different variables in the 1993, 1998, and 2003 stud-
ies, where the number of weeks from last antimicrobial courses
is used in the models instead of the number of antimicrobial
courses in the preceding 12 months. The time duration of 2–7
weeks from last antimicrobial treatment compared to �8 weeks
was the only significant risk factor for PNSP carriage in all the
three analyses.
Factors associated with carriage of erythromycin-resistant
pneumococci: All of the variables tested for association with
carriage of PNSP were also tested for association with carriage
of erythromycin-resistant pneumococci with multivariate back-
ward stepwise logistic regression model (number of children in
analysis� 524, �2 � 5.35, df� 1, p � 0.027). As for PNSP
carriage, the number of antimicrobial treatments was the only
independent risk factor for carriage of erythromycin-resistant
pneumococci, odds ratio 1.18 for each treatment (95% CI
1.03–1.35), p � 0.0157. The association of using a particular
antimicrobial class was compared with using any other class or
no antibiotic. By testing the risk of using a particular antimi-
crobial class versus not having used an antimicrobial agent, the
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FIG. 1. The proportion of PNSP (typeable and nontypeable,
typeable strains only, and serotype 6B only), and antimicrobial
use in the years 1993, 1998, and 2003.
use of macrolides and amoxicillin� clavulanic acid was asso-
ciated with carriage of erythromycin-resistant pneumococci
(p � 0.081 and p � 0.043, respectively), but not the other
classes.
DISCUSSION
Observing the rates of PNSP together with antimicrobial use
at three occasions over a 10-year period in four communities
in different parts of Iceland gives important clues regarding the
epidemiology of PNSP. Antimicrobial use was highest at the
first study in 1993 (1.5 AM courses/child per year) and had
come down by a third at the last study in 2003. At the same
time, there was little overall change in the rates of PNSP (8.5,
8.1, and 9.5% respectively), yet by excluding nontypeable pneu-
mococci the PNSP rate has also come down by almost a third
(8.5, 8.1, and 5.9% respectively). The association between the
rates of antimicrobial use and resistance is not surprising, and
in that sense these studies do little but confirm previous stud-
ies. However, the design of our studies allows us to look at the
changes within individual communities at different times.
There are much greater changes taking place within the in-
dividual communities, changes that may be difficult to explain
by antimicrobial use alone. In 1998, there was marked increase
in PNSP rates in the two communities, which had had the low-
est PNSP rates in 1993, despite significant decrease in antimi-
crobial use. The increase was only due to an increase in mul-
tiresistant serotype 6B strains (representative phenotypically
identical strains have previously been shown to belong to the
Spanish Icelandic clone, i.e., Spain6B-2)16,19 and was explained
by clonal spread into “virgin” communities.2 The current study
does indeed support that explanation, as that serotype (clone)
has now disappeared from these two communities, probably due
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TABLE 3. UNIVARIATE ANALYSIS ON DIFFERENT VARIABLES FOR CHILDREN CARRYING PNSP COMPARED TO CHILDREN
CARRYING PENICILLIN-SUSCEPTIBLE PNEUMOCOCCI
Penicillin-
Number susceptible
Variable children pneumococci PNSP p value
Residence Area H 258 134 20 0.280
Area V 301 199 15
Area E 207 108 12
Area B 58 34 3
Age Mean 4.16 Mean 3.78
(95% CI 4.01–4.30) (95% CI 3.03–4.25)
Sex Male 430 249 29 0.462
Female 394 226 21
Number of Mean 1.40 Mean 1.63
siblings (95% CI 1.30–1.50) (95% CI 1.31–1.95)
Day-care Yes 752 443 46
attendance No 70 31 4 0.764
Smoking in the Yes 148 94 6
household No 671 378 44 0.255
Tympanostomy Yes 279 169 20
tubes at No 689 391 37 0.175
sampling time
Number of Mean 0.95 Mean 1.78 �0.001
antimicrobial (95% CI 0.82–1.09) (95% CI 1.24–2.32)
(AM) courses 
last 12 months
Number of weeks Mean 21.50 Mean 10.82 �0.001
from last AM (95% CI 19.46–23.53) (95% CI 7.58–14.06)
treatment
Prophylactic Yes 12 2
AM last 12 No 460 48 0.635
months
Type of last AM Amoxicillin 105 52 (25.9%) 12 (34.3%) 0.938
Amox.-clav.acid 87 49 (24.4%) 13 (37.1%) 0.144
Fenox.m.pc. 32 15 (7.5%) 1 (2.9%) 0.478
Trimethophrim- 23 14 (7.0%) 1 (2.9%) 0.705
sulpha
Erythromycin 20 13 (6.5%) 0
Azithromycin 71 41 (20.4%) 6 (17.1%) 0.820
Cefuroxime 6 5 (2.5%) 0
Cefalexin 9 5 (2.5%) 1 (2.9%) 1.000
Dicloxacillin 8 7 (3.5%) 1 (2.9%) 1.000
to increased herd immunity to that particular clone and reduced
antimicrobial use. The five yearly data are demonstrated in Fig.
3A and the proposed prevalence of the Spanish-Icelandic clone
with time in the different areas in Fig. 3B. Therefore, it is rea-
sonable to state that clonal spread in specific geographical ar-
eas can have more profound effects on the rates of PNSP than
antimicrobial use. Such changes may be more difficult to de-
tect in large populations, yet similar changes took place with
Streptococcus pyogenes clones in Finland.6 We can also state
that the time period from the onset to the end of the epidemic
wave for a particular clone is less than 10 years. In addition, it
is likely that the extent of antimicrobial use will determine both
the peak prevalence and the subsequent endemic prevalence.
Pneumococcal vaccination has not been recommended for chil-
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TABLE 4. ASSOCIATION OF POTENTIAL RISK FACTORS WITH CARRIAGE OF TYPEABLE AND NONTYPEABLE
(NONENCAPSULATED) PNSP
Typeable Nontypeable
Variable PNSP PNSP p value
Age Mean 3.18 Mean 3.77
(95% CI 2.64–3.72) (95% CI 2.63–4.90)
Gender Male 18 11 1.000
Female 13 8
Number of siblings Mean 1.18 Mean 2.08
(95% CI 0.86–1.51) (95% CI 1.13–3.04)
Daycare attendance Yes 29 17 0.629
No 2 2
Smoking in the household Yes 3 3 0.661
No 28 16
Tympanostomy tubes Yes 13 7 0.774
anytime No 18 12
Tympanostomy tube at Yes 7 3 0.727
sampling time No 23 14
Prophylactic antimicrobial Yes 2 0
(AM) last 12 months No 29 19
Number of AM courses last Mean 2.36 Mean 2.33
12 months (95% CI 1.66–3.07) (95% CI 1.71–2.96)
Number of weeks from last Mean 11.64 Mean 9.33
AM treatment (95% CI 7.00–16.27) (95% CI 5.00–13.66)
FIG. 2. Odds ratio for carrying PNSP as opposed to susceptible pneumococci, according to multivariate logistic regression
analysis for the 1993, 1998, and 2003 studies. TT, Tympanostomy tubes.
dren in Iceland, unless they belong to specific risk groups. Very
few children have been vaccinated with the new conjugate vac-
cines, and therefore vaccinations should not play a role in the
changing epidemiology.
The Spanish Icelandic clone appears to have disappeared
from two of the communities (B and E), continued to decline
in one (H), but surprisingly remained stable in one community
(V). This cannot be explained by lack of herd immunity, be-
cause the clone has been present in that area at least since 1993.
The continued high antimicrobial use in the area could perhaps
explain why the clone is still present in 2003 and it is tempt-
ing to conclude that rapidly increasing use of azithromycin (one
third of all prescriptions in 2003, and much higher than in the
other areas) has established a favorable selective environment
for this macrolide-resistant clone. This environment may also
have led to the marked increase in the number of erythromycin-
resistant and penicillin-susceptible pneumococci in that area. 
In fact, the long half-life and low serum concentrations of
azithromycin have been associated with increased resistance
rates.5
The nontypeable pneumococci all had a rough appearance
and are probably nonencapsulated, although this has not been
confirmed with molecular investigations. Such rough (nonen-
capsulated) strains had not been observed in the previous two
studies. It is unlikely that such rough strains were missed in the
previous studies because all the agar plates from the 1998 and
2003 studies were read by the same senior biomedical labora-
tory scientist, and their appearance in 2003 could indicate the
introduction of novel clone(s). In a recent study of pneumo-
cocci colonizing children attending day-care centers in Lisbon,
Portugal, 7.4% were nontypeable, but after retesting and PCR
of the lytA and psaA genes the true nontypeable rate was 5.9%.
This rate had increased from 3.8% in 1997 to 11% in 1999 and
the strains were genetically diverse, although a dominant clone
accounted for about half the strains. Most of the strains (86%)
were resistant to antibiotics.17 Another recent study of 121 non-
typeable strains from Finland, also showed genetic diversity,
yet the majority belonged to a single lineage with defective cap-
sular locus. Comparison with the multilocus sequence typing
database showed that strains of that lineage have spread inter-
continentally.14 The significance of penicillin nonsusceptibility
in the nontypeable pneumococci is not clear. Although such
strains have lost their main virulence determinant, they may still
be important as reservoirs of resistance genes.
Although the three studies only give three snapshots of the
resistance situation, we have reliable information about the an-
timicrobial use in the study areas in the years preceding the
snapshots and could sample at least 74% of the children in the
study areas, giving very representative snapshots. Adding fur-
ther strength to the studies was having the same investigators
take all of the nasopharyngeal samples in all areas for all of the
studies, and the same biomedical laboratory scientists inocu-
lating and reading most of the agar plates.
In conclusion, for small communities, the spread of resistant
clones appears to be the main reason for rapid and significant
changes in pneumococcal resistance rates. Recent antimicrobial
use is the most consistent and important risk factor for carriage
of resistant pneumococci and the choice of antimicrobial class
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FIG. 3. The proportion of multiresistant serotype 6B strains (phenotypically identical to the Spanish-Icelandic clone) in the dif-
ferent areas in 1993, 1998, and 2003 (A), and the postulated epidemic curves for the Spanish-Icelandic clone in the four study
areas (B).
may influence the selective environment favoring particular re-
sistant clones.
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APPENDIX
Informed parental consent and questionnaire 2003.
Upplýsingar um rannsóknina:
Sýklalyfjanotkun og ónæmar bakteríur í nefkoki barna
Ábyrgðamaður: Vilhjálmur Ari Arason, heimilislæknir, Heilsugæslu-
stöð­inni Sólvangi, Hafnarfirð­i (Sími: 550 26 70, GSM: 8959156 ). 
(Aðrir umsjónarmenn og samstarfsaðilar: Prófessor Jóhann Ágúst Sigurðsson, Heimilislæknisfræði, Lækna-
deild Háskóla Íslands, Dr. Sigurður Guðmundsson, landlæknir og prófessor Karl G.Kristinsson, sýklafræðingur, 
Landsspítala-Háskólasjúkrahús. Rannsóknin er gerð í  samvinnu við lækna heilsugæslustöðvarinnar).
Tilgangur og ávinningur rannsóknarinnar: Tíðni baktería sem eru 
ónæmar fyrir sýklalyfjum fer vaxandi, einkum svonefndra pneumó-
kokka í nefkoki barna. Margar rannsóknir (meðal annars  þær sem 
gerðar voru í Vestmannaeyjum, Egilsstöðum, Bolungarvík og í Hafn-
arfirð­i á árunum 1993 og 1998), sýna tengsl milli þessarar þróunar 
og mikillar notkunar á sýklalyfjum. Tilgangur  rannsóknar nú er að 
endurtaka fyrri rannsóknir hér á landi  5 árum eftir síðustu rannsókn. 
Ræktaðar verða bakteríur úr nefkoki barna á aldrinum 1-6 ára með því 
að­ taka strok úr nefi með­ bómullarpinna, fengnar upplýsingar um sýk-
ingar og notkun sýklalyfja, samkvæmt spurningablaði og samkvæmt 
upplýsingum úr sjúkraskrá heilsugæslustöðvarinnar. Markmiðið er 
sem fyrr að­ skoð­a árangur fyrri úrlausna og finna að­ferð­ir til þess að­ 
minnka ört vaxandi tíðni ónæmra bakteríustofna gegn sýklalyfjum.
Þátttaka barns felst í því að:
1) Foreldri fyllir út í  spurningalista þar sem spurt er m.a um sýkla-
lyfjanotkun barnsins, (verður einnig athugað í sjúkraskrá), notkun 
röra í hljóðhimnur og viðhorf foreldis til sýklalyfjanotkunar.  
2) Stroksýni verður tekið úr nefi barnsins með bómullarpinna sem 
er barninu að skaðlausu og án teljandi óþæginda (e.t.v smá kláði í 
nefi á eftir og hnerri).
Sýnatakan er framkvæmd í leikskólunum eða skólanum af rannsókn-
arað­ilum (ef foreldri er búið­ að­ samþykkja þátttöku skriflega) eða á 
Heilsugæslustöðinni ef foreldri óskar eftir.
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Stroksýnið er sent til Sýkladeildar Landspítala-Háskólasjúkrahúss 
og eingöngu notað til ræktunar á bakteríum og athugun á hugsanlegu 
ónæmi þeirra gegn sýklalyfjum. 
Viðkomandi heilsugæslulæknar fá sent bréf ef barn greinist með 
penicíllin ónæman pneumókokk (foreldrar geta fengið upplýsingar 
hjá þeim ef um er að ræða spurningu um meðhöndlun á efri loftvega-
sýkingum með sýklalyfjum).
Persónuupplýsingum sem ekki tilheyra sjúkraskrá barnsins verður 
eytt að lokinni úrvinnslu innan 2ja ára frá sýnatökunni.
Fyllsta trúnaðar verður gætt  hvað varðar allar upplýsingar sem 
aflað­ verð­ur. Farið­ verð­ur með­ persónuupplýsingar og skráningu þe-
irra í samræmi við lög um persónuvernd nr. 77/2000. Rannsóknin 
hefur jafnframt hlotið leyfi Vísindasiðanefndar og Persónuverndar. 
Úrvinnsla gagna er í höndum umsjónarmanna og fer eingöngu  fram 
innanlands. Niðurstöður rannsókna verða eingöngu birtar fyrir hópa 
og ekki persónugreinanlegar. Tekið skal fram að rannsóknin beinist 
ekki að erfðaefnum eða ættartengslum.
Forráðarmönnum er hvenær sem er heimilt að afturkalla samþyk-
ki til þátttöku í rannsókninni. Gögnum um barnið sem tilheyra þessa-
ri rannsókn verður þá eytt. Hætti barn þátttöku mun það ekki í neinu 
tilviki skerða þá heilbrigðisþjónustu sem barninu stendur annars til 
boða í heilsugæslunni.  
Ef þú hefur spurningar um rétt þinn sem þátttakandi í vísinda-
rannsókn eða vilt hætta þátttöku í rannsókninni getur þú snúið þér 
til Vísindasiðanefndar, Laugavegi 103, 105 Reykjavík. Sími: 551-
7100, fax: 551-1444
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Samþykki foreldris um þátttöku barnsins: 
Kæru foreldrar
Erindi bréfsins er að leita eftir þátttöku barns yðar í rannsókn sem 
felst í því að taka nefstrok úr barninu, svara spurningalista og 
skoðun sjúkraskrár samkvæmt nánari lýsingum á meðfylgjandi 
upplýsingablaði sem foreldri/forráðamaður heldur eftir fyrir sig.
Rannsóknin er framkvæmd á leikskólum/skólum bæjarins og Heilsu-
gæslustöðinni, á tímabilinu  31. mars - 9. apríl 2003. 
Foreldrar sem samþykkja þátttöku eru góðfúslega beðnir um að 
straðfesta það með undirskrift sinni hér að neðan og að svara 
meðfylgjandi spurningalista.
Blaðinu með spurningalistanum má síðan skila til leikskóla/skóla 
barnsins eða á Heilsugæslustöðina ef barnið kemur til sýnatöku þar. 
 
nafn barns:_______________________  kt.___________________
sími:______________
nafn foreldris/
forráðamanns:_________________________ kt. ______________    
Dagsetning samþykkis:______ / _______ 2003
Fyrir hönd rannsóknarhóps,Vilhjálmur Ari Arason, læknir
Ef þú hefur spurningar um rétt þinn sem þátttakandi í vísinda-
rannsókn eða vilt hætta þátttöku í rannsókninni getur þú snúið þér til 
Vísindasiðanefndar, Laugavegi 103, 105 Reykjavík. Sími: 551-7100, 
fax: 551-1444.
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Spurningalisti 
(krossið við eða svarið spurningum eftir sem við á)
Aldur foreldris/forráðamanns sem svarar spurningum ____ ára
Karl   ❏          Kona  ❏
Svarið hvað ykkur finnst réttast:
Á að meðhöndla eyrnabóglur með sýklalyfjum?
Alltaf  ❏
Stundum  ❏
Aldrei  ❏
Veit ekki  ❏
Á að meðhöndla kvef með sýklalyfjum?
Alltaf          ❏
Stundum ❏
Aldrei   ❏
Veit ekki  ❏
Takið afstöðu til neðangreindra fullyrðinga:
Sumir sýklar (bakteríur) eru að verða ónæmir fyrir sýklalyfjum. 
Sammála (já)   ❏
Hlutlaus   ❏
Ósammála (nei)  ❏
Veit ekki   ❏
Ofnotkun sýklalyfja getur leitt til þess að þau tapi virkni sinni.
Sammála (já)   ❏
Hlutlaus   ❏
Ósammála (nei)  ❏
Veit ekki   ❏
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Er barnið í dagvistun/leikskóla/skóla: Já  ❏             Nei  ❏
Nafn á leikskóla/skóla: __________________________________
Fjöldi systkina á heimilinu? _______________
Hve oft hefur barnið fengið sýklalyf sl 12 mán? _____________
Ástæður og fjöldi sýklalyfjameðferða sl. 12 mán. (skrifið fjölda 
meðferða fyrir aftan sjúkdómsgreiningu eftir því sem við á):
Hálsbólga   ________ Skútabólga (kinnholubólga)________
Eyrnabólga ________ Húðsýking  ____________
Berkjubólga ________ Þvagfærasýking ____________
Lungnabólga ________ Aðrar ástæður  ____________
Barnið verið á samfeldri sýklalyfjameðferð  (3 vikur eða lengur 
samfellt) sl. 12 mán.? já  ❏             nei  ❏
Ef já, hvers vegna (við hverskonar sýkingu)? _________________
 
Ef barn hefur fengið sýklalyfjameðferð á árinu, hvað eru marg-
ar vikur frá síðustu meðferð?  __________  vikur 
Eða
Er barnið á sýklalyfjameðferð nú,  hvað hefur sýklalyfjameðferð 
þá staðið í marga daga? __________  dagar 
 
Ef barn hefur fengið sýklalyf sl. 12 mán., hver var ástæða fyrir 
síðustu sýklalyfjameðferð barnsins? _______________________
og hvaða sýklalyf fékk barnið þá? _________________________
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Hafa kokkirtlar (nefkirtlarnir)  verið fjarlægðir úr barninu? 
Já              ❏
Nei             ❏
Veit ekki    ❏
Ef já, þá hver/hvar/hvenær_________________________________
______________________________________________________
Hafa hálseitlar/hálskirtlar (tonsillur) verið frjarlægðir? 
Já              ❏
Nei             ❏
Veit ekki    ❏
Ef já, þá hver/hvar/hvenær_________________________________
______________________________________________________
Hversu oft að meðaltali fór barnið þitt í sund á aldrinum
a) 0 – 1 árs?: ________ sinni á ári
b) 1 – 2 ára?: ________ sinni á ári 
c) 2 – 3 ára?: ________ sinni á ári
d) 3 – 4 ára?: ________ sinni á ári 
e) 4 – 5 ára?: ________ sinni á ári 
f) 5 – 6 ára?: ________ sinni á ári 
g) 6 – 7 ára?: ________ sinni á ári 
Aldur við fyrstu sundferðir? _________ ára
Er reykt á heimilinu? 
Já                  ❏
Nei  ❏
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Hefur barnið þitt einhven tíman haft rör í eyrum?
Já              ❏
Nei             ❏
Veit ekki    ❏
Ef já, hversu gamalt var það þegar það fékk fyrst rör? ______ ára 
Hefur barnið þitt rör í eyra núna?   
Já              ❏
Nei             ❏
Veit ekki    ❏
Ef já við­ spurningu hvort barnið­ sé með­ eð­a hafi verið­ með­ rör vin­
samlega svarið eftirtöldum spurningum:
Geturðu nefnt helstu ástæðurnar fyrir rörísetningu að þínu mati 
(Má merkja við fleiri en einn, gjarnan forgangsraða fyrstu 3 frá 
1-3)
a) Var áður alltaf að fá eyrnabólgu .......................  ❏
b) Var alltaf að fá sýklalyf.....................................  ❏
c) Var með vökva í eyrum..................................... ❏
d) Heyrði illa ........................................................ ❏
e) Svaf illa ............................................................ ❏
f) Var alltaf með kvef og hor ................................     ❏ 
g) Lækirinn taldið þetta ráðlegt  ........................... ❏
h) Vegna ráðlegginga frá vinum og kunningjum...   ❏
i) Aðrar ástæður:________________________________________
Skánaði barninu eftir röraísetningu?   
Já              ❏
Nei             ❏
Veit ekki    ❏
  
Ef já hvað skánaði?: _____________________________________
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Telurðu vera einhverjar sérstakar skýringar á því að barnið þitt 
var „eyrnabarn“ (t.d.)
Í ættinni?  Já ❏              Nei ❏
  
Rysjótt veðurfar? Já ❏           Nei ❏ 
 
Reykingar á  heimilinu? Já ❏            Nei ❏
Annað: _________________________________  
Takk fyrir

Paper V.  Arason et al. MDR 2006  ERRATUM PAGE 173 
TABLE 3. UNIVARIATE ANALYSIS ON DIFFERENT VARIABLES FOR CHILDREN 
CARRYING  PNSP COMPARED TO CHILDREN CARRYING  PENICILLIN SUSCEPTIBLE 
PNEUMOCOCCI. 
Variable  
Number 
children 
Penicillin 
susceptible 
pneumococci
Penicillin 
non-susceptible 
pneumococci
P value 
Residence Area H 258 134 20  0.280 
 Area V 301 199 15   
 Area E 207 108 12   
 Area B 58 34 3   
Age   Mean 4.16 
(95%CI 4.01-4.30) 
Mean 3.78 
(95%CI 3.03-4.25)
Male  430 249 29 0.462 Sex 
Female  394 226 21  
Number of 
siblings. 
  Mean1.40 
(95%CI 1.30-1.50) 
Mean 1.63 
(95%CI 1.31-1.95)
Yes  752 443 46   Daycare 
attendance No  70 31 4 0.764 
Yes 148 94 6  Smoking in the  
household. No 671 378 44 0.255 
Yes 279 169 20Tympanostomy 
tubes any time. No 538 301 30 0.766 
Yes 111 70 10Tympanostomy 
tubes at 
sampling time. 
No 689 391 37 0.175 
Number of 
antimicrobial 
(AM)courses 
last 12 months. 
  Mean 0.95 
(95%CI 0.82-1.09) 
Mean 1.78 
(95%CI 1.24-2.32)
<0.001 
Number of 
weeks from last 
AM treatment. 
   Mean 21.50 
(95%CI 19.46-23.53)
Mean 10.82 
(95%CI 7.58-14.06)
<0.001 
Yes  12 2  Prophylactic 
AM 
last 12 months.  
No  460 48 0.635 
Type of last AM Amoxicillin 105 52 (25.9%) 12 (34.3%) 0.938 
 Amox.-clav.acid 87 49 (24.4%) 13 (37.1%) 0.144 
 Fenox.m.pc. 32 15 (7.5%) 1 (2.9%) 0.478 
 Trimethophrim-
sulpha 
23 14 (7.0%) 1 (2.9%) 0.705 
 Erythromycin 20 13 (6.5%) 0  
 Azithromycin 71 41 (20.4%) 6 (17.1%) 0.820 
 Cefuroxime 6 5 (2.5%) 0  
 Cefalexin 9 5 (2.5%) 1 (2.9%) 1.000 
 Dicloxacillin 8 7 (3.5%) 1 (2.9%) 1.000 
